

# **in vivo**

**International Journal of Experimental and  
Clinical Pathophysiology and Drug Research**

PRINT ISSN: 0258-851X – ONLINE ISSN: 1791-7549

**Volume 26  
2012**

**INDEX**



## Editorial Board

- N.J. AGNANTIS, *Department of Pathology, University of Ioannina, Ioannina, Greece*  
D. ANDERSON, *Department of Biomedical Sciences, University of Bradford, Bradford, West Yorkshire, UK*  
J.P.A. BAAK, *Department of Pathology, Stavanger University Hospital, Stavanger, Norway*  
V. BARAK, *Department of Oncology, Hadassah University Hospital, Jerusalem, Israel*  
M.H. BARCELLOS-HOFF, *Department of Radiation Oncology, New York University School of Medicine, New York, NY, USA*  
Y. BECKER, *Department of Biochemistry, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel*  
K. BEIER, *Department of Histology, University of Basel, Basel, Switzerland*  
S. BEN-EFRAIM, *Department of Human Microbiology, University of Tel-Aviv, Tel-Aviv, Israel*  
M. BERGQVIST, *Department of Oncology, Radiology and Clinical Immunology, University Hospital, Uppsala, Sweden*  
R. BJERKVIG, *Norlux Neuro-Oncology, Department of Biomedicine, University of Bergen, Bergen, Norway*  
B. BODEY, *Department of Pathology, University of Southern California, Reseda, CA, USA*  
D.A. BUTTERFIELD, *Department of Biological and Physical Chemistry, University of Kentucky, Lexington, KY, USA*  
M. CARAGLIA, *Department of Experimental Oncology, National Institute of Tumours Fondazione G. Pascale, Naples, Italy*  
P. CHANDRA, *Department of Molecular Biology, Frankfurt University, Frankfurt am Main, Germany*  
J.-G. CHUNG, *Department of Medicine, China Medical College, Taichung, Taiwan, ROC*  
L.A. COHEN, *Northampton, MA, USA*  
A.I. CONSTANTINOU, *Department of Biological Sciences, University of Cyprus, Nicosia, Cyprus*  
T. DALIANIS, *Department of Pathology-Oncology, Karolinska Institute, Stockholm, Sweden*  
G. DELICONSTANTINOS, *Department of Experimental Physiology, University of Athens Medical School, Athens, Greece*  
D.T. DENHARDT, *Department of Cell Biology and Neurosciences, Rutgers University, Piscataway, NJ, USA*  
W. DEN OTTER, *VUMC - Department of Urology, Amsterdam, The Netherlands*  
K. DE MEIRLEIR, *Department of Human Physiology and Medicine, Faculty of Physical Education and Physiotherapy, Vrije Universiteit Brussel, Brussels, Belgium*  
L. DE RIDDER, *Department of Anatomy, Embryology and Histology, University of Ghent, Ghent, Belgium*  
E.P. DIAMANDIS, *Department of Pathology and Laboratory Medicine, University of Toronto, Toronto, Ontario, Canada*  
T. EFFERTH, *Department of Pharmaceutical Biology, Institute of Pharmacy and Biochemistry, University of Mainz, Germany*  
I. EMBER, *Department of Public Health, University of Pécs Medical School, Pécs, Hungary*  
W. ENGSTRÖM, *Department of Molecular Biosciences, Swedish University of Agricultural Sciences, Uppsala, Sweden*  
M. ESKELINEN, *Department of Surgery, University Hospital of Kuopio, Kuopio, Finland*  
J.A. FERNANDEZ-POL, *Metalloproteomics, LLC, Chesterfield, MO, USA*  
S. FERRONE, *Department of Immunology, University of Pittsburgh, Pittsburgh, PA, USA*  
G. FIORENTINI, *UOC Oncologia, Azienda Ospedaliera Marche Nord, Pesaro, Italy*  
P.B. FISHER, *Virginia Commonwealth University, School of Medicine, Richmond, VA, USA*  
I. FREITAS, *Dipartimento di Biologia Animale, University of Pavia, Pavia, Italy*  
M. FRIEDRICH, *Department of Obstetrics and Gynecology, Klinikum Krefeld, Krefeld, Germany*  
R.E. FRIEDRICH, *Department of Oral and Maxillofacial Surgery, Eppendorf University Hospital, Hamburg, Germany*  
R. GANAPATHI, *Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland, OH, USA*  
Z. GATALICA, *Department of Pathology and Creighton Medical Laboratories, Creighton University Medical Center, Omaha, NE, USA*  
D.H. GILDEN, *Department of Neurology, University of Colorado Denver School of Medicine, Aurora, CO, USA*  
G. GITSCH, *Department of Gynecology and Obstetrics, University of Freiburg Medical Center, Freiburg, Germany*  
J.S. GREENBERGER, *Department of Radiation Oncology, University of Pittsburgh, Pittsburgh, PA, USA*

- J.W. GREINER**, *National Cancer Institute, NIH, Bethesda, MD, USA*
- D.S. GRIDLEY**, *Department of Radiation Medicine, Radiation Research Laboratories, Loma Linda University and Medical Center, Loma Linda, CA, USA*
- C.J. GRUBBS**, *Department of Nutrition Sciences, University of Alabama, Birmingham, AL, USA*
- F. GUADAGNI**, *IRCCS San Raffaele, Rome, Italy*
- F. HALBERG**, *Chronobiology Laboratories, University of Minnesota, Minneapolis, MN, USA*
- R.R. HARDY**, *Fox Chase Cancer Center, Philadelphia, PA, USA*
- J. HAU**, *Department of Comparative Medicine, University of Copenhagen, Denmark*
- M. HAUER-JENSEN**, *Arkansas Cancer Research Center, University of Arkansas Medical Sciences, Little Rock, AR, USA*
- G.H. HEPPNER**, *Department of Immunology, Michigan Cancer Foundation, Detroit, MI, USA*
- K. HIBI**, *Department of Surgery, Showa University Fujigaoka Hospital, Yokohama, Japan*
- S.A. IMAM**, *Huntington Medical Research Institutes, Gene Therapy Program, Pasadena, CA, USA*
- C.G. IOANNIDES**, *Department of Gynecologic Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA*
- J.R. IZBICKI**, *Chirurgische Universitätsklinik, Universitätskrankenhaus Hamburg, Germany*
- K.S. JEONG**, *Department of Pathology, College of Veterinary Medicine, Kyungpook National University, Daegu, S. Korea*
- I. KISS**, *Institute of Preventive Medicine, Medical School, University of Pécs, Pécs, Hungary*
- M. KOUTSILIERIS**, *Department of Experimental Physiology, University of Athens Medical School, Athens, Greece*
- G.R.F. KRUEGER**, *Department of Anatomy II, Center for Anatomy, The University of Cologne Medical School, Cologne, Germany*
- B. KRUSLIN**, *Department of Pathology, Ljudevit Jurak University, Sestre milosrdnice University Hospital, Zagreb, Croatia*
- S.A. LAMPRECHT**, *Division of Clinical Biochemistry, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer-Sheva, Israel*
- G. LANDBERG**, *Department of Laboratory Medicine, Lund University, Lund, Sweden*
- I. LELONG-REBEL**, *Lab. de Biophotonique et Pharmacologie, Université de Strasbourg, Illkirch, France*
- J. LEROY**, *IRCAD, University of Strasbourg, France*
- B. LÉYLAND-JONES**, *Edith Sanford Breast Cancer Research, Sanford Health, Sioux Falls, SD, USA*
- W. LICHTENEGGER**, *Charité Campus Virchow-Klinikum, Berlin, Germany*
- P. MADARNAS**, *Department of Pathology, University of Sherbrooke, Québec, Canada*
- H. MAEDA**, *Faculty of Pharmaceutical Sciences, Sojo University, Kumamoto, Japan*
- M. MAREEL**, *Laboratory of Experimental Cancerology, State University, Ghent, Belgium*
- G. MARTORANA**, *Policlinico S. Orsola Malpighi, University of Bologna, Bologna, Italy*
- D.P. MIKHAILIDIS**, *Department of Chemical Pathology, The Royal Free Hospital, London, UK*
- J. MOLNÁR**, *Department of Medical Microbiology and Immunobiology, Faculty of Medicine, University of Szeged, Szeged, Hungary*
- H.C. MORSE III**, *Laboratory of Immunopathology, NIH, Rockville, MD, USA*
- N. MOTOHASHI**, *Department of Medicinal Chemistry, Meiji Pharmaceutical University, Tokyo, Japan*
- R.M. NAGLER**, *Department of Oral and Maxillofacial Surgery, Rambam Medical Center, Haifa, Israel*
- R. NARAYANAN**, *Department of Biological Sciences, Florida Atlantic University, Boca Raton, FL, USA*
- K. NILSSON**, *Tumor Biology Laboratory, Department of Pathology, University Hospital, Uppsala, Sweden*
- K.R. NORUM**, *Institute for Nutrition Research, University of Oslo, Oslo, Norway*
- R.F. NOVAK**, *Shriners Hospitals for Children International, Tampa, FL, USA*
- K. OGAWA**, *Department of Surgery, Tokyo Women's Medical University Medical Center East, Tokyo, Japan*
- M. PAGÉ**, *Département de Biologie, Division de Biochimie, Université Laval, Québec, Canada*

- P. PANTAZIS**, *Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA*
- M.-F. POUPON**, *Institut Curie, Section de Recherche, Paris, France*
- F.M. ROBERTSON**, *Department of Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA*
- D. RUBELLO**, *Department of Nuclear Medicine, PET Unit, S. Maria della Misericordia Hospital, IOV, Rovigo, Italy*
- C.A. RUBIO**, *Karolinska Institute, Pathology Research Laboratory, Stockholm, Sweden*
- G.R. RUTTEMAN**, *Department of Clinical Sciences of Companion Animals, University of Utrecht, Utrecht, The Netherlands*
- H. SAKAGAMI**, *Department of Dental Pharmacology, Meikai University School of Dentistry, Saitama, Japan*
- G. SAVA**, *Institutes of Biological Research, Fondazione Callerio-Onlus, Trieste, Italy*
- D. SCHIFFER**, *Neuro-bio-oncology Center, Policlinico di Monza Foundation, University of Turin, Vercelli, Italy*
- L.D. SHULTZ**, *The Jackson Laboratory, Bar Harbor, ME, USA*
- G. SICA**, *Istituto di Istologia ed Embriologia, Universita Cattolica del Sacro Cuore, Roma, Italy*
- R.M. SNAPKA**, *Department of Radiology, The Ohio State University, Columbus, OH, USA*
- G.-I. SOMA**, *Institutes for Health Sciences, Tokushima Bunri University, Tokushima, Japan*
- T.A. SPRINGER**, *Department of Pathology, Harvard Medical School, Boston, MA, USA*
- T. TAKAHASHI**, *Aichi Cancer Center, Nagoya, Japan*
- N. TANAKA**, *Department of Animal Pharmaceutical Science, Chiba Institute of Science, Chiba, Japan*
- K.D. TEW**, *Department of Pharmacology, Medical University of South Carolina, Charleston, SC, USA*
- G.C. TORRE**, *Centro Ippocrate, Vico Cosmelli 4, Finale Ligure (SV), Italy*
- B. TRIBUKAIT**, *Department of Medical Radiobiology, Karolinska Hospital, Stockholm, Sweden*
- J. VADGAMA**, *Department of Internal Medicine, Charles E. Drew University of Medicine and Science, Los Angeles, CA, USA*
- J.K. VISHWANATHA**, *Graduate School of Biomedical Sciences, University of North Texas Health Science Center, Fort Worth, TX, USA*
- N. WATANABE**, *Department of Clinical Laboratory Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan*
- W. WEBER**, *Clinical Cancer Etiology Unit, Basel, Switzerland*
- L.M. WEINER**, *Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA*
- J.A. WERNER**, *Department of Otolaryngology, Head and Neck Surgery, Marburg, Germany*
- S. YLÄ-HERTTUALA**, *Department of Molecular Medicine, A.I. Virtanen Institute, University of Kuopio, Finland*
- H. YOSHIDA**, *Department of Pathology, Kagoshima University, Kagoshima, Japan*



## Acknowledgements

The following Organisations supported many of the works published in IN VIVO, Volume 26, 2012.

- American Cancer Society, Atlanta, GA, U.S.A.  
American Society for Microbiology, Washington, D.C., U.S.A.  
Ark Therapeutics Group, London, U.K.  
Austrian Science Fund (FWF), Austrian Science Fund, Vienna, Austria  
Austrian Science Fund (FWF), Vienna, Austria
- Balkan Union of Oncology (B.U.ON.)  
BAM Federal Institute for Materials Research and Testing, Berlin, Germany  
Bioerevna, Athens, Greece  
Blum Kovler Foundation, Chicago, IL, U.S.A.  
British Heart Foundation, London, U.K.
- Cancer Association, North Rhine Westphalia, Germany  
Cancer Federation, Banning, CA, U.S.A.  
Cancer Research Center of Excellence, Singapore, Republic of Singapore  
Cancer Research Laboratory, University of California, Berkeley, CA, U.S.A.  
Carol Davila University of Medicine and Pharmacy, Bucharest, Romania  
Charles University, Prague, Czech Republic  
Children's Cancer Research Fund, Minneapolis, MN, U.S.A.  
China Medical University, Taichung City, Taiwan, R.O.C.  
City of Tsuruoka, Japan  
Concorde Group S.p.A., Modena, Italy  
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Brasília, Brazil  
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Brasília, Brazil  
Creating the Center of Excellence, University of Szeged, Szeged, Hungary
- Danish Council for Strategic Research, Copenhagen, Denmark  
Department of Clinical Pathology, Cheng Hsin General Hospital, Taipei, Taiwan, R.O.C.  
Department of Health, Fong-Yuan Hospital, Executive Yuan, Taipei, Taiwan, R.O.C.  
Department of Pathology, Karolinska University Hospital, Stockholm, Sweden  
Department of Pediatrics, National Jewish Medical and Research Center, Denver, CO, U.S.A.  
Department of Radiation Medicine, Loma Linda University Medical Center, Loma Linda, CA, U.S.A.
- Department of Veterans' Affairs, Washington, D.C., U.S.A.  
Deutsche Forschungsgemeinschaft, Bonn, Germany  
Dilab, Lund, Sweden  
Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Duke University Medical Center, Durham, NC, U.S.A.
- European Social Fund
- Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa  
Finnish Academy, Helsinki, Finland  
Finnish Cultural Foundation of Northern Savo, University of Kuopio, Kuopio, Finland  
Finnish Foundation for Cardiovascular Research, Helsinki University, Helsinki, Finland  
Fundação de Amparo a Pesquisa de Minas Gerais (FAPEMIG), Sao Paulo, Brazil  
Fundação para a Ciência e a Tecnologia (FCT), Portugal  
FUTURA-onlus, Rome, Italy  
FUTURA-onlus, Rome, Italy
- German Academic Exchange Service (DAAD), Bonn, Germany  
Graduate School, University of Minnesota, Minneapolis, MN, U.S.A.  
Greek Scholarships Foundation (IKY), Athens, Greece
- Harry S. Truman Memorial Veterans' Hospital, Columbia, MO, U.S.A.  
Herbert C. Wenske Foundation, Chicago, IL, U.S.A.  
Hungarian Scientific Research Fund, Budapest, Hungary
- Japan Society for the Promotion of Science, Japan  
Jyväskylä Central Hospital, Jyväskylä, Finland
- Lawn Manor Beth Jacob Hebrew Congregation, Chicago, IL, U.S.A.  
Leica Microsystems AB, Stockholm, Sweden
- M.D. Anderson Cancer Center, Houston, TX, U.S.A.  
Maud Kuistila Foundation, Helsinki, Finland  
Max Goldenberg Foundation, Chicago, IL, U.S.A.  
Medical School, Goethe University, Frankfurt am Main, Germany  
Medtronic, Fridley, MN, U.S.A.

- Ministry of Education, Science and Culture, Japan  
Ministry of Health, Prague, Czech Republic  
Ministry of Science, Education and Sports, Croatia  
Miyata Science Research Foundation, Asahi University,  
Mizuho, Japan  
Molecular and Genetic Imaging Core (MAGIC)/NRPGM,  
Taipei, Taiwan, R.O.C.  
Molecular Physiology Laboratory, School of Physiology,  
University of the Witwatersrand, Johannesburg, South  
Africa
- National Aeronautics and Space Administration (NASA),  
Washington, D.C., U.S.A.  
National Brain Tumor Society, Watertown, MA, U.S.A.  
National Cancer Institute (NCI), National Institute of Health,  
Bethesda, MD, U.S.A.  
National Institute for Basic Biology, Okazaki, Japan  
National Institute of Environmental Health Sciences (NIEHS),  
Research Triangle Park (RTP), NC, U.S.A.  
National Institute of Health, Bethesda, MD, U.S.A.  
National Institutes of Natural Sciences, Tokyo, Japan  
National Research Council (CONICET), Buenos Aires,  
Argentina  
National Research Foundation of Korea (NRF), Ministry of  
Education, Science and Technology, Republic of Korea  
National Science Council of Taiwan, Taipei, Taiwan, R.O.C.  
National Science Council, Taipei, Taiwan  
National Science Council, Taipei, Taiwan, R.O.C
- Ohio State University Comprehensive Cancer Center,  
Columbus, OH, U.S.A.  
Okazaki Institute for Integrative Bioscience, Okazaki, Japan
- Oppenheimer Memorial Trust, Cape Town, South Africa  
Orion-Farmos Research Foundation, Espoo, Finland
- Paul Blümel Stiftung, Hannover, Germany
- Rural Development Administration, Suwon, Republic of Korea
- Safeway/Dominicks Campaign for Breast Cancer Awareness,  
Chicago, IL, U.S.A.  
School of Biological and Medical Sciences, College of  
Science, RIT, Rochester, NY, U.S.A.  
School of Medicine, University of Missouri, Columbia, MO,  
U.S.A.  
Second University of Naples, Naples, Italy  
Sigrid Juselius Foundation, Helsinki, Finland  
Szegeed Foundation of Cancer Research, University of Szegeed,  
Szegeed, Hungary
- Taiwan Department of Health, China Medical University  
Hospital, Taipei, Taiwan, R.O.C.  
Takeda Science Foundation, Japan  
Terry Fox Cancer Research Lab, China Medical University  
Hospital, Taichung, Taiwan
- University of Kuopio, Kuopio, Finland  
University of Leeds, Leeds, U.K.  
University of Medicine and Pharmacy of Târgu Mureș, Târgu  
Mureș, Romania  
University of Southampton, Southampton, U.K.  
University of Thessaly, Larissa, Greece
- Yamagata Prefectural Government, Japan



## Contents, Volume 26, 2012

### Number 1

#### *Experimental Studies*

15-Lipoxygenase-1 Induces Lipid Peroxidation and Apoptosis, and Improves Survival in Rat Malignant Glioma. H. VIITA, A. PACHOLSKA, F. AHMAD, J. TIETÄVÄINEN, J. NAARALA, A. HYVÄRINEN, T. WIRTH, S. YLÄ-HERTTUALA ( <i>Kuopio; Joensuu, Finland</i> ).....	1
Repopulation of the Irradiation Damaged Lung with Bone Marrow-derived Cells. M.E. BERNARD, H. KIM, M.S. RAJAGOPALAN, B. STONE, U. SALIMI, J.-C. RWIGEMA, M.W. EPPERLY, H. SHEN, J.P. GOFF, D. FRANICOLA, T. DIXON, S. CAO, X. ZHANG, H. WANG, D.B. STOLZ, J.S. GREENBERGER ( <i>Pittsburgh, PA, USA</i> ).....	9
Description of a New Xenograft Model of Metastatic Neuroblastoma Using NOD/SCID/ <i>Il2rg</i> Null (NSG) Mice. H. SARTELET, L. DURRIEU, F. FONTAINE, C. NYALENDO, É. HADDAD ( <i>Montréal, QC, Canada</i> ) .....	19
<i>In Vivo</i> MRI of Intraspinally Injected SPIO-labelled Human CD34+ Cells in a Transgenic Mouse Model of ALS. S. WILLENBROCK, S. KNIPPENBERG, M. MEIER, R. HASS, P. WEFSTAEDT, I. NOLTE, H. MURUA ESCOBAR, S. PETRI ( <i>Hannover, Germany</i> ).....	31
Gene Expression Changes Induced by HIPEC in a Murine Model of Gastric Cancer. L. GRAZIOSI, A. MENCARELLI, B. RENGA, C. SANTORELLI, F. CANTARELLA, W. BUGIANTELLA, E. CAVAZZONI, A. DONINI, S. FIORUCCI ( <i>Perugia, Italy</i> ).....	39
Ethanol Inhibits B16-BL6 Melanoma Metastasis and Cell Phenotypes Associated with Metastasis. K. KUSHIRO, N.P. NÚÑEZ ( <i>Austin, TX, USA</i> ) .....	47
<i>p53</i> Codon 72 Polymorphism in Oral Exfoliated Cells in a Sudanese Population. L. SAND, M.M. JALOULI, J. JALOULI, D. SAPKOTA, S.O. IBRAHIM ( <i>Uppsala, Sweden; Bergen, Norway</i> ) .....	59
Non-invasive Monitoring of Immunization Progress in Mice via IgG from Feces. J.J. CARVALHO, M.A. WALTER, Y. BAERMANN-STAPEL, M.G. WELLER, U. PANNE, J.A. SCHENK, R.J. SCHNEIDER ( <i>Berlin; Potsdam-Golm, Germany</i> ) .....	63
A Novel der(16)t(3;16)(p25;q24) in a Patient with Ovarian Cancer. K.-W. MIN, Y.-S. MOON, C.-H. CHO, H.-T. KIM ( <i>Daegu; Pohang, Gyungbuk, South Korea</i> ).....	71
Dexamethasone plus Octreotide Regimen Increases Anticancer Effects of Docetaxel on TRAMP-C1 Prostate Cancer Model. P. DALEZIS, G.D. GEROMICHALOS, D.T. TRAFALIS, N. PISSIMISSIS, D. PANAGIOTOPOULOU, G. GALAKTIDOU, E. PAPAGEORGIOU, A. PAPAGEORGIOU, Z. DAIFOTI, M. LYMPERI, M. KOUTSILIERIS ( <i>Athens; Thessaloniki, Greece</i> ) .....	75
Retinoid X Receptor Alpha (RXR $\alpha$ ) and Peroxisome Proliferator-activated Receptor Gamma (PPAR $\gamma$ ) Expression in Breast Cancer: An Immunohistochemical Study. N. DITSCH, T. VREKOUSSIS, M. LENHARD, I. RÜHL, J. GALLWAS, T. WEISSENBACHER, K. FRIESE, D. MAYR, A. MAKRIGIANNAKIS, U. JESCHKE ( <i>Munich, Germany; Heraklion, Greece</i> ).....	87

Comparative Analysis between Nasolabial and Island Pedicle Flaps in the Ala Nose Reconstruction. Prospective Study. C. MONARCA, M.I. RIZZO, A. PALMIERI, S. CHIUMMARIELLO, P. FINO, N. SCUDERI ( <i>Rome; Perugia, Italy</i> ).....	93
Suppression of Caco-2 and HEK-293 Cell Proliferation by <i>Kigelia africana</i> , <i>Mimusops zeyheri</i> and <i>Ximania caffra</i> Seed Oils. E. CHIVANDI, E. CAVE, B.C. DAVIDSON, K.H. ERLWANGER, D. MOYO, M.T. MADZIVA ( <i>Johannesburg, Republic of South Africa; Bonaire, Dutch Caribbean</i> ) .....	99
Dopamine: Effect of Concentration and pH on the Electron Emission. Reaction Mechanisms. N. GETOFF, E. BRENN, S. YING ( <i>Vienna, Austria</i> ) .....	107
DMBA Induces Deregulation of miRNA Expression of <i>let-7</i> , <i>miR-21</i> and <i>miR-146a</i> in CBA/CA Mice. K. JUHÁSZ, K. GOMBOS, M. SZIRMAI, P. RÉVÉSZ, I. MAGDA, K. GÓCZE, I. EMBER ( <i>Pécs, Hungary</i> ).....	113
KISS1/KISS1R Expression in Eutopic and Ectopic Endometrium of Women Suffering from Endometriosis. A. MAKRI, P. MSAOUEL, C. PETRAKI, D. MILINGOS, A. PROTOPAPAS, A. LIAPI, A. ANTSAKLIS, C. MAGKOU, M. KOUTSILIERIS ( <i>Athens, Greece</i> ) .....	119
Cytochrome c: Electron Emission, Photodegradation and Mutual Interaction with Vitamin C. N. GETOFF, G. WALDER ( <i>Vienna, Austria</i> ) .....	129
<i>Clinical Studies</i>	
Paneth Cells and Goblet Cells Express the Neuroendocrine Peptide Synaptophysin. I- Normal Duodenal Mucosa. C. RUBIO ( <i>Stockholm, Sweden</i> ).....	135
A Successful Combined Treatment with Dermal Substitutes and Products of Regenerative Medicine in a Patient Affected by Extravasation Injury from Hypertonic Solution. M.G. ONESTI, S. CARELLA, M. MARUCCIA, C. MARCHESE, P. FINO, N. SCUDERI ( <i>Rome, Italy</i> ).....	139
Skin Phototype and Local Trauma in the Onset of Balanitis Xerotica Obliterans (BXO) in Circumcised Patients. M. VILLA, E. DRAGONETTI, M. GRANDE, P. BOVE, S. SANSALONE, F. RULLI, R. TAMBUCCI, G. TUCCI, A. BALDI ( <i>Rome; Naples, Italy</i> ).....	143
Association of Vacuum-assisted Closure and Platelet Gel for the Definitive Surgical Repair of an Enterocutaneous Fistula: A Case Report. M. SCALA, F. SPAGNOLO, M. TRAPASSO, P. STRADA, L. MORESCO, P. SANTI ( <i>Genova, Italy</i> ) .....	147
Absence of Cytomegalovirus from the Gastrointestinal Tract of Patients with Active Crohn' s Disease. M.T. AARNIO, J.P. BÖHM, K.P. NUORVA, R.I. PITKÄNEN, T.H. KUOPIO, M.E. VOUTILAINEN ( <i>Jyväskylä, Finland</i> ).....	151
Feasibility of Conservative Medical Treatment for Pyoderma Gangrenosum. P. FIORAMONTI, M.G. ONESTI, P. FINO, S. DI RONZA, V. SORVILLO, P. PERSICHETTI ( <i>Rome, Italy</i> ).....	157
Oral Angioleiomyoma: A Rare Pathological Entity. D. MENDITTI, L. LAINO, L. NASTRI, U. CARUSO, P. FIORE, A. BALDI ( <i>Naples, Italy</i> ) .....	161
Potential Prevention of Thromboembolism by Genetic Counseling and Testing for Two Common Thrombophilia Mutations. C. YAPIJAKIS, T. ANTONIADI, K. SALAVOURA, C. VOUMVOURAKIS, E. VAIRAKTARIS ( <i>Athens, Greece; Bristol, UK</i> ) .....	165

A Rare Case of Postauricular Spontaneous Keloid in an Elderly Patient. C. MONARCA, M. MARUCCIA, F. PALUMBO, P. PARISI, N. SCUDERI ( <i>Rome, Italy</i> ) .....	173
--	-----

## Number 2

### Experimental Studies

Effects of Changes in Vertical Occlusal Dimension on Heart Rate Fluctuations in Guinea Pigs. H. TAGA, Y. AZUMA, K. MAEHARA, S. NOMURA ( <i>Niigata; Gifu; Saitama, Japan</i> ).....	177
Order-of-magnitude Estimates of Latency (Time to Appearance) and Refill Time of a Cancer from a Single Cancer ‘ Stem’ Cell Compared by an Exponential and a Logistic Equation. K.M. ANDERSON, M. RUBENSTEIN, P. GUINAN, M. PATEL ( <i>Chicago, IL, USA; Panchgani, Maharashtra, India</i> ).....	183
<i>In Vivo</i> Monitoring of Natural Killer Cell-dependent Clearance of Lung Metastasis Using Dynamic Positron Emission Tomography. C. KRUSCHINSKI, Y. HAMA, T. SKRIPULETZ, B. VASKE, W.H. KNAPP, R.E. SCHMIDT, R. PABST, S. VON HÖRSTEN, M. HOFMANN ( <i>Hannover; Erlangen, Germany</i> ).....	191
Black Tea Polyphenols Inhibit Tumor Proteasome Activity. T. MUJTABA, Q. PING DOU ( <i>Detroit, MI, USA</i> ) .....	197
Screening for Efflux Pump Systems of Bacteria by the New Acridine Orange Agar Method. A. MARTINS, L. AMARAL ( <i>Szeged, Hungary; Lisbon, Portugal; Brussels, Belgium</i> ).....	203
3,3’ -Diindolylmethane Increases Serum Interferon- $\gamma$ Levels in the K14-HPV16 Transgenic Mouse Model for Cervical Cancer. D.W. SEPKOVIC, L. RAUCCI, J. STEIN, A.D. CARLISLE, K. AUBORN, H.B. KSIESKI, T. NYIRENDA, H.L. BRADLOW ( <i>Hackensack, NJ; Manhasset, NY, USA</i> ) .....	207
Quantitative Effects of Diet on Fecal Corticosterone Metabolites in Two Strains of Laboratory Mice. O. KALLIOKOSKI, K.R. JACOBSEN, A.C. TEILMANN, J. HAU, K.S.P. ABELSON ( <i>Copenhagen, Denmark</i> ) .....	213
The Activity of 16 New Hydantoin Compounds on the Intrinsic and Overexpressed Efflux Pump System of <i>Staphylococcus aureus</i> . A. DYMEK, A. ARMADA, J. HANDZLIK, M. VIVEIROS, G. SPENGLER, J. MOLNAR, K. KIEĆ-KONONOWICZ, L. AMARAL ( <i>Krakow, Poland; Lisbon, Portugal; Brussels, Belgium; Szeged, Hungary</i> ) .....	223
* Review: Potential Therapy of Multidrug-resistant and Extremely Drug-resistant Tuberculosis with Thioridazine. L. AMARAL, J. MOLNAR ( <i>Lisbon, Portugal; Szeged, Hungary</i> ) .....	231
Comparative Transcriptional Profiling in HIV-Infected Patients Using Human Stress Arrays: Clues to Metabolic Syndrome. V. ESPOSITO, L. MANENTE, R. VIGLIETTI, G. PARRELLA, R. PARRELLA, M. GARGIULO, V. SANGIOVANNI, A. PERNA, A. BALDI, A. DE LUCA, A. CHIRIANNI ( <i>Naples, Italy</i> ) .....	237
Intercellular Adhesion Molecule (ICAM)-1 and Vascular Cell Adhesion Molecule (VCAM)-1 at the Early Stages of Atherosclerosis in a Rat Model. L. FOTIS, G. AGROGIANNIS, I.S. VLACHOS, A. PANTOPOULOU, A. MARGONI, M. KOSTAKI, C. VERIKOKOS, D. TZIVRAS, D.P. MIKHAILIDIS, D. PERREA ( <i>Athens, Greece; London, UK</i> ).....	243

Cartilage Defect Regeneration by <i>Ex Vivo</i> Engineered Autologous Microtissue – Preliminary Results. U. MEYER, H.-P. WIESMANN, J. LIBERA, R. DEPFRICH, C. NAUJOKS, J. HANDSCHEL (Düsseldorf; Dresden; Teltow, Germany) .....	251
Comparative Study of Biological Activity of Three Commercial Products of <i>Sasa senanensis</i> Rehder Leaf Extract. H. SAKAGAMI, S. IWAMOTO, T. MATSUTA, K. SATOH, C. SHIMADA, T. KANAMOTO, S. TERAKUBO, H. NAKASHIMA, Y. MORITA, A. OHKUBO, T. TSUDA, K. SUNAGA, M. KITAJIMA, H. OIZUMI, T. OIZUMI (Saitama; Tokyo; Kanagawa, Japan) .....	259
Induction of Non-apoptotic Cell Death by <i>Odontioda Marie Noel</i> ‘Velano’ Extracts in Human Oral Squamous Cell Carcinoma Cell Lines. Y. MASUDA, R. SUZUKI, H. SAKAGAMI, N. UMEMURA, J.-Y. UEDA, Y. SHIRATAKI (Saitama; Toyama, Japan) .....	265
Cardiovascular Prosthetic Surgery: An Analysis of Cellular and Molecular Patterns Underlying Valve Implantation Failure. G. MAZZARELLA, A. BIANCO, A. LUCARIELLO, L. SAVARESE, A. FIUMARELLA, F. CERASUOLO, F. FERRARACCIO, A. DE LUCA (Naples, Italy).....	271
Inhibition of Quorum Sensing and Efflux Pump System by Trifluoromethyl Ketone Proton Pump Inhibitors. Z.G. VARGA, A. ARMADA, P. CERCA, L. AMARAL, M.A.A. MIOR A. SUBKI, M.A. SAVKA, E. SZEGEDI, M. KAWASE, N. MOTOHASHI, J. MOLNÁR (Szeged; Kecskemét, Hungary; Rochester, NY, USA; Ehime; Tokyo, Japan).....	277
Suppression of Pre Adipocyte Differentiation and Promotion of Adipocyte Death by Anti-HIV Drugs. L. MANENTE, A. LUCARIELLO, C. COSTANZO, R. VIGLIETTI, G. PARRELLA, R. PARRELLA, M. GARGIULO, A. DE LUCA, A. CHIRIANNI, V. ESPOSITO (Naples, Italy).....	287
Activity of Fourteen New Hydantoin Compounds on the Human ABCB1 Efflux Pump. A. MARTINS, A. DYMEK, J. HANDZLIK, G. SPENGLER, A. ARMADA, J. MOLNAR, K. KII C-KONONOWICZ, L. AMARAL (Crakow, Poland; Szeged, Hungary; Lisbon, Portugal; Brussels, Belgium) .....	293
Differentiation of Human Osteoprogenitor Cells Increases after Treatment with Pulsed Electromagnetic Fields. M. ESPOSITO, A. LUCARIELLO, I. RICCIO, V. RICCIO, V. ESPOSITO, G. RICCARDI (Naples, Italy).....	299
Induction of Non-apoptotic Cell Death in Human Oral Squamous Cell Carcinoma Cell Lines by <i>Rhinacanthus nasutus</i> Extract. H. HORII, R. SUZUKI, H. SAKAGAMI, N. UMEMURA, J.-Y. UEDA, Y. SHIRATAKI (Saitama; Toyama Japan) .....	305

### Clinical Studies

Skin Metastasis in Patient with Hairy Cell Leukemia: Case Report and Review of Literature. P. FINO, P. FIORAMONTI, M.G. ONESTI, D. PASSARETTI, N. SCUDERI (Rome, Italy) .....	311
Sentinel Lymph Node Biopsy under Local Anaesthesia versus General Anaesthesia: Reliability and Cost-effectiveness Analysis in 153 Patients with Malignant Melanoma. P. COVARELLI, M. BADOLATO, G.M. TOMASSINI, V. POPONESI, C. LISTORTI, E. CASTELLANI, C. BOSELLI, G. NOYA (Perugia, Italy).....	315
Detecting Plasma Cell Precursors in Autoimmune Hepatitis. C.A. RUBIO (Stockholm, Sweden).....	319

Extensive Sublingual Epidermoid Cyst – Diagnosis by Immunohistological Analysis and Proof by Podoplanin. A.T. ASSAF, M. HEILAND, M. BLESSMANN, R.E. FRIEDRICH, J. ZUSTIN, A. AL-DAM (Hamburg, Germany) .....	323
Association of Adiponectin and Placental Growth Factor in Amniotic Fluid with Second Trimester Fetal Growth. E. KALAMPOKAS, N. VRACHNIS, E. SAMOLI, D. RIZOS, Z. ILIODROMITI, S. SIFAKIS, T. KALAMPOKAS, N. VITORATOS, G. CREATSAS, D. BOTSIS (Athens; Heraklion, Greece) .....	327
Usefulness of History-taking in Non-specific Abdominal Pain: A Prospective Study of 1333 Patients with Acute Abdominal Pain in Finland. M. ESKELINEN, P. LIPPONEN (Kuopio, Finland).....	335
 <b>Number 3</b>	
<i>Experimental Studies</i>	
Ionizing Irradiation Protection and Mitigation of Murine Cells by Carbamazepine is p53 and Autophagy Independent. H. KIM, M.E. BERNARD, A. FARKAS, J. GOFF, R. KALASH, F. HOUGHTON, D. SHIELDS, D. FRANICOLA, T. DIXON, X. ZHANG, M. EPPERLY, H. WANG, M.C. COBANOGLU, J.S. GREENBERGER (Pittsburgh; Erie, PA, USA).....	341
Effects of Culture Supernatant from <i>Lactobacillus pentosus</i> Strain SPT84 on Autonomic Nerve Activity in Rats. Y. BEPPU, T. IZUMO, Y. HORII, J. SHEN, Y. FUJISAKI, T. NAKASHIMA, N. TSURUOKA, K. NAGAI (Osaka; Kyoto, Japan).....	355
Human Chorionic Gonadotropin Inhibits N-Methyl-N-nitrosourea-induced Mammary Carcinoma Growth in Female Lewis Rats. T. YURI, Y.-C. LAI, K. YOSHIZAWA, A. TSUBURA (Osaka, Japan) .....	361
<i>In Vitro</i> Effects of Doxycycline on Inflammatory Cytokines and Gelatinases in Chronic Rhinosinusitis. J.U. SOMMER, J.D. SCHULTZ, J. GROSSBAIER, J. STERN-STRAETER, K. HÖRMANN, A. SAUTER (Mannheim, Germany) .....	369
Canine Malignant Mammary Gland Neoplasms with Advanced Clinical Staging Treated with Carboplatin and Cyclooxygenase Inhibitors. G.E. LAVALLE, C.B. DE CAMPOS, A.C. BERTAGNOLLI, G.D. CASSALI (Belo Horizonte, MG; Eldorado do Sul, RS, Brazil) .....	375
* Review: The Role of Nonsteroidal Antiinflammatory Drugs and Cyclooxygenase-2 Inhibitors on Experimental Colitis. A.P. RIBEIRO PAIOTTI, P. MARCHI, S.J. MISZPUTEN, C.T. FUJIYAMA OSHIMA, M. FRANCO, D.A. RIBEIRO (São Paulo, SP, Brazil).....	381
* Review: Oxidative Stress-mediated Biomolecular Damage and Inflammation in Tumorigenesis. F. SESTI, O.E. TSITSILONIS, A. KOTSINAS, I.P. TROUGAKOS (Athens, Greece).....	395
The Cytotoxic Protein Can Induce Autophagocytosis in Addition to Apoptosis in MCF-7 Human Breast Cancer Cells. G.-T. YANG, Y.-L. YU, P.-L. CHOU, H.-F. TSAI, L.-A. CHEN, Y.H. CHEN, K.-J. SU, J.-J. WANG, D.-T. BAU, C.-W. WEI (Hualien; New Taipei City; Taichung; Taipei, Taiwan, ROC; Atlanta, GA, USA) .....	403



Biological Activity of SE-10, Granulated Powder of <i>Sasa senanensis</i> Rehder Leaf Extract. H. SAKAGAMI, T. MATSUTA, K. SATOH, S. OHTSUKI, C. SHIMADA, T. KANAMOTO, S. TERAKUBO, H. NAKASHIMA, Y. MORITA, A. OHKUBO, T. TSUDA, K. SUNAGA, J. MAKI, T. SUGIURA, M. KITAJIMA, H. OIZUMI, T. OIZUMI ( <i>Saitama; Tokyo; Kanagawa; Matsuyama, Japan</i> ) .....	411
Efficacy of a Proapoptotic Peptide towards Cancer Cells. C.E. JÄKEL, K. MESCHENMOSER, Y. KIM, H. WEIHER, I.G.H. SCHMIDT-WOLF ( <i>Rheinbach; Bonn, Germany</i> ) .....	419
Retinal and Renal Vascular Permeability Changes Caused by Stem Cell Stimulation in Alloxan-induced Diabetic Rats, Measured by Extravasation of Fluorescein. Z. DOCZI-KERESZTESI, J. JUNG, I. KISS, T. MEZEI, L. SZABO, I. EMBER ( <i>Targu Mures, Romania; P1 cs; Eger, Hungary</i> ) .....	427
Evaluation of Genotoxicity and Subclinical Toxicity of <i>Agaricus blazei</i> Murrill in the Ames Test and in Histopathological and Biochemical Analysis. J.-B. CHANG, H.-F. LU, N.-C. LIAO, C.-S. LEE, M.-Y. YEH, C.-M. LIU, M.-T. CHUNG, A. MAN-KUAN, J.-J. LIN, M.-F. WU, J.-G. CHUNG ( <i>Taipei; Hsinchu; New Taipei; Taichung, Taiwan, ROC</i> ) .....	437
Venous Graft for Reconstruction of Neoplastic and Post-traumatic Eyelid Defects. G.M. TOMASSINI, V. ANSIDEI, A.L. RICCI, C. CAGINI, F. CENCETTI, S. SIMONETTI, P. COVARELLI ( <i>Perugia, Italy</i> ) .....	447
<i>Clinical Studies</i>	
Nasolabial Cyst: Case Report with Respect to Immunohistochemical Findings. R.E. FRIEDRICH, H.A. SCHEUER, A.T. ASSAF, J. ZUSTIN ( <i>Hamburg, Germany</i> ) .....	453
Angiomyolipomatous Hamartoma of the Inguinal Lymph Node – Report of Two Cases and Literature Review. T. DŽOMBETA, M. FRANČINA, K. MATKOVIĆ, I. MARKOVIĆ, Z. JUKIĆ, C. LEŽ, B. KRUXLIN ( <i>Zagreb; Nova Gradixka; Zabok, Croatia</i> ) .....	459
Local Tolerance of a Sublingual Nicotine Tablet, an Open Single-centre Study. L. SAND, A.-K. LEKERUD, M. WALLSTRÖM, J.M. HIRSCH ( <i>Uppsala; Gothenburg, Sweden</i> ) .....	463
An Antibiotic Care Bundle Approach Based on Results of Rapid Molecular Screening for Nasal Carriage of Methicillin-resistant <i>Staphylococcus aureus</i> in the Intensive Care Unit. P. STANO, M. AVOLIO, R. DE ROSA, M.L. MODOLO, S.M.M. BASSO, F. LUMACHI, A. CAMPORESE ( <i>Pordenone; Padova, Italy</i> ) .....	469
Heterogeneity of DNA Ploidy in Endometrial Carcinoma: Comparison of Different Tissue Samples Obtained during Diagnosis and Treatment. P. LIBALOVA, Z. VERNEROVA, L. HUBICKOVA-HERINGOVA, D. PINTEROVA, K. KOLOSTOVA, V. BOBEK, K. TIKOVSKY, D. HOUSA, M. KUBECOVA, L. PECEN, B. SVOBODA ( <i>Prague, Czech Republic; Dyfed, UK</i> ) .....	473
Influence of Gender on Mortality and Need for Extracorporeal Membrane Oxygenation in Neonates with Congenital Diaphragmatic Hernia. S. BERLIT, A. HORNE MANN, T. SCHAI BLE, W. NEFF, R. SCHAFFELDER, J. SIEMER, M. SÜTTERLIN, S. KEHL ( <i>Mannheim, Germany</i> ) .....	481

**Number 4**

\* Review: *In Vivo* Models for Defining Molecular Subtypes of the Primitive Neuroectodermal Tumor Genome: Current Challenges and Solutions. J.D. LARSON, D.A. LARGAESPADA (Minneapolis, MN, USA)..... 487

Amino Acid Chloramine Damage to Proliferating Cell Nuclear Antigen in Mammalian Cells. S.A. SALAMA, R.M. SNAPKA (Columbus, OH, USA; Cairo, Egypt) ..... 501

\* Review: The Effect of Insulin-like Growth Factor II in the Regulation of Tumour Cell Growth *In Vitro* and Tumourigenesis *In Vivo*. M. HALJE, M. NORDIN, D. BERGMAN, W. ENGSTRÖM (Uppsala, Sweden) ..... 519

\* Review: Exploring Anticarcinogenic Agents in a Rat Hepatocarcinogenesis Model – Focus on Selenium and Statins. L. BJÖRKHEM-BERGMAN, L. EKSTRÖM, L.C. ERIKSSON (Stockholm, Sweden) ..... 527

A Comprehensive Procedural Approach to Genotyping *KRAS* and *BRAF* from Paraffin Embedded Tissues for Diagnostic Purposes. R. PALMIROTTA, G. LUDOVICI, M.L. DE MARCHIS, B. LEONE, V. FORMICA, G.M. ETTORRE, F. CAVALIERE, D. DELLA-MORTE, P. FERRONI, M. ROSELLI, F. GUADAGNI (Rome, Italy; Miami, FL, USA) ..... 537

Selenite Enhances and Prolongs the Efficacy of Cisplatin Treatment of Human Ovarian Tumor Xenografts. P.B. CAFFREY, G.D. FRENKEL (California, PA; Newark, NJ, USA) ..... 549

Expanded Effector Memory T-lymphocytes in DBA/2 Mice Do Not Inhibit the Growth of SL2 Tumours. J. JURŠĚNAITĚ, I. GIRKONTAITĚ, M. MAURICAS, R. EIDUKEVIČIUS, D. CHARACIEJUS (Vilnius, Lithuania) ..... 553

Experimental Murine Model of Primary High Grade Undifferentiated Pleomorphic Sarcoma Not Otherwise Specified. D.J. TILKORN, I. STRICKER, J. HAUSER, A. RING, I. SCHMITZ, L. STEINSTRÄESSER, H.-U. STEINAU, A. DAIGELER, S. AL-BENNA (Bochum, North Rhine-Westphalia, Germany) ..... 559

Tumor-educated Macrophages Promote Tumor Growth and Peritoneal Metastasis in an Orthotopic Nude Mouse Model of Human Pancreatic Cancer. R.S. MENEN, M.K. HASSANEIN, M. MOMIYAMA, A. SUETSUGU, A.R. MOOSSA, R.M. HOFFMAN, M. BOUVET (San Diego; San Francisco, East Bay, CA, USA; Yokohama; Gifu, Japan) ..... 565

Urokinase Plasminogen Activator, uPAR, MMP-2, and MMP-9 in the C6-Glioblastoma Rat Model. P.J. SCHULER, M. BENDSZUS, S. KUEHNEL, S. WAGNER, T.K. HOFFMANN, R. GOLDBRUNNER, G.H. VINCE (Essen; Heidelberg; Würzburg; Göttingen; Cologne, Germany) ..... 571

The Effect of Automated Blood Sampling on Corticosterone Levels, Body Weight and Daily Food Intake in Permanently Catheterized Male BALB/c Mice. A.C. TEILMANN, K.R. JACOBSEN, O. KALLIOKOSKI, A.K. HANSEN, J. HAU, K.S.P. ABELSON (Copenhagen; Frederiksberg, Denmark)..... 577

Positron-emission Tomography (PET) Imaging Agents for Diagnosis of Human Prostate Cancer: Agonist vs. Antagonist Ligands. P.K. NANDA, B.E. WIENHOFF, T.L. ROLD, G.L. SIECKMAN, A.F. SZCZODROSKI, T.J. HOFFMAN, B.E. ROGERS, C.J. SMITH (Columbia; St. Louis, MO, USA)..... 583

The Challenge of Tumor Heterogeneity – Different Phenotypes of Cancer Stem Cells in a Head and Neck Squamous Cell Carcinoma Xenograft Mouse Model. C. GEIBLER, M. HAMBEK, M. LEINUNG, M. DIENSTHUBER, D. GASSNER, T. STÖVER, J. WAGENBLAST ( <i>Frankfurt am Main, Germany</i> ) .....	593
* Review: Fluorescent Protein-based Tumor Models. V. YAGUBLU, Z. AHMADOVA, M. HAFNER, M. KEESE ( <i>Mannheim; Heidelberg; Frankfurt, Germany; Baku, Azerbaijan</i> ) .....	599
Antitumor Protection by NGcGM3/VSSP Vaccine Against Transfected B16 Mouse Melanoma Cells Overexpressing N-Glycolylated Gangliosides. V.I. SEGATORI, L.L. OTERO, L.E. FERNANDEZ, D.E. GOMEZ, D.F. ALONSO, M.R. GABRI ( <i>Bernal, Buenos Aires, Argentina; Havana, Cuba</i> ).....	609
Imaging EGFR Phosphorylation in Intact Human Pancreatic Carcinoma Cells. R. MAGDEBURG, M. KESSLER, R. BOENNINGHOFF, M. KEESE ( <i>Mannheim; Frankfurt, Germany</i> ) .....	619
* Review: Mouse Models of Inflammatory Bowel Disease - Insights into the Mechanisms of Inflammation-associated Colorectal Cancer. D. MLADENOVA, M.R.J. KOHONEN-CORISH ( <i>Sydney, NSW, Australia</i> ) .....	627
* Review: <i>In Vivo</i> Models for Measuring Placental Glutathione-S-transferase (GST-P 7-7) Levels: A Suitable Biomarker for Understanding Cancer Pathogenesis. J. NOGUTI, L.F. BARBISAN, A. CESAR, C.D. SEABRA, R.B. CHOUERI, D.A. RIBEIRO ( <i>Sao Paulo, Brazil</i> ).....	647
Protection Against Copper-induced Cytotoxicity by Inclusion of Gold. T. YAMAZAKI, M. KOBAYASHI, K. HIRANO, H. ONUKI, J. SHIMADA, A. YAMAZAKI, Y. HIBINO, H. NAKAJIMA, Y. YOKOTE, S. TAKEMOTO, Y. ODA, H. SAKAGAMI ( <i>Saitama; Chiba, Japan</i> ) .....	651
Effect of Three Fluoride Compounds on the Growth of Oral Normal and Tumor Cells. A. MENA ACRA, H. SAKAGAMI, T. MATSUTA, K. ADACHI, S. OTSUKI, H. NAKAJIMA, T. KOH, M. MACHINO, T. OGIHARA, K. WATANABE, S. WATANABE, A. VISOSO SALGADO, N.M. MONTIEL BASTIDA ( <i>Saitama, Japan; Toluca, State of Mexico, Mexico</i> ).....	657
Chrysin, a Natural and Biologically Active Flavonoid, Influences a Murine Leukemia Model <i>In Vivo</i> through Enhancing Populations of T-and B-Cells, and Promoting Macrophage Phagocytosis and NK Cell Cytotoxicity. C.-C. LIN, C.-S. YU, J.-S. YANG, C.-C. LU, J.-H. CHIANG, J.-P. LIN, C.-L. KUO, J.-G. CHUNG ( <i>Taichung, Taiwan, ROC</i> ).....	665
Sorafenib Inhibits TPA-Induced MMP-9 and VEGF Expression via Suppression of ERK/NF-κB Pathway in Hepatocellular Carcinoma Cells. I.-T. CHIANG, Y.-C. LIU, W.-H. WANG, F.-T. HSU, H.-W. CHEN, W.-J. LIN, W.-Y. CHANG, J.-J. HWANG ( <i>Taipei; Yilan; Changhua; Taoyuan, Taiwan, ROC</i> ).....	671
Immediately Preoperative Use of Biological Therapy Does not Influence Liver Regeneration after Large Resection - Porcine Experimental Model with Monoclonal Antibody against Epidermal Growth Factor. V. LISKA, V. TRESKA, H. MIRKA, J. BENES, O. VYCITAL, J. BRUHA, P. PITULE, T. SKALICKY, A. SUTNAR, A. CHLUMSKA, J. RACEK, L. TREFIL, J. FINEK, L. HOLUBEC ( <i>Pilsen, Czech Republic</i> ).....	683
Metallothionein Colon Crypt Immuno-positivity as a Rapid <i>In Vivo</i> Essay for Drug Efficacy Studies. F. MORI, C. DELLA ROCCA, D. LAZZARO ( <i>Rome, Italy</i> ) .....	693



Bone Healing Effects of Diode Laser (808 nm) on a Rat Tibial Fracture Model. J. SON, Y.-B. KIM, Z. GE, S.-H. CHOI, G. KIM ( <i>Chungbuk, South Korea; Beijing, PR China</i> ).....	703
CXCR4/SDF-1 $\alpha$ -mediated Chemotaxis in an <i>In Vivo</i> Model of Metastatic Esophageal Carcinoma. S.J. GROS, H. GRAEFF, A. DRENCKHAN, N. KURSCHAT, M. BLESSMANN, T. RAWNAQ, J.R. IZBICKI ( <i>Hamburg, Germany</i> ) .....	711
Changes of Blood Fluidity in the Early Hepatopathy in Rats. S. ISHIKAWA, T. ISHIKAWA, K. ASANO, T. ANZAI, T. NAKANISHI-UEDA, M. SUNAGAWA, T. MOROBOSHI, T. HISAMITSU ( <i>Tokyo; Kanagawa, Japan</i> ) .....	719
* Review: BBN as an Urothelial Carcinogen. C. VASCONCELOS-N $\text{\AA}$ BREGA, A. COLAHO, C. LOPES, P. A. OLIVEIRA ( <i>Vise; Vila Real; Oporto, Portugal</i> ).....	727
Errata .....	741

## Number 5

### *Experimental Studies*

Analysis of Minocycline as a Countermeasure Against Acute Radiation Syndrome. S. MEHROTRA, M. J. PECAUT and D.S. GRIDLEY ( <i>Loma Linda, CA, USA</i> ).....	743
Effects of Curcumin and Capsaicin Irradiated with Visible Light on Murine Oral Mucosa. N. OKADA, E. MURAOKA, S. FUJISAWA and M. MACHINO ( <i>Sakado, Japan</i> ) .....	759
A Comparative Study of Phytoestrogen Action in Mitigating Apoptosis Induced by Oxidative Stress. A.J. ONDRICEK, A.K. KASHYAP, S.I. THAMAKE and J.K. VISHWANATHA ( <i>Dallas; Fort Worth, TX, USA</i> ) ....	765
* Review: Chios Mastic Gum: A Plant-produced Resin Exhibiting Numerous Diverse Pharmaceutical and Biomedical Properties. K.S. DIMAS, P. PANTAZIS and R. RAMANUJAM ( <i>Larissa, Greece; Columbus, OH, USA</i> ) .....	777
Spontaneous Mutant ICR Kuru2 Might Be Another Shaker-2 Deaf Mouse. M. WATANABE, N. AKIYAMA, Y. MANOME, N. HASEGAWA ( <i>Yokohama; Tokyo, Japan</i> ) .....	787
Effects of Antibodies to EG-VEGF on Angiogenesis in the Chick Embryo Chorioallantoic Membrane. S. FEFLEA, A.M. CIMPEAN, R.A. CEASU, P. GAJE and M. RAICA ( <i>Timis, Romania</i> ) .....	793
* Review: Impact of Mediators Present in Amniotic Fluid on Preterm Labour. N. VRACHNIS, S. KARAVOLOS, Z. ILIODROMITI, S. SIFAKIS, C. SIRISTATIDIS, G. MASTORAKOS and G. CREATSAS ( <i>Athens; Heraklion, Greece; Gateshead, United Kingdom</i> ) .....	799
Influence of Maternal Smoking during Pregnancy on Oxidant Status in Amniotic Fluid. R. DITTRICH, A. SCHIBEL, I. HOFFMANN, A. MUELLER, M.W. BECKMANN and S. CUPISTI ( <i>Erlangen, Germany</i> ) .....	813
New Findings Concerning the Mutual Action of Hormones and Receptors. N. GETOFF and M. STEINBRECHER ( <i>Vienna, Austria</i> ) .....	819
Comparison of Nine Media in the Culture of Human Ovarian Granulosa Lutein Cells. G. BOURAKI, C. METALLINO, M. SIMOPOULOU, K. CHARALABOPOULOS and B. ASIMAKOPOULOS ( <i>Alexandroupolis, Greece</i> ) .....	823

Doxorubicin Induces Early Embryo Apoptosis by Inhibiting Poly(ADP ribose) Polymerase. Q.-L. WANG, S.-C. SUN, J. HAN, Y.-C. KWAK, N.-H. KIM and X.-S. CUI ( <i>Cheongju, South Korea</i> ) .....	827
The Effects of Cetrorelix and Triptorelin on the Viability and Steroidogenesis of Cultured Human Granulosa Luteinized Cells. C. METALLINO, F. KÖSTER, K. DIEDRICH, N. NIKOLETTOS and B. ASIMAKOPOULOS ( <i>Alexandroupolis, Greece; Lübeck, Germany</i> ) .....	835
<i>Clinical Studies</i>	
Treatment of Sleep Apnoea Using a Mandibular Advancement Splint – An Open Prospective Study. A.-K. LEKERUD, L. SAND, A.-K. ENGLUND and J.M. HIRSCH ( <i>Uppsala, Sweden</i> ) .....	841
An Odontogenic Keratocystic Tumor in the Buccal Space: An Unusual Site of Origin and a Review of the Literature. A. GRÖBE, H. HANKEN, M. BLESSMANN, J. ZUSTIN, M. HEILAND and A. AL-DAM ( <i>Hamburg, Germany</i> ) .....	847
Obesity Effects on Cyclophosphamide-induced DNA Damage in Hematopoietic Cell Transplant Recipients. L. A. JOHNSON, N. TRETYAKOVA and P. A. JACOBSON ( <i>Minneapolis, MN, USA</i> ) .....	853
An Easy Method to Quantify Plasma Cells in Celiac Disease. C.A. RUBIO, D. BUHRKHUL, M. PERDIKI and M. IDESTRÖM ( <i>Stockholm, Sweden</i> ) .....	859
Comparing Bioelectrical Impedance Values in Assessing Early Upper Limb Lymphedema after Breast Cancer Surgery. S. BERLIT, J. BRADE, B. TUSCHY, A. HORNEMANN, H. LEWELING, V. EGHARDT and M. SÜTTERLIN ( <i>Mannheim, Germany</i> ) .....	863
The Impact of Ultrasound Contrast Medium Administration on the Right Ventricle in Patients with Heart Failure. D. BRAMOS, A. KALADARIDOU, E. SKALTSIOTIS, C. TRIKA, D. TAKOS, C. PAMBOUCAS, G. KOTTIS and S. TOUMANIDIS ( <i>Athens, Greece</i> ) .....	869

## Number 6

### *Experimental Studies*

Proteomic Profiling to Identify Prognostic Biomarkers in Heart Failure. P.A. SCOTT, B. ZEIDAN, L.L. NG, M. ZEB, J.A. ROSENGARTEN, S. GARBIS, N.P. CURZEN, J.M. MORGAN, P.A. TOWNSEND ( <i>Southampton; Leicester, UK; Athens, Greece</i> ) .....	875
Acclimatization of Mice to Different Cage Types and Social Groupings with Respect to Fecal Secretion of IgA and Corticosterone Metabolites. C.J. BUNDGAARD, O. KALLIOKOSKI, K.S. ABELSON, J. HAU ( <i>Copenhagen, Denmark</i> ) .....	883
The Zebrafish- <i>Danio rerio</i> – Is a Useful Model for Measuring the Effects of Small-molecule Mitigators of Late Effects of Ionizing Irradiation. M.W. EPPERLY, N. BAHARY, M. QUADER, V. DEWALD, J.S. GREENBERGER ( <i>Pittsburgh, PA, USA</i> ) .....	889
Sequential Changes in the Expression of Wnt- and Notch-related Genes in the Vagina and Uterus of Ovariectomized Mice after Estrogen Exposure. T. NAKAMURA, S. MIYAGAWA, Y. KATSU, T. SATO, T. IGUCHI, Y. OHTA ( <i>Yamagata; Okazaki; Sapporo; Yokohama; Tottori, Japan</i> ) .....	899
Inhibition of Biofilm Formation on Ventilation Tubes by Surface Modification. J.-J. SONG, I. NOH, S.-W. CHAE ( <i>Goyang; Seoul, South Korea</i> ) .....	907

Accumulation and Pharmacokinetics of Estrogenic Chemicals in the Pre- and Post-hatch Embryos of the Frog <i>Rana rugosa</i> . M. TAKASE, H. SHINTO, Y. TAKAO, T. IGUCHI ( <i>Higashi-Hiroshima; Nagasaki; Okazaki, Japan</i> ) .....	913
Histology, Bioenergetics and Oxidative Stress in Mouse Liver Exposed to <i>N</i> -Diethylnitrosamine. N.P. SANTOS, I.C. PEREIRA, M.J. PIRES, C. LOPES, R. ANDRADE, M.M. OLIVEIRA, A. COLAÇO, F. PEIXOTO, P.A. OLIVEIRA ( <i>Vila Real; Porto, Portugal</i> ) .....	921
Palliative Intralesional Interleukin-2 Treatment in Dogs with Urinary Bladder and Urethral Carcinomas. U. KONIETSCHKE, E. TESKE, K. JURINA, C. STOCKHAUS ( <i>Haar, Germany; Utrecht, The Netherlands</i> ) .....	931
No Compensation in VEGF Expression Follows Antisense Suppression of BCL-2 Activity. M. RUBENSTEIN, C.M.P. HOLLOWELL, P. GUINAN ( <i>Chicago, IL, USA</i> ).....	937
Comparative Inhibitory Effects of Magnolol, Honokiol, Eugenol and <i>bis</i> -Eugenol on Cyclooxygenase-2 Expression and Nuclear Factor Kappa B Activation in RAW264.7 Macrophage-like Cells Stimulated with Fimbriae of <i>Porphyromonas gingivalis</i> . Y. MURAKAMI, A. KAWATA, Y. SEKI, T. KOH, K. YUHARA, T. MARUYAMA, M. MACHINO, S. ITO, Y. KADOMA, S. FUJISAWA ( <i>Sakado-City; Tokyo, Japan</i> ).....	941
Variations in the Expression and Distribution Pattern of AQP5 in Acinar Cells of Patients with Sialadenosis. A. TEYMOORTASH, S. WIEGAND, M. BORKELOH, M. BETTE, A. RAMASWAMY, S. STEINBACH-HUNDT, A. NEFF, J.A. WERNER, R. MANDIC ( <i>Marburg, Germany</i> ).....	951
Pilot Clinical Study of <i>Sasa senanensis</i> Rehder Leaf Extract Treatment on Lichenoid Dysplasia. T. MATSUTA, H. SAKAGAMI, S. TANAKA, M. MACHINO, M. TOMOMURA, A. TOMOMURA, T. YASUI, K. ITOH, T. SUGIURA, M. KITAJIMA, H. OIZUMI, T. OIZUMI ( <i>Saitama; Tokyo; Kanagawa, Japan</i> ) .....	957
Amentoflavone Induces Cell-cycle Arrest and Apoptosis in MCF-7 Human Breast Cancer Cells via Mitochondria-dependent Pathway. J.-S. PEI, C.-C. LIU, Y.-N. HSU, L.-L. LIN, S.-C. WANG, J.-G. CHUNG, D.-T. BAU, S.-S. LIN ( <i>TaoYuan; Taichung, Taiwan, ROC</i> ).....	963
Chlorogenic Acid Induces Apoptotic Cell Death in U937 Leukemia Cells through Caspase and Mitochondria-dependent Pathways. J.-S. YANG, C.-W. LIU, Y.-S. MA, S.-W. WENG, N.-Y. TANG, S.-H. WU, B.-C. JI, C.-Y. MA, Y.-C. KO, S. FUNAYAMA, C.-L. KUO ( <i>Taichung; Changhua; Taipei; Chiayi, Taiwan, ROC; Saitama, Japan</i> ) .....	971
Detection of Invasive Fungal Pathogens by Real-time PCR and High-resolution Melting Analysis. F. SOMOGYVARI, A. HORVATH, J. SERLY, H. MAJOROS, C. VAGVOLGYI, Z. PETO ( <i>Szeged, Hungary</i> ).....	979
Immunohistological Characterization of Thymic Dendritic Cells. A. PAPOUDOU-BAI, M. BAI, M. DOUKAS, K. STEFANAKI, P. SPYRIDONOS, G. KARATZIAS, A. BARBOUTI, V. GALANI, P. KANAVAROS ( <i>Ioannina; Athens, Greece</i> ) .....	985
In Search of New Biological Activities of Isolates from <i>Odontoglossum Harvengtense</i> ‘Tutu’ . R. SUZUKI, T. TANAKA, M. YAMAMOTO, H. SAKAGAMI, M. TOMOMURA, A. TOMOMURA, K. SATOH, Y. SHIRATAKI ( <i>Sakado; Tokyo, Japan</i> ).....	993
Oral Carcinogenesis Is not Achieved in Different Carcinogen-treated PAI-1 Transgenic and Wild-type Mouse Models. D. AVGOUSTIDIS, T. NISYRIOS, E. NKENKE, R. LIJNEN, V. RAGOS, D. PERREA, I. DONTA, A. VAENA, C. YAPIJAKIS, E. VAIRAKTARIS ( <i>Athens, Greece; Erlangen, Germany; Leuven, Belgium</i> ).....	1001

Anti-UV/HIV Activity of Kampo Medicines and Constituent Plant Extracts. T. KATO, N. HORIE, T. MATSUTA, U. NAOKI, T. SHIMOYAMA, T. KANEKO, T. KANAMOTO, S. TERAOKUBO, H. NAKASHIMA, K. KUSAMA, H. SAKAGAMI ( <i>Moroyama; Sakado; Tokyo; Kawasaki, Japan</i> ) .....	1007
Pilot Study of Changes in Salivary Metabolic Profiles Induced by Template Therapy. S. TANAKA, H. TAGA, K. MAEHARA, A. KANESHIMA, M. MACHINO, H. ONUMA, M. KANEKO, H. SAKAGAMI, M. SUGIMOTO, T. SOGA, M. TOMITA ( <i>Sakado; Tokyo; Yamagata; Kyoto, Japan</i> ) .....	1015
<i>Clinical Studies</i>	
Factors Involved in Sudden Coagulation Observed in Patients with Acute Myocardial Infarction. A. PINELLI, S. TRIVULZIO, G. ROSSONI, R. REDAELLI, S. BRENNI ( <i>Milan, Italy</i> ) .....	1021
Evaluation of Aortic Valve Stenosis Using a Hybrid Approach of Doppler Echocardiography and Inert Gas Rebreathing. K. HAMM, F. TRINKMANN, F. HEGGEMANN, J. GRUETTNER, G. SCHMID-BINDERT, M. BORGGREFE, D. HAGHI, J. SAUR ( <i>Mannheim, Germany</i> ) .....	1027
Cardiac Computed Tomographic Angiography in Patients with Acute Chest Pain and Moderately-increased Troponin. J. GRUETTNER, D. HAGHI, T. HENZLER, P. KRAUS, M. BORGGREFE, S.O. SCHOENBERG, C. FINK, T. WALTER ( <i>Mannheim, Germany</i> ) .....	1035
Relationship between Bone Formation Markers Bone Alkaline Phosphatase, Osteocalcin and Amino-terminal Propeptide of Type I Collagen and Bone Mineral Density in Elderly Men. Preliminary Results. F. LUMACHI, R. ORLANDO, F. FALLO, S.M.M. BASSO ( <i>Padova; Pordenone, Italy</i> ) .....	1041
An Unilateral Basal Bone Defect of the Mandible Occupied by Fatty Tissue: Stafne' s Cavity. R.E. FRIEDRICH, J. ZUSTIN, H.A. SCHEUER, A.T. ASSAF, A. GRÖBE ( <i>Hamburg, Germany</i> ) .....	1045
Incidentally Discovered Asymptomatic Splenic Hamartoma with Rapidly Expansive Growth: A Case Report. S.M.M. BASSO, S. SULFARO, B. MARZANO, G. FANTI, G.B. CHIARA, F. LUMACHI ( <i>Pordenone; Padova, Italy</i> ) .....	1049
A Case of Hydroxyurea-induced Leg Ulcer after Definitive Treatment Suspension in a Patient Affected by Thrombocytopenia: Effectiveness of a New Collagenase. P. FIORAMONTI, P. FINO, P. PARISI, N. SCUDERI, M.G. ONESTI ( <i>Rome, Italy</i> ) .....	1053
Predictive Role of Thymidine Phosphorylase Expression in Patients with Colorectal Cancer and its Association with Angiogenesis-related Proteins and Extracellular Matrix Components. A. MITSELOU, E. IOACHIM, U. SKOUFI, C. TSIRONIS, K.E. TSIMOGIANNIS, C. SKOUFI, T. VOUGIOUKLAKIS, E. BRIASOULIS ( <i>Ioannina, Greece</i> ) .....	1057
Influence of Overweight in Elderly Patients Undergoing Vaginal Surgery Due to Pelvic Floor Disorders. B. TUSCHY, S. BERLIT, S. KEHL, M. SÜTTERLIN, S. BUSSEN ( <i>Mannheim, Germany</i> ) .....	1069
Ropivacaine versus Levobupivacaine for Minor Breast Surgery in Outpatients: Inversion of Postoperative Pain Relief Efficacy. A.Z. MANFÈ, M. MARCHESINI, A. BORTOLATO, P. FELTRACCO, F. LUMACHI ( <i>Padova, Italy</i> ) .....	1075
Leptomeningeal Metastasis in Melanoma: a Prospective Clinical Study of Nine Patients. E. PAPE, E. DESMEDT, F. ZAÏRI, M.-C. BARANZELLI, V. DZIWNIEL, F. DUBOIS, J. BONNETERRE, L. MORTIER, E. LE RHUN ( <i>Lille; Villeneuve d' Ascq, France</i> ) .....	1079

Intraoral Lymphoepithelial Carcinoma of the Minor Salivary Glands. D. MENDITTI, L. LAINO, M. MILANO, C. CAPUTO, M. BOCCELLINO, A. D'AVINO, A. BALDI ( <i>Naples, Italy</i> ).....	1087
Subcutaneous Angioleiomyoma of the Nasal Tip Report of a Rare Case. M.G.ONESTI, M. MARUCCIA, S. CARELLA, A. ROSSI, G. SODA, N. SCUDERI ( <i>Rome, Italy</i> ) .....	1091
Prevalence of Thrombosis-related DNA Polymorphisms in a Healthy Greek Population. C. YAPIJAKIS, Z. SEREFOGLOU, A.M. NIXON, A. VYLLIOTIS, V. RAGOS, E. VAIRAKTARIS ( <i>Athens, Greece</i> ).....	1095
Anterior Lingual Mandibular Bone Depression in an 11-Year-old Child. R.E. FRIEDRICH, H.A. SCHEUER, A. GRÖBE ( <i>Hamburg, Germany</i> ).....	1103
Index 2012.....	1109
Reviews (pages 231, 381, 395, 487, 519, 527, 599, 627, 647, 727, 777, 799)	



## Subject Index

(Figures refer to page numbers)

- 3R concept, immunization monitoring, IgG, coproantibodies, feces, animal welfare, 63
- A2780 tumor cells, cisplatin, selenite, ovarian cancer, xenografts, 549
- ABCB1, hydantoin, Pg-P1, multidrug resistance, 293
- Abdominal pain, diagnosis, symptoms, history, 335
- Acclimatization, animal welfare, secretory IgA, housing conditions, mice, fecal corticosterone, social grouping, 883
- Accusampler, automated blood sampling, refinement, stress, corticosterone, food intake, body weight, BALB/c mice, 577
- Acinar gland, aquaporin 5, sialadenosis, salivary gland, 951
- Acridine orange (AO), multidrug resistance, Gram-negative and Gram positive bacteria, *Escherichia coli*, *Salmonella enterica* serovar Enteritidis, *Staphylococcus aureus*, agar method, evaluation of efflux pump activity, 203
- ACTH, stress, dietary fat, C57bl/6, BALB/c mice, fetal corticosterone, 213
- Activated macrophages, *Odontoglossum Harvengtense* 'Tutu', cytotoxicity, osteoclastogenesis, 993
- Acute coronary syndrome, chest pain, coronary computed tomography angiography, emergency department, risk stratification, triple-rule-out, troponin, 1035
- Acute myocardial infarction (AMI), coronary artery diseases (CAD), unstable atherosclerotic plaque, matrix metalloproteinase-9 (MMP-9), neutrophil gelatinase-associated lipocalin (NGAL), prothrombin fragment (F1+2), antithrombin III, 1021
- Adipocyte differentiation, HAART, HIV infection, lipodystrophy, metabolic syndrome, oxidative stress, saquinavir, efavirenz, stavudine, antiretroviral therapies, 287
- Adipokines, amniotic fluid, human adiponectin, placental growth factor (PLGF), small for gestational age (SGA), appropriate for gestational age (AGA), large for gestational age (LGA), fetal growth, 327
- Ag(NH<sub>3</sub>)<sub>2</sub>F, sodium fluoride, 5-FU, cytotoxicity, tumor specificity, apoptosis, OSCC, T98G, U87MG, HL-60 cells, 657
- Agar method, multidrug resistance, Gram-negative and Gram positive bacteria, *Escherichia coli*, *Salmonella enterica* serovar Enteritidis, *Staphylococcus aureus*, acridine orange (AO), evaluation of efflux pump activity, 203
- Agaricus blazei* Murill, genotoxicity, subclinical toxicity, Ames test, histopathology, serum biomarker analysis, ALT, AST, 437
- Agonist, bombesin, antagonist, copper, microPET, 583
- AHL, quorum sensing, CV026, trifluoromethyl ketones, efflux pump, 277
- ALDH1A1, tumor stem cells, CSC, CD44, Ki 67, EGFR, xenograft mouse model, 593
- Alloxan, diabetic retinopathy, nephropathy, stem cell stimulation, experimental diabetes, FITC-BSA, Olimpqi Stem×Cell, 427
- ALS, *in vivo* imaging, cell transplantation, SPIO, umbilical cord blood stem cells, MRI, tracking, MTH53A cells, SOD1-ALS mouse, CD34<sup>+</sup>, 31
- ALT, *agaricus blazei* Murill, genotoxicity, subclinical toxicity, Ames test, histopathology, serum biomarker analysis, AST, 437
- Amentoflavone, cell-cycle arrest, apoptosis, breast cancer, MCF-7 cancer cells, mitochondria, 963
- Ames test, *agaricus blazei* Murill, genotoxicity, subclinical toxicity, histopathology, serum biomarker analysis, ALT, AST, 437
- Amino acid chloramines, inflammation, HOCl, protein damage, PCNA, 501
- Amniotic fluid, adipokines, human adiponectin, placental growth factor (PLGF), small for gestational age (SGA), appropriate for gestational age (AGA), large for gestational age (LGA), fetal growth, 327
- Amniotic fluid, mediators, immune regulation, preterm labour, cytokines, prostaglandins, leukotrienes, interleukins, cell adhesion molecules, review, 799
- Amniotic fluid, obstetrics, labor, fetal health, low-density lipoprotein, antioxidants, maternal smoking, 813
- Angiogenesis, EG-VEGF, chick embryo chorioallantoic membrane, targeting, 793
- Angioleiomyoma, vascular leiomyoma, subcutaneous tumor, nasal tumor, benign tumor, 1091
- Angiomyolipomatous hamartoma, inguinal, lymph node, case report, 459
- Animal model, <sup>18</sup>F-FDG-PET, lung metastasis, F344 rats, MADB 106 cells, NK cells, 191
- Animal welfare, acclimatization, secretory IgA, housing conditions, mice, fecal corticosterone, social grouping, 883
- Animal welfare, immunization monitoring, IgG, coproantibodies, feces, 3R concept, 63
- Antagonist, bombesin, agonist, copper, microPET, 583
- Anterior lingual mandibular bone depression, Stafne's cavity, sublingual gland, magnetic resonance imaging, ultrasound, cone beam computed tomography, 1103
- Anti-HIV, glycyrrhizin, Kampo medicine, UV protection, 1007
- Anti-HIV, *Sasa senanensis* Rehder, leaf extract, anti-UV, radical scavenging, CYP3A4 inhibition, Fe(II), lignin, 259
- Anti-HIV, *Sasa senanensis* Rehder, leaf extract, anti-UV, radical scavenging, CYP3A4 inhibition, ESR spectroscopy, MT-4, HSC-2, HPC, HGF cells, 411



- Antimicrobial peptides, (KLAKLAK)<sub>2</sub>, targeted tumor therapy, MDA-MB435S, T24, DU145, Tet21N, Wac2 cells, breast cancer xenografts, 419
- Antioxidant enzymes, *N*-Diethylnitrosamine (DEN), mice, liver, oxidative stress, 921
- Antioxidant therapy, radiation fibrosis, zebrafish, 889
- Antioxidants, obstetrics, labor, fetal health, low-density lipoprotein, maternal smoking, amniotic fluid, 813
- Antioxidants, phytoestrogens, oxidative stress, neuroprotection, neurodegenerative disease, glaucoma, RGC-5 cells, 765
- Antioxidative activity, magnolol, honokiol, eugenol, RAW264.7 cells, cytotoxicity, COX-2, NF- $\kappa$ B, orbital energy, 941
- Antiretroviral therapies, HAART, HIV infection, lipodystrophy, adipocyte differentiation, metabolic syndrome, oxidative stress, saquinavir, efavirenz, stavudine, 287
- Antiretroviral therapies, HAART, HIV infection, lipodystrophy, oxidative stress, metabolic syndrome, 237
- Antisense, bcl-2, prostate cancer, VEGF, 937
- Antithrombin III, acute myocardial infarction (AMI), coronary artery diseases (CAD), unstable atherosclerotic plaque, matrix metalloproteinase-9 (MMP-9), neutrophil gelatinase-associated lipocalin (NGAL), prothrombin fragment (F1+2), 1021
- Anti-UV, *Sasa senanensis* Rehder, leaf extract, anti-HIV, radical scavenging, CYP3A4 inhibition, Fe(II), lignin, 259
- Anti-UV, *Sasa senanensis* Rehder, leaf extract, anti-HIV, radical scavenging, CYP3A4 inhibition, ESR spectroscopy, MT-4, HSC-2, HPC, HGF cells, 411
- Aortic stenosis, severity graduation, echocardiography, Doppler, inert gas rebreathing, hybrid approach, 1027
- Apoptosis induction, *odontioda* Marie Noel 'Velano' extract, cytotoxicity, oral squamous cell carcinoma, HSC-2, HSC-3, HSC-4 cell lines, 265
- Apoptosis induction, *Rhinacanthus nasutus* extract, cytotoxicity, OSCC, HL-60, HSC-2, HSC-3, HSC-4 cells, 305
- Apoptosis, 15-lipoxygenase-1, gene therapy, glioma, lipid peroxidation, caspase-3, 1
- Apoptosis, amentoflavone, cell-cycle arrest, breast cancer, MCF-7 cancer cells, mitochondria, 963
- Apoptosis, chlorogenic acid, U937 leukemia cells, caspases, mitochondrial dysfunction, 971
- Apoptosis, doxorubicin, *PARP*, zygote, the early embryonic development, 827
- Apoptosis, MCF-7, phagocytosis, autophagy, 403
- Apoptosis, sodium fluoride, Ag(NH<sub>3</sub>)<sub>2</sub>F, 5-FU, cytotoxicity, tumor specificity, OSCC, T98G, U87MG, HL-60 cells, 657
- Appropriate for gestational age (AGA), adipokines, amniotic fluid, human adiponectin, placental growth factor (PLGF), small for gestational age (SGA), large for gestational age (LGA), fetal growth, 327
- Aquaporin 5, sialadenosis, salivary gland, acinar gland, 951
- Arp, black tea, theaflavins, proteasome, Opm1 multiple myeloma cells, 197
- Arrhythmias, implantable cardioverter defibrillators, heart failure, biomarkers, mortality, proteomics, SELDI-TOF MS, 875
- Aspergillus*, *Candida*, ITS, high-resolution melting (HRM), real-time PCR, 979
- AST, *Agaricus blazei* Murill, genotoxicity, subclinical toxicity, Ames test, histopathology, serum biomarker analysis, ALT, 437
- Atherosclerosis, vascular cell adhesion molecule, intercellular adhesion molecule, high-density lipoprotein cholesterol, vasa vasorum, 243
- Athymic mice, pleomorphic sarcoma NOS, xenograft model, soft tissue sarcoma, 559
- Au/Cu alloy, gingival fibroblast, cytotoxicity, oxidation, elution, HGF cells, 651
- Autoimmune hepatitis, liver, plasma cell precursors, *MUM1*, differential diagnosis, 319
- Autologous graft, eyelid, reconstructive surgery, surgical technique, venous graft, 447
- Automated blood sampling, Accusampler, refinement, stress, corticosterone, food intake, body weight, BALB/c mice, 577
- Autonomic nerve, *Lactobacillus pentosus* strain S-PT84, culture supernatant, brown adipose tissue, thermogenesis, rats, 355
- Autophagy, MCF-7, phagocytosis, apoptosis, 403
- Autophagy, radioprotection, radiation mitigation, *p53*, carbamazepine, murine hematopoietic progenitor cells, bone marrow stromal cells, Lewis lung carcinoma cells, 341
- B16-BL6, ethanol, Kiss1, melanoma metastasis, Snai1, E-cadherin, 47
- Balanitis, BXO, circumcision, phototype, phimosis, *Lichen sclerosus*, 143
- BALB/c mice, automated blood sampling, Accusampler, refinement, stress, corticosterone, food intake, body weight, 577
- BALB/c mice, stress, dietary fat, ACTH, C57bl/6, fetal corticosterone, 213
- Bcl-2, antisense, prostate cancer, VEGF, 937
- Benign tumor, vascular leiomyoma, angioleiomyoma, subcutaneous tumor, nasal tumor, 1091
- Biofilm, ventilation tube, PEG coating, streptococcus pneumoniae R6, 907
- Biological consequences, dopamine, electron emission, 107



- Biological therapy, epidermal growth factor, epidermal growth factor receptor, liver surgery, liver regeneration, porcine model, cetuximab, 683
- Biomarkers, implantable cardioverter defibrillators, heart failure, mortality, arrhythmias, proteomics, SELDI-TOF MS, 875
- Biomedical properties, *Pistacia lentiscus*, mastic gum, pharmacological properties, review, 777
- Biomolecular damage, cancer, inflammation, oxidative stress, review, 395
- Bionect Start<sup>®</sup>, hydroxyurea, thrombocythemia, circumferential wound, leg ulcers, 1053
- Biosensor, tumor model, fluorescence, GFP, FRET, review, 599
- Bisphenol A, pharmacokinetics, 17 $\alpha$ -ethynylestradiol, nonylphenol, 17 $\beta$ -estradiol, frog, *Rana rugosa*, 913
- Black tea, theaflavins, proteasome, Arp, Opm1 multiple myeloma cells, 197
- Bladder, canine, transitional cell carcinoma, interleukin-2, urinary, urethral carcinoma, 931
- Blood fluidity, hepatopathy, platelet aggregation, 719
- BMD, blood fluidity, bone turnover markers, osteocalcin, bone alkaline phosphatase, PICP, elderly men, 1041
- BMI, obstructive sleep apnoea, mandibular advancement splint, snoring, 841
- Body weight, automated blood sampling, Accusampler, refinement, stress, corticosterone, food intake, BALB/c mice, 577
- Bombesin, agonist, antagonist, copper, microPET, 583
- Bone alkaline phosphatase, bone turnover markers, osteocalcin, PICP, BMD, elderly men, 1041
- Bone healing, diode laser, rat, tibial fracture, 703
- Bone marrow stromal cells, radioprotection, radiation mitigation, autophagy, *p53*, carbamazepine, murine hematopoietic progenitor cells, Lewis lung carcinoma cells, 341
- Bone marrow, CCSP, GCV, lung repair, GFP, surfactant protein C, FOXJ1, 9
- Bone marrow, pulsed electromagnetic field, differentiation, osteoprogenitor cells, stromal cells, 299
- Bone metastases, docetaxel, octreotide, dexamethasone, TRAMP-C1 cells, SSTR1-5, 75
- Bone resorption, stafne's cavity, mandibular bone defect, lingual bone depression of mandible, 1045
- Bone turnover markers, osteocalcin, bone alkaline phosphatase, PICP, BMD, elderly men, 1041
- BRAF, colorectal cancer, mutational analysis, KRAS, concurrent mutation, genotyping, 537
- Breast cancer xenografts, antimicrobial peptides, (KLAKLAK)<sub>2</sub>, targeted tumor therapy, MDA-MB435S, T24, DU145, Tet21N, Wac2 cells, 419
- Breast cancer, amentoflavone, cell-cycle arrest, apoptosis, MCF-7 cancer cells, mitochondria, 963
- Breast cancer, chorionic gonadotropin, estrogen, *N*-methyl-*N*-nitrosourea, progesterone, female Lewis rats, 361
- Breast cancer, RXR $\alpha$ , PPAR $\gamma$ , positive lymph nodes, 87
- Breast cancer, single-frequency bioelectrical impedance, lymphedema of the upper limb, phase angle, resistance, 863
- Breast surgery, local anesthetic, ropivacaine, levobupivacaine, pain relief, outpatients, 1075
- Brown adipose tissue, *Lactobacillus pentosus* strain S-PT84, culture supernatant, autonomic nerve, thermogenesis, rats, 355
- Buccal space, keratocystic odontogenic tumor, unusual site of origin, case report, 847
- BXO, circumcision, phototype, balanitis, phimosis, *Lichen sclerosus*, 143
- C57bl/6, stress, dietary fat, ACTH, BALB/c mice, fetal corticosterone, 213
- C6-glioma, uPA, rat model, infiltration, glioblastoma multiforme, 571
- Caco-2 cells, indigenous fruit-bearing tree seed oils, HEK-293 cells, growth suppression, essential fatty acids, *Kigelia africana*, *Mimusops zeyheri*, *Ximenia caffra*, 99
- Celiac disease, plasma cell precursors, *MUM1*, 859
- Cancer growth, exponential logistic equations, 183
- Cancer prevention, cervical cancer, 3, 3'-diindolylmethane, interferon- $\gamma$ , K14-HPV16 transgenic mouse model, serum estrogen metabolites, gas chromatography, 207
- Cancer, biomolecular damage, inflammation, oxidative stress, review, 395
- Cancer, *in vivo* models, GST-P 7-7, review, 647
- Cancer, sialic acid, *N*-glycolylated gangliosides, cytidine monophospho-*N*-acetylneuraminic acid hydroxylase, immunotherapy, 609
- Candida*, *Aspergillus*, ITS, high-resolution melting (HRM), real-time PCR, 979
- Canine, mammary gland, neoplasm, carboplatin, COX-2, 375
- Canine, transitional cell carcinoma, interleukin-2, urinary, bladder, urethral carcinoma, 931
- CAPAN1, EGFR, pancreatic carcinoma, imaging, HPAC, HUVECs cells, 619
- Capsaicin, curcumin, visible light, photodynamic therapy, oral cancer, oral mucosa, 759
- Carbamazepine, radioprotection, radiation mitigation, autophagy, *p53*, murine hematopoietic progenitor cells, bone marrow stromal cells, Lewis lung carcinoma cells, 341
- Carboplatin, canine, mammary gland, neoplasm, COX-2, 375
- Carcinogenesis, hepatocarcinogenesis, liver cancer, rat model, selenium, statins, HMGCoA reductase inhibitors, thioredoxin reductase, glutathione peroxidase, review, 527

- Carcinogenesis, PAI-1, mice, oral cancer, transgenic, 4-NQO, DMBA, model, 1001
- Carcinogenesis, urothelial, *N*-butyl-*N*-(4-hydroxybutyl) nitrosamine, tumours, review, 727
- Cardiac valves, perivalvular tissues, inflammation, cardiovascular prosthetic surgery, 271
- Cardiovascular prosthetic surgery, cardiac valves, perivalvular tissues, inflammation, 271
- Cardiovascular risk factors, coagulation factors, DNA polymorphisms, genetic predisposition, Greece, single-nucleotide polymorphisms, thrombophilia, 1095
- Care bundle, methicillin-resistant *Staphylococcus aureus*, MRSA, nasal carriage, colonization, infection, 469
- Cartilage, tissue engineering, microspheres, tissue repair, scaffold-free, 251
- Case report, angiomyolipomatous hamartoma, inguinal, lymph node, 459
- Case report, keratocystic odontogenic tumor, buccal space, unusual site of origin, 847
- Caspase-3, 15-lipoxygenase-1, apoptosis, gene therapy, glioma, lipid peroxidation, 1
- Caspases, chlorogenic acid, apoptosis, U937 leukemia cells, mitochondrial dysfunction, 971
- CCSP, GCV, bone marrow, lung repair, GFP, surfactant protein C, FOXJ1, 9
- CD11b, chrysin, WEHI-3 murine leukemia cells, T- and B-cells, macrophage phagocytosis, NK cell cytotoxicity, CD3, CD19, 665
- CD19, chrysin, WEHI-3 murine leukemia cells, T- and B-cells, macrophage phagocytosis, NK cell cytotoxicity, CD3, CD11b, 665
- CD3, chrysin, WEHI-3 murine leukemia cells, T- and B-cells, macrophage phagocytosis, NK cell cytotoxicity, CD19, CD11b, 665
- CD34, colorectal cancer, thymidine phosphorylase, extracellular matrix components, ki-67, VEGF, PCNA, 1057
- CD34<sup>+</sup>, *in vivo* imaging, cell transplantation, ALS, SPIO, umbilical cord blood stem cells, MRI, tracking, MTH53A cells, SOD1-ALS mouse, 31
- CD44, murine tumour model, memory T lymphocytes, CD8, CD62L, 553
- CD44, tumor stem cells, CSC, ALDH1A1, Ki 67, EGFR, xenograft mouse model, 593
- CD62L, murine tumour model, memory T lymphocytes, CD8, CD44, 553
- CD8, murine tumour model, memory T lymphocytes, CD44, CD62L, 553
- Cell adhesion molecules, mediators, immune regulation, amniotic fluid, preterm labour, cytokines, prostaglandins, leukotrienes, interleukins, review, 799
- Cell transplantation, *in vivo* imaging, ALS, SPIO, umbilical cord blood stem cells, MRI, tracking, MTH53A cells, SOD1-ALS mouse, CD34<sup>+</sup>, 31
- Cell-cycle arrest, amentoflavone, apoptosis, breast cancer, MCF-7 cancer cells, mitochondria, 963
- Central nervous system primitive neuroectodermal tumor, medulloblastoma, *in vivo* models, Sleeping Beauty transposon mutagenesis, genetic origins, review, 487
- Cervical cancer, 3, 3'-diindolylmethane, interferon- $\gamma$ , cancer prevention, K14-HPV16 transgenic mouse model, serum estrogen metabolites, gas chromatography, 207
- Cetuximab, epidermal growth factor, epidermal growth factor receptor, liver surgery, biological therapy, liver regeneration, porcine model, 683
- Chemotaxis, esophageal carcinoma, *in vivo* model, metastasis model, OE19 cells, 711
- Chest pain, acute coronary syndrome, coronary computed tomography angiography, emergency department, risk stratification, triple-rule-out, troponin, 1035
- Chick embryo chorioallantoic membrane, EG-VEGF, angiogenesis, targeting, 793
- Chlorogenic acid, apoptosis, U937 leukemia cells, caspases, mitochondrial dysfunction, 971
- Chorionic gonadotropin, breast cancer, estrogen, *N*-methyl-*N*-nitrosourea, progesterone, female Lewis rats, 361
- Chronic rhinosinusitis, doxycycline, CRS, IL-5, MMP-9, eotaxin-3, inflammatory cytokines, gelatinases, 369
- Chrysin, WEHI-3 murine leukemia cells, T- and B-cells, macrophage phagocytosis, NK cell cytotoxicity, CD3, CD19, CD11b, 665
- Circumcision, BXO, phototype, balanitis, phimosis, *Lichen sclerosus*, 143
- Circumferential wound, hydroxyurea, thrombocytopenia, Bionect Start<sup>®</sup>, leg ulcers, 1053
- Cisplatin, neuroblastoma, mouse model, xenograft, metastasis, NSG, 19
- Cisplatin, selenite, ovarian cancer, xenografts, A2780 tumor cells, 549
- Coagulation factor V, thromboembolism, thrombosis, prothrombin, genetics, genetic counseling, 165
- Coagulation factors, cardiovascular risk factors, DNA polymorphisms, genetic predisposition, Greece, single-nucleotide polymorphisms, thrombophilia, 1095
- Colon cancer, metallothionein, stem cell, Musashi, dimethylhydrazine, 5-FU, rofecoxib-vioxx, MS275 5-azadeoxycytine, 693
- Colonization, methicillin-resistant *Staphylococcus aureus*, MRSA, nasal carriage, infection, care bundle, 469
- Colorectal cancer, inflammatory bowel disease, mouse models inflammation, review, 627
- Colorectal cancer, mutational analysis, BRAF, KRAS, concurrent mutation, genotyping, 537
- Colorectal cancer, thymidine phosphorylase, extracellular matrix components, CD34, ki-67, VEGF, PCNA, 1057
- Concurrent mutation, colorectal cancer, mutational analysis, BRAF, KRAS, genotyping, 537

- Cone beam computed tomography, anterior lingual mandibular bone depression, Stafne's cavity, sublingual gland, magnetic resonance imaging, ultrasound, 1103
- Congenital diaphragmatic hernia, gender, ECMO, neonate, 481
- Conservative treatment, *Pyoderma gangrenosum*, differential diagnosis, 157
- Copper, bombesin, agonist, antagonist, microPET, 583
- Coproantibodies, immunization monitoring, IgG, feces, animal welfare, 3R concept, 63
- Coronary artery diseases (CAD), acute myocardial infarction (AMI), unstable atherosclerotic plaque, matrix metalloproteinase-9 (MMP-9), neutrophil gelatinase-associated lipocalin (NGAL), prothrombin fragment (F1+2), antithrombin III, 1021
- Coronary computed tomography angiography, acute coronary syndrome, chest pain, emergency department, risk stratification, triple-rule-out, troponin, 1035
- Corticosterone, automated blood sampling, Accusampler, refinement, stress, food intake, body weight, BALB/c mice, 577
- COX-2 inhibitors, NSAIDs, IBD, experimental colitis, cyclooxygenase, review, 381
- COX-2, canine, mammary gland, neoplasm, carboplatin, 375
- COX-2, magnolol, honokiol, eugenol, antioxidative activity, RAW264.7 cells, cytotoxicity, NF- $\kappa$ B, orbital energy, 941
- Crohn's disease, cytomegalovirus infection, immunohistochemistry, surgery, 151
- CRS, chronic rhinosinusitis, doxycycline, IL-5, MMP-9, eotaxin-3, inflammatory cytokines, gelatinases, 369
- CSC, tumor stem cells, CD44, ALDH1A1, Ki 67, EGFR, xenograft mouse model, 593
- Culture medium, ovarian granulosa lutein cells, HGL-5 cells, 823
- Culture supernatant, *Lactobacillus pentosus* strain S-PT84, autonomic nerve, brown adipose tissue, thermogenesis, rats, 355
- Curcumin, capsaicin, visible light, photodynamic therapy, oral cancer, oral mucosa, 759
- CV026, quorum sensing, trifluoromethyl ketones, AHL, efflux pump, 277
- Cyclooxygenase, NSAIDs, COX-2 inhibitors, IBD, experimental colitis, review, 381
- Cyclophosphamide, transplantation, DNA adducts, obesity, pharmacokinetics, hematopoietic cell transplant recipients, 853
- CYP3A4 inhibition, *Sasa senanensis* Rehder, leaf extract, anti-HIV, anti-UV, radical scavenging, Fe(II), lignin, 259
- CYP3A4 inhibition, *Sasa senanensis* Rehder, leaf extract, anti-HIV, anti-UV, radical scavenging, ESR spectroscopy, MT-4, HSC-2, HPC, HGF cells, 411
- Cytidine monophospho-*N*-acetylneuraminic acid hydroxylase, sialic acid, *N*-glycosylated gangliosides, cancer, immunotherapy, 609
- Cytochrome c, vitamin C, formation of e<sup>-</sup>aq, photolysis, mutual electron transfer, 129
- Cytokeratin, nasolabial cyst, podoplanin, p63, dysontogenetic cyst, non-odontogenic cyst, 453
- Cytokines, ionizing radiation, lymphocytes, hematopoiesis, minocycline, 743
- Cytokines, mediators, immune regulation, amniotic fluid, preterm labour, prostaglandins, leukotrienes, interleukins, cell adhesion molecules, review, 799
- Cytomegalovirus infection, Crohn's disease, immunohistochemistry, surgery, 151
- Cytotoxicity, Au/Cu alloy, gingival fibroblast, oxidation, elution, HGF cells, 651
- Cytotoxicity, magnolol, honokiol, eugenol, antioxidative activity, RAW264.7 cells, COX-2, NF- $\kappa$ B, orbital energy, 941
- Cytotoxicity, *odontioda* Marie Noel 'Velano' extract, apoptosis induction, oral squamous cell carcinoma, HSC-2, HSC-3, HSC-4 cell lines, 265
- Cytotoxicity, *Odontoglossum* Harvengtense 'Tutu', activated macrophages, osteoclastogenesis, 993
- Cytotoxicity, *Rhinacanthus nasutus* extract, apoptosis induction, OSCC, HL-60, HSC-2, HSC-3, HSC-4 cells, 305
- Cytotoxicity, sodium fluoride, Ag(NH<sub>3</sub>)<sub>2</sub>F, 5-FU, tumor specificity, apoptosis, OSCC, T98G, U87MG, HL-60 cells, 657
- Deep infiltrating endometriosis, KISS1, KISS1R, GPR54, eutopic endometrium, ectopic endometrium, ovarian endometriotic cyst, 119
- Dendritic cells, immunohistochemistry, thymus, 985
- Der(16)t(3;16), ovarian cancer, simple chromosomal aberration, translocation, 71
- Dermal substitutes, extravasation, premature neonates, regenerative medicine, 139
- Dexamethasone, docetaxel, octreotide, TRAMP-C1 cells, bone metastases, SSTR1-5, 75
- DFNB3, mouse model, non-syndromic deafness, shaker-2, myoXV gene, 787
- Diabetic retinopathy, nephropathy, stem cell stimulation, alloxan, experimental diabetes, FITC-BSA, Olimpiq StemxCell, 427
- Diagnosis, abdominal pain, symptoms, history, 335
- Dietary fat, stress, ACTH, C57bl/6, BALB/c mice, fetal corticosterone, 213
- Differential diagnosis, liver, plasma cell precursors, *MUMI*, autoimmune hepatitis, 319
- Differential diagnosis, oral cavity, leiomyoma, histopathology, 161
- Differential diagnosis, *Pyoderma gangrenosum*, conservative treatment, 157

- Differentiation, pulsed electromagnetic field, bone marrow, osteoprogenitor cells, stromal cells, 299
- 3'-diindolylmethane, cervical cancer, 3, interferon- $\gamma$ , cancer prevention, K14-HPV16 transgenic mouse model, serum estrogen metabolites, gas chromatography, 207
- 7, 12-Dimethylbenz( $\alpha$ )anthracene, miRNA, let-7a, miR-21, miR-146a, 113
- 12-Dimethylbenz( $\alpha$ )anthracene, 7, miRNA, let-7a, miR-21, miR-146a, 113
- Dimethylhydrazine, metallothionein, stem cell, colon cancer, Musashi, 5-FU, rofecoxib-vioxx, MS275 5-azadeoxycytine, 693
- Diode laser, bone healing, rat, tibial fracture, 703
- DMBA, PAI-1, mice, oral cancer, transgenic, 4-NQO, carcinogenesis, model, 1001
- DNA adducts, transplantation, cyclophosphamide, obesity, pharmacokinetics, hematopoietic cell transplant recipients, 853
- DNA ploidy, heterogeneity, endometrial carcinoma, flow cytometry, 473
- DNA polymorphisms, cardiovascular risk factors, coagulation factors, genetic predisposition, Greece, single-nucleotide polymorphisms, thrombophilia, 1095
- Docetaxel, octreotide, dexamethasone, TRAMP-C1 cells, bone metastases, SSTR1-5, 75
- Dopamine, electron emission, biological consequences, 107
- Doppler, aortic stenosis, severity graduation, echocardiography, inert gas rebreathing, hybrid approach, 1027
- Doxorubicin, *PARP*, apoptosis, zygote, the early embryonic development, 827
- Doxycycline, chronic rhinosinusitis, CRS, IL-5, MMP-9, eotaxin-3, inflammatory cytokines, gelatinases, 369
- Drug-resistant tuberculosis, multidrug-resistant tuberculosis, MDRTB, XDRTB, phenothiazines, thioridazine, 231
- DUI45, antimicrobial peptides, (KLAKLAK)<sub>2</sub>, targeted tumor therapy, MDA-MB435S, T24, Tet21N, Wac2 cells, breast cancer xenografts, 419
- Duodenum, paneth cells, synaptophysin, lysozyme, goblet cells, 135
- Dysontogenetic cyst, nasolabial cyst, podoplanin, p63, cytokeratin, non-odontogenic cyst, 453
- E-cadherin, ethanol, B16-BL6, Kiss1, melanoma metastasis, Snai1, 47
- Echocardiography, aortic stenosis, severity graduation, Doppler, inert gas rebreathing, hybrid approach, 1027
- ECMO, congenital diaphragmatic hernia, gender, neonate, 481
- Ectopic endometrium, KISS1, KISS1R, GPR54, eutopic endometrium, ovarian endometriotic cyst, deep infiltrating endometriosis, 119
- Efavirenz, HAART, HIV infection, lipodystrophy, adipocyte differentiation, metabolic syndrome, oxidative stress, saquinavir, stavudine, antiretroviral therapies, 287
- Efflux pump, quorum sensing, CV026, trifluoromethyl ketones, AHL, 277
- EGFR, pancreatic carcinoma, imaging, CAPAN1, HPAC, HUVECs cells, 619
- EGFR, tumor stem cells, CSC, CD44, ALDH1A1, Ki 67, xenograft mouse model, 593
- EG-VEGF, angiogenesis, chick embryo chorioallantoic membrane, targeting, 793
- Elderly men, bone turnover markers, osteocalcin, bone alkaline phosphatase, PICP, BMD, 1041
- Elderly, gynaecological surgery, overweight, pelvic floor disorder, 1069
- Electron emission, dopamine, biological consequences, 107
- Electron transfer, hormone receptor complex, 17 $\beta$ -estradiol, methionine-enkephaline, 819
- Elution, Au/Cu alloy, gingival fibroblast, cytotoxicity, oxidation, HGF cells, 651
- Emergency department, acute coronary syndrome, chest pain, coronary computed tomography angiography, risk stratification, triple-rule-out, troponin, 1035
- Endometrial carcinoma, DNA ploidy, heterogeneity, flow cytometry, 473
- Eotaxin-3, chronic rhinosinusitis, doxycycline, CRS, IL-5, MMP-9, inflammatory cytokines, gelatinases, 369
- Epidermal growth factor receptor, epidermal growth factor, liver surgery, biological therapy, liver regeneration, porcine model, cetuximab, 683
- Epidermal growth factor, epidermal growth factor receptor, liver surgery, biological therapy, liver regeneration, porcine model, cetuximab, 683
- Epidermoid cyst, sublingual, MRI, podoplanin (D2-40), 323
- Epstein-Barr virus, lymphoepithelioma, oral tumor, 1087
- Escherichia coli*, multidrug resistance, Gram-negative and Gram positive bacteria, *Salmonella enterica* serovar Enteritidis, *Staphylococcus aureus*, acridine orange (AO), agar method, evaluation of efflux pump activity, 203
- Esophageal carcinoma, chemotaxis, *in vivo* model, metastasis model, OE19 cells, 711
- ESR spectroscopy, *sasa senanensis* Rehder, leaf extract, anti-HIV, anti-UV, radical scavenging, CYP3A4 inhibition, MT-4, HSC-2, HPC, HGF cells, 411
- Essential fatty acids, indigenous fruit-bearing tree seed oils, Caco-2 cells, HEK-293 cells, growth suppression, *Kigelia africana*, *Mimusops zeyheri*, *Ximenia caffra*, 99
- Estradiol, GnRH analogues, viability, granulosa luteinized cells, progesterone, 835
- 17 $\beta$ -estradiol, hormone receptor complex, electron transfer, methionine-enkephaline, 819
- 17 $\beta$ -estradiol, pharmacokinetics, 17 $\alpha$ -ethynylestradiol, bisphenol A, nonylphenol, frog, *Rana rugosa*, 913



- Estrogen, breast cancer, chorionic gonadotropin, *N*-methyl-*N*-nitrosourea, progesterone, female Lewis rats, 361
- Estrogen, mouse, uterus, vagina, p21 and Notch signaling, Wnt family genes, 899
- Ethanol, B16-BL6, Kiss1, melanoma metastasis, Snail, E-cadherin, 47
- 17 $\alpha$ -ethynylestradiol, pharmacokinetics, bisphenol A, nonylphenol, 17 $\beta$ -estradiol, frog, *Rana rugosa*, 913
- Eugenol, magnolol, honokiol, antioxidative activity, RAW264.7 cells, cytotoxicity, COX-2, NF- $\kappa$ B, orbital energy, 941
- Eutopic endometrium, KISS1, KISS1R, GPR54, ectopic endometrium, ovarian endometriotic cyst, deep infiltrating endometriosis, 119
- Evaluation of efflux pump activity, multidrug resistance, Gram-negative and Gram positive bacteria, *Escherichia coli*, *Salmonella enterica* serovar Enteritidis, *Staphylococcus aureus*, acridine orange (AO), agar method, 203
- Excessive autonomic nerve, vertical occlusal dimension, VOD, heart rate fluctuations, 177
- Experimental colitis, NSAIDs, COX-2 inhibitors, IBD, cyclooxygenase, review, 381
- Experimental diabetes, diabetic retinopathy, nephropathy, stem cell stimulation, alloxan, FITC-BSA, Olimpqi Stem $\times$ Cell, 427
- Exponential logistic equations, cancer growth, 183
- Extracellular matrix components, colorectal cancer, thymidine phosphorylase, CD34, ki-67, VEGF, PCNA, 1057
- Extravasation, premature neonates, dermal substitutes, regenerative medicine, 139
- Eyelid, reconstructive surgery, autologous graft, surgical technique, venous graft, 447
- F344 rats, <sup>18</sup>F-FDG-PET, lung metastasis, animal model, MADB 106 cells, NK cells, 191
- Fe(II), *Sasa senanensis* Rehder, leaf extract, anti-HIV, anti-UV, radical scavenging, CYP3A4 inhibition, lignin, 259
- Fecal corticosterone, acclimatization, animal welfare, secretory IgA, housing conditions, mice, social grouping, 883
- Feces, immunization monitoring, IgG, coproantibodies, animal welfare, 3R concept, 63
- Female Lewis rats, breast cancer, chorionic gonadotropin, estrogen, *N*-methyl-*N*-nitrosourea, progesterone, 361
- Fetal corticosterone, stress, dietary fat, ACTH, C57bl/6, BALB/c mice, 213
- Fetal growth, adipokines, amniotic fluid, human adiponectin, placental growth factor (PLGF), small for gestational age (SGA), appropriate for gestational age (AGA), large for gestational age (LGA), 327
- Fetal health, obstetrics, labor, low-density lipoprotein, antioxidants, maternal smoking, amniotic fluid, 813
- <sup>18</sup>F-FDG-PET, lung metastasis, animal model, F344 rats, MADB 106 cells, NK cells, 191
- Fistula, platelet gel, VAC therapy, regenerative surgery, wound healing, 147
- FITC-BSA, diabetic retinopathy, nephropathy, stem cell stimulation, alloxan, experimental diabetes, Olimpqi Stem $\times$ Cell, 427
- Flow cytometry, DNA ploidy, heterogeneity, endometrial carcinoma, 473
- Fluorescence imaging, pancreatic cancer, orthotopic mouse models, macrophages, tumor microenvironment, red fluorescent protein, green fluorescent protein, 565
- Fluorescence, tumor model, GFP, FRET, biosensor, review, 599
- Food intake, automated blood sampling, Accusampler, refinement, stress, corticosterone, body weight, BALB/c mice, 577
- Formation of e<sup>-</sup>aq, cytochrome *c*, vitamin C, photolysis, mutual electron transfer, 129
- FOXJ1, CCSP, GCV, bone marrow, lung repair, GFP, surfactant protein C, 9
- FRET, tumor model, fluorescence, GFP, biosensor, review, 599
- Frog, pharmacokinetics, 17 $\alpha$ -ethynylestradiol, bisphenol A, nonylphenol, 17 $\beta$ -estradiol, *Rana rugosa*, 913
- 5-FU, metallothionein, stem cell, colon cancer, Musashi, dimethylhydrazine, rofecoxib-vioxx, MS275 5-azadeoxycytine, 693
- 5-FU, sodium fluoride, Ag(NH<sub>3</sub>)<sub>2</sub>F, cytotoxicity, tumor specificity, apoptosis, OSCC, T98G, U87MG, HL-60 cells, 657
- Gas chromatography, cervical cancer, 3, 3'-diindolylmethane, interferon- $\gamma$ , cancer prevention, K14-HPV16 transgenic mouse model, serum estrogen metabolites, 207
- Gastric cancer, HIPEC, peritoneal carcinomatosis, MKN45 cells, NOD-SCID mice, 39
- GCV, CCSP, bone marrow, lung repair, GFP, surfactant protein C, FOXJ1, 9
- Gelatinases, chronic rhinosinusitis, doxycycline, CRS, IL-5, MMP-9, eotaxin-3, inflammatory cytokines, 369
- Gender, congenital diaphragmatic hernia, ECMO, neonate, 481
- Gene therapy, 15-Lipoxygenase-1, apoptosis, glioma, lipid peroxidation, caspase-3, 1
- General anaesthesia, melanoma, sentinel node biopsy, surgery, local anaesthesia, healthcare costs, 315
- Genetic counseling, thromboembolism, thrombosis, coagulation factor V, prothrombin, genetics, 165
- Genetic origins, medulloblastoma, central nervous system primitive neuroectodermal tumor, *in vivo* models, Sleeping Beauty transposon mutagenesis, review, 487
- Genetic predisposition, cardiovascular risk factors, coagulation factors, DNA polymorphisms, Greece, single-nucleotide polymorphisms, thrombophilia, 1095

- Genetics, thromboembolism, thrombosis, coagulation factor V, prothrombin, genetic counseling, 165
- Genotoxicity, *Agaricus blazei* Murill, subclinical toxicity, Ames test, histopathology, serum biomarker analysis, ALT, AST, 437
- Genotyping, colorectal cancer, mutational analysis, BRAF, KRAS, concurrent mutation, 537
- GFP, CCSP, GCV, bone marrow, lung repair, surfactant protein C, FOXJ1, 9
- GFP, tumor model, fluorescence, FRET, biosensor, review, 599
- Gingival fibroblast, Au/Cu alloy, cytotoxicity, oxidation, elution, HGF cells, 651
- Glaucoma, phytoestrogens, antioxidants, oxidative stress, neuroprotection, neurodegenerative disease, RGC-5 cells, 765
- Glioblastoma multiforme, uPA, C6-glioma, rat model, infiltration, 571
- Glioma, 15-lipoxygenase-1, apoptosis, gene therapy, lipid peroxidation, caspase-3, 1
- Glutathione peroxidase, hepatocarcinogenesis, liver cancer, rat model, carcinogenesis, selenium, statins, HMGCoA reductase inhibitors, thioredoxin reductase, review, 527
- Glycyrrhizin, Kampo medicine, UV protection, anti-HIV, 1007
- GnRH analogues, viability, granulosa luteinized cells, estradiol, progesterone, 835
- Goblet cells, duodenum, paneth cells, synaptophysin, lysozyme, 135
- GPR54, KISS1, KISS1R, eutopic endometrium, ectopic endometrium, ovarian endometriotic cyst, deep infiltrating endometriosis, 119
- Gram-negative and Gram positive bacteria, multidrug resistance, *Escherichia coli*, *Salmonella enterica* serovar Enteritidis, *Staphylococcus aureus*, acridine orange (AO), agar method, evaluation of efflux pump activity, 203
- Granulosa luteinized cells, GnRH analogues, viability, estradiol, progesterone, 835
- Greece, cardiovascular risk factors, coagulation factors, DNA polymorphisms, genetic predisposition, single-nucleotide polymorphisms, thrombophilia, 1095
- Green fluorescent protein, pancreatic cancer, orthotopic mouse models, macrophages, tumor microenvironment, fluorescence imaging, red fluorescent protein, 565
- Growth suppression, indigenous fruit-bearing tree seed oils, Caco-2 cells, HEK-293 cells, essential fatty acids, *Kigelia africana*, *Mimusops zeyheri*, *Ximenia caffra*, 99
- GST-P 7-7, cancer, *in vivo* models, review, 647
- Gynaecological surgery, elderly, overweight, pelvic floor disorder, 1069
- HAART, HIV infection, lipodystrophy, adipocyte differentiation, metabolic syndrome, oxidative stress, saquinavir, efavirenz, stavudine, antiretroviral therapies, 287
- HAART, HIV infection, lipodystrophy, oxidative stress, metabolic syndrome, antiretroviral therapies, 237
- Hairy cell leukemia, HCL, leukemia cutis, peripheral venous cannula, 311
- HCL, hairy cell leukemia, leukemia cutis, peripheral venous cannula, 311
- Healthcare costs, melanoma, sentinel node biopsy, surgery, local anaesthesia, general anaesthesia, 315
- Heart failure, implantable cardioverter defibrillators, biomarkers, mortality, arrhythmias, proteomics, SELDI-TOF MS, 875
- Heart failure, ultrasound contrast agent, right ventricle, 869
- Heart rate fluctuations, vertical occlusal dimension, VOD, excessive autonomic nerve, 177
- HEK-293 cells, indigenous fruit-bearing tree seed oils, Caco-2 cells, growth suppression, essential fatty acids, *Kigelia africana*, *Mimusops zeyheri*, *Ximenia caffra*, 99
- Hematopoiesis, ionizing radiation, cytokines, lymphocytes, minocycline, 743
- Hematopoietic cell transplant recipients, transplantation, cyclophosphamide, DNA adducts, obesity, pharmacokinetics, 853
- Hepatocarcinogenesis, liver cancer, rat model, carcinogenesis, selenium, statins, HMGCoA reductase inhibitors, thioredoxin reductase, glutathione peroxidase, review, 527
- Hepatocellular carcinoma, sorafenib, NF- $\kappa$ B, MMP-9, VEGF, Huh 7 cells, 671
- Hepatopathy, blood fluidity, platelet aggregation, 719
- Heterogeneity, DNA ploidy, endometrial carcinoma, flow cytometry, 473
- HGF cells, Au/Cu alloy, gingival fibroblast, cytotoxicity, oxidation, elution, 651
- HGF cells, *Sasa senanensis* Rehder, leaf extract, anti-HIV, anti-UV, radical scavenging, CYP3A4 inhibition, ESR spectroscopy, MT-4, HSC-2, HPC, 411
- HGL-5 cells, ovarian granulosa lutein cells, culture medium, 823
- High-density lipoprotein cholesterol, atherosclerosis, vascular cell adhesion molecule, intercellular adhesion molecule, *Vasa vasorum*, 243
- High-resolution melting (HRM), *Candida*, *Aspergillus*, ITS, real-time PCR, 979
- HIPEC, gastric cancer, peritoneal carcinomatosis, MKN45 cells, NOD-SCID mice, 39
- Histological exam, spontaneous keloid, postauricular lesion, 173
- Histopathology, *Agaricus blazei* Murill, genotoxicity, subclinical toxicity, Ames test, serum biomarker analysis, ALT, AST, 437
- Histopathology, oral cavity, leiomyoma, differential diagnosis, 161
- History, abdominal pain, diagnosis, symptoms, 335

- HIV infection, HAART, lipodystrophy, adipocyte differentiation, metabolic syndrome, oxidative stress, saquinavir, efavirenz, stavudine, antiretroviral therapies, 287
- HIV infection, HAART, lipodystrophy, oxidative stress, metabolic syndrome, antiretroviral therapies, 237
- HL-60 cells, sodium fluoride, Ag(NH<sub>3</sub>)<sub>2</sub>F, 5-FU, cytotoxicity, tumor specificity, apoptosis, OSCC, T98G, U87MG, 657
- HL-60, *Rhinacanthus nasutus* extract, cytotoxicity, apoptosis induction, OSCC, HSC-2, HSC-3, HSC-4 cells, 305
- HMGCoA reductase inhibitors, hepatocarcinogenesis, liver cancer, rat model, carcinogenesis, selenium, statins, thioredoxin reductase, glutathione peroxidase, review, 527
- HOCl, inflammation, amino acid chloramines, protein damage, PCNA, 501
- Honokiol, magnolol, eugenol, antioxidative activity, RAW264.7 cells, cytotoxicity, COX-2, NF- $\kappa$ B, orbital energy, 941
- Hormone receptor complex, electron transfer, 17 $\beta$ -estradiol, methionine-enkephaline, 819
- Housing conditions, acclimatization, animal welfare, secretory IgA, mice, fecal corticosterone, social grouping, 883
- HPAC, EGFR, pancreatic carcinoma, imaging, CAPAN1, HUVECs cells, 619
- HPC, *Sasa senanensis* Rehder, leaf extract, anti-HIV, anti-UV, radical scavenging, CYP3A4 inhibition, ESR spectroscopy, MT-4, HSC-2, HGF cells, 411
- HSC-2, *odontioda* Marie Noel 'Velano' extract, cytotoxicity, apoptosis induction, oral squamous cell carcinoma, HSC-3, HSC-4 cell lines, 265
- HSC-2, *Rhinacanthus nasutus* extract, cytotoxicity, apoptosis induction, OSCC, HL-60, HSC-3, HSC-4 cells, 305
- HSC-2, *Sasa senanensis* Rehder, leaf extract, anti-HIV, anti-UV, radical scavenging, CYP3A4 inhibition, ESR spectroscopy, MT-4, HPC, HGF cells, 411
- HSC-3, *odontioda* Marie Noel 'Velano' extract, cytotoxicity, apoptosis induction, oral squamous cell carcinoma, HSC-2, HSC-4 cell lines, 265
- HSC-3, *Rhinacanthus nasutus* extract, cytotoxicity, apoptosis induction, OSCC, HL-60, HSC-2, HSC-4 cells, 305
- HSC-4 cell lines, *odontioda* Marie Noel 'Velano' extract, cytotoxicity, apoptosis induction, oral squamous cell carcinoma, HSC-2, HSC-3, 265
- HSC-4 cells, *Rhinacanthus nasutus* extract, cytotoxicity, apoptosis induction, OSCC, HL-60, HSC-2, HSC-3, 305
- Huh 7 cells, hepatocellular carcinoma, sorafenib, NF- $\kappa$ B, MMP-9, VEGF, 671
- Human adiponectin, adipokines, amniotic fluid, placental growth factor (PLGF), small for gestational age (SGA), appropriate for gestational age (AGA), large for gestational age (LGA), fetal growth, 327
- HUVECs cells, EGFR, pancreatic carcinoma, imaging, CAPAN1, HPAC, 619
- Hybrid approach, aortic stenosis, severity graduation, echocardiography, Doppler, inert gas rebreathing, 1027
- Hydantoin derivatives, *Staphylococcus aureus* ATCC 25923 wild-type, *Staphylococcus aureus* HPV-107, intrinsic efflux pump, Qac efflux pump, oxacillin, inhibition of efflux pumps, reversal of resistance to oxacillin, 223
- Hydantoin, Pg-P1, ABCB1, multidrug resistance, 293
- Hydroxyurea, thrombocythemia, Bionect Start<sup>®</sup>, circumferential wound, leg ulcers, 1053
- IBD, NSAIDs, COX-2 inhibitors, experimental colitis, cyclooxygenase, review, 381
- IGF-II, tumour, *in vitro*, *in vivo*, tumourigenesis, review, 519
- IgG, immunization monitoring, coproantibodies, feces, animal welfare, 3R concept, 63
- IL-5, chronic rhinosinusitis, doxycycline, CRS, MMP-9, eotaxin-3, inflammatory cytokines, gelatinases, 369
- IL-6, *Sasa senanensis* Rehder extract, lichenoid displasia, saliva, IL-8, osteoclastogenesis, 957
- IL-8, *Sasa senanensis* Rehder extract, lichenoid displasia, saliva, IL-6, osteoclastogenesis, 957
- Imaging, EGFR, pancreatic carcinoma, CAPAN1, HPAC, HUVECs cells, 619
- Immune regulation, mediators, amniotic fluid, preterm labour, cytokines, prostaglandins, leukotrienes, interleukins, cell adhesion molecules, review, 799
- Immunization monitoring, IgG, coproantibodies, feces, animal welfare, 3R concept, 63
- Immuno-histochemistry, Crohn's disease, cytomegalovirus infection, surgery, 151
- Immunohistochemistry, dendritic cells, thymus, 985
- Immunotherapy, sialic acid, *N*-glycolylated gangliosides, cytidine monophospho-*N*-acetylneuraminic acid hydroxylase, cancer, 609
- Implantable cardioverter defibrillators, heart failure, biomarkers, mortality, arrhythmias, proteomics, SELDI-TOF MS, 875
- In vitro*, IGF-II, tumour, *in vivo*, tumourigenesis, review, 519
- In vivo* imaging, cell transplantation, ALS, SPIO, umbilical cord blood stem cells, MRI, tracking, MTH53A cells, SOD1-ALS mouse, CD34<sup>+</sup>, 31
- In vivo* model, esophageal carcinoma, chemotaxis, metastasis model, OE19 cells, 711
- In vivo* models, cancer, GST-P 7-7, review, 647
- In vivo* models, medulloblastoma, central nervous system primitive neuroectodermal tumor, Sleeping Beauty transposon mutagenesis, genetic origins, review, 487

- In vivo*, IGF-II, tumour, *in vitro*, tumourigenesis, review, 519
- Indigenous fruit-bearing tree seed oils, Caco-2 cells, HEK-293 cells, growth suppression, essential fatty acids, *Kigelia africana*, *Mimusops zeyheri*, *Ximenia caffra*, 99
- Inert gas rebreathing, aortic stenosis, severity graduation, echocardiography, Doppler, hybrid approach, 1027
- Infection, methicillin-resistant *Staphylococcus aureus*, MRSA, nasal carriage, colonization, care bundle, 469
- Infiltration, uPA, C6-glioma, rat model, glioblastoma multiforme, 571
- Inflammation, biomolecular damage, cancer, oxidative stress, review, 395
- Inflammation, cardiac valves, perivalvular tissues, cardiovascular prosthetic surgery, 271
- Inflammation, HOCl, amino acid chloramines, protein damage, PCNA, 501
- Inflammatory bowel disease, mouse models inflammation, colorectal cancer, review, 627
- Inflammatory cytokines, chronic rhinosinusitis, doxycycline, CRS, IL-5, MMP-9, eotaxin-3, gelatinases, 369
- Inguinal, angiomyolipomatous hamartoma, lymph node, case report, 459
- Inhibition of efflux pumps, *Staphylococcus aureus* ATCC 25923 wild-type, *Staphylococcus aureus* HPV-107, intrinsic efflux pump, Qac efflux pump, hydantoin derivatives, oxacillin, reversal of resistance to oxacillin, 223
- Intercellular adhesion molecule, atherosclerosis, vascular cell adhesion molecule, high-density lipoprotein cholesterol, vasa vasorum, 243
- Interferon- $\gamma$ , cervical cancer, 3, 3'-diindolylmethane, cancer prevention, K14-HPV16 transgenic mouse model, serum estrogen metabolites, gas chromatography, 207
- Interleukin-2, canine, transitional cell carcinoma, urinary, bladder, urethral carcinoma, 931
- Interleukins, mediators, immune regulation, amniotic fluid, preterm labour, cytokines, prostaglandins, leukotrienes, cell adhesion molecules, review, 799
- Intrathecal chemotherapy, melanoma, leptomeningeal metastasis, liposomal cytarabine, 1079
- Intrinsic efflux pump, *Staphylococcus aureus* ATCC 25923 wild-type, *Staphylococcus aureus* HPV-107, Qac efflux pump, hydantoin derivatives, oxacillin, inhibition of efflux pumps, reversal of resistance to oxacillin, 223
- Ionizing radiation, cytokines, lymphocytes, hematopoiesis, minocycline, 743
- Island flap, nasal ala, skin cancer, nasolabial flap, nose reconstruction, 93
- ITS, *Candida*, *Aspergillus*, high-resolution melting (HRM), real-time PCR, 979
- K14-HPV16 transgenic mouse model, cervical cancer, 3, 3'-diindolylmethane, interferon- $\gamma$ , cancer prevention, serum estrogen metabolites, gas chromatography, 207
- Kampo medicine, glycyrrhizin, UV protection, anti-HIV, 1007
- Keratocystic odontogenic tumor, buccal space, unusual site of origin, case report, 847
- Ki 67, tumor stem cells, CSC, CD44, ALDH1A1, EGFR, xenograft mouse model, 593
- Ki-67, colorectal cancer, thymidine phosphorylase, extracellular matrix components, CD34, VEGF, PCNA, 1057
- Kigelia africana*, indigenous fruit-bearing tree seed oils, Caco-2 cells, HEK-293 cells, growth suppression, essential fatty acids, *Mimusops zeyheri*, *Ximenia caffra*, 99
- Kiss1, ethanol, B16-BL6, melanoma metastasis, Snai1, E-cadherin, 47
- KISS1, KISS1R, GPR54, eutopic endometrium, ectopic endometrium, ovarian endometriotic cyst, deep infiltrating endometriosis, 119
- KISS1R, KISS1, GPR54, eutopic endometrium, ectopic endometrium, ovarian endometriotic cyst, deep infiltrating endometriosis, 119
- (KLAKLAK)2, antimicrobial peptides, targeted tumor therapy, MDA-MB435S, T24, DU145, Tet21N, Wac2 cells, breast cancer xenografts, 419
- KRAS, colorectal cancer, mutational analysis, BRAF, concurrent mutation, genotyping, 537
- Labor, obstetrics, fetal health, low-density lipoprotein, antioxidants, maternal smoking, amniotic fluid, 813
- Lactobacillus pentosus* strain S-PT84, culture supernatant, autonomic nerve, brown adipose tissue, thermogenesis, rats, 355
- Large for gestational age (LGA), adipokines, amniotic fluid, human adiponectin, placental growth factor (PLGF), small for gestational age (SGA), appropriate for gestational age (AGA), fetal growth, 327
- Leaf extract, *Sasa senanensis* Rehder, anti-HIV, anti-UV, radical scavenging, CYP3A4 inhibition, Fe(II), lignin, 259
- Leaf extract, *Sasa senanensis* Rehder, anti-HIV, anti-UV, radical scavenging, CYP3A4 inhibition, ESR spectroscopy, MT-4, HSC-2, HPC, HGF cells, 411
- Leg ulcers, hydroxyurea, thrombocytopenia, Bionect Start<sup>®</sup>, circumferential wound, 1053
- Leiomyoma, oral cavity, histopathology, differential diagnosis, 161
- Leptomeningeal metastasis, melanoma, intrathecal chemotherapy, liposomal cytarabine, 1079
- Let-7a, 7, 12-dimethylbenz( $\alpha$ )anthracene, miRNA, miR-21, miR-146a, 113
- Leukemia cutis, hairy cell leukemia, HCL, peripheral venous cannula, 311
- Leukotrienes, mediators, immune regulation, amniotic fluid, preterm labour, cytokines, prostaglandins,



- interleukins, cell adhesion molecules, review, 799
- Levobupivacaine, local anesthetic, ropivacaine, pain relief, breast surgery, outpatients, 1075
- Lewis lung carcinoma cells, radioprotection, radiation mitigation, autophagy, *p53*, carbamazepine, murine hematopoietic progenitor cells, bone marrow stromal cells, 341
- Lichen sclerosus, BXO, circumcision, phototype, balanitis, phimosis, 143
- Lichenoid displasia, *Sasa senanensis* Rehder extract, saliva, IL-6, IL-8, osteoclastogenesis, 957
- Lignin, *Sasa senanensis* Rehder, leaf extract, anti-HIV, anti-UV, radical scavenging, CYP3A4 inhibition, Fe(II), 259
- Lingual bone depression of mandible, stafne's cavity, mandibular bone defect, bone resorption, 1045
- Lipid peroxidation, 15-lipoxygenase-1, apoptosis, gene therapy, glioma, caspase-3, 1
- Lipodystrophy, HAART, HIV infection, adipocyte differentiation, metabolic syndrome, oxidative stress, saquinavir, efavirenz, stavudine, antiretroviral therapies, 287
- Lipodystrophy, HAART, HIV infection, oxidative stress, metabolic syndrome, antiretroviral therapies, 237
- Liposomal cytarabine, melanoma, leptomeningeal metastasis, intrathecal chemotherapy, 1079
- 15-Lipoxygenase-1, apoptosis, gene therapy, glioma, lipid peroxidation, caspase-3, 1
- Liver cancer, hepatocarcinogenesis, rat model, carcinogenesis, selenium, statins, HMGCoA reductase inhibitors, thioredoxin reductase, glutathione peroxidase, review, 527
- Liver regeneration, epidermal growth factor, epidermal growth factor receptor, liver surgery, biological therapy, porcine model, cetuximab, 683
- Liver surgery, epidermal growth factor, epidermal growth factor receptor, biological therapy, liver regeneration, porcine model, cetuximab, 683
- Liver, *N*-diethylnitrosamine (DEN), mice, oxidative stress, antioxidant enzymes, 921
- Liver, plasma cell precursors, *MUM1*, differential diagnosis, autoimmune hepatitis, 319
- Local anaesthesia, melanoma, sentinel node biopsy, surgery, healthcare costs, general anaesthesia, 315
- Local anesthetic, ropivacaine, levobupivacaine, pain relief, breast surgery, outpatients, 1075
- Low-density lipoprotein, obstetrics, labor, fetal health, antioxidants, maternal smoking, amniotic fluid, 813
- Lung metastasis, <sup>18</sup>F-FDG-PET, animal model, F344 rats, MADB 106 cells, NK cells, 191
- Lung repair, CCSP, GCV, bone marrow, GFP, surfactant protein C, FOXJ1, 9
- Lymph node, angiomyolipomatous hamartoma, inguinal, case report, 459
- Lymphedema of the upper limb, single-frequency bioelectrical impedance, breast cancer, phase angle, resistance, 863
- Lymphocytes, ionizing radiation, cytokines, hematopoiesis, minocycline, 743
- Lymphoepithelioma, Epstein-Barr virus, oral tumor, 1087
- Lysozyme, duodenum, paneth cells, synaptophysin, goblet cells, 135
- Macrophage phagocytosis, chrysin, WEHI-3 murine leukemia cells, T- and B- cells, NK cell cytotoxicity, CD3, CD19, CD11b, 665
- Macrophages, pancreatic cancer, orthotopic mouse models, tumor microenvironment, fluorescence imaging, red fluorescent protein, green fluorescent protein, 565
- MADB 106 cells, <sup>18</sup>F-FDG-PET, lung metastasis, animal model, F344 rats, NK cells, 191
- Magnetic resonance imaging, anterior lingual mandibular bone depression, Stafne's cavity, sublingual gland, ultrasound, cone beam computed tomography, 1103
- Magnolol, honokiol, eugenol, antioxidative activity, RAW264.7 cells, cytotoxicity, COX-2, NF- $\kappa$ B, orbital energy, 941
- Mammary gland, canine, neoplasm, carboplatin, COX-2, 375
- Mandibular advancement splint, obstructive sleep apnoea, snoring, BMI, 841
- Mandibular bone defect, stafne's cavity, lingual bone depression of mandible, bone resorption, 1045
- Mastic gum, *Pistacia lentiscus*, pharmacological properties, biomedical properties, review, 777
- Maternal smoking, obstetrics, labor, fetal health, low-density lipoprotein, antioxidants, amniotic fluid, 813
- Matrix metalloproteinase-9 (MMP-9), acute myocardial infarction (AMI), coronary artery diseases (CAD), unstable atherosclerotic plaque, neutrophil gelatinase-associated lipocalin (NGAL), prothrombin fragment (F1+2), antithrombin III, 1021
- MCF-7 cancer cells, amentoflavone, cell-cycle arrest, apoptosis, breast cancer, mitochondria, 963
- MCF-7, phagocytosis, autophagy, apoptosis, 403
- MDA-MB435S, antimicrobial peptides, (KLAKLAK)<sub>2</sub>, targeted tumor therapy, T24, DU145, Tet21N, Wac2 cells, breast cancer xenografts, 419
- MDRTB, multidrug-resistant tuberculosis, drug-resistant tuberculosis, XDRTB, phenothiazines, thioridazine, 231
- Mediators, immune regulation, amniotic fluid, preterm labour, cytokines, prostaglandins, leukotrienes, interleukins, cell adhesion molecules, review, 799
- Medulloblastoma, central nervous system primitive neuroectodermal tumor, *in vivo* models, Sleeping Beauty transposon mutagenesis, genetic origins, review, 487
- Melanoma metastasis, ethanol, B16-BL6, Kiss1, Snai1, E-cadherin, 47

- Melanoma, leptomeningeal metastasis, intrathecal chemotherapy, liposomal cytarabine, 1079
- Melanoma, sentinel node biopsy, surgery, local anaesthesia, healthcare costs, general anaesthesia, 315
- Memory T lymphocytes, murine tumour model, CD8, CD44, CD62L, 553
- Metabolic syndrome, HAART, HIV infection, lipodystrophy, adipocyte differentiation, oxidative stress, saquinavir, efavirenz, stavudine, antiretroviral therapies, 287
- Metabolic syndrome, HAART, HIV infection, lipodystrophy, oxidative stress, antiretroviral therapies, 237
- Metabolite profiling, template therapy, salivary glycine, 1015
- Metallothionein, stem cell, colon cancer, Musashi, dimethylhydrazine, 5-FU, rofecoxib-vioxx, MS275 5-azadeoxycytine, 693
- Metastasis model, esophageal carcinoma, chemotaxis, *in vivo* model, OE19 cells, 711
- Metastasis, neuroblastoma, mouse model, xenograft, cisplatin, NSG, 19
- Methicillin-resistant *Staphylococcus aureus*, MRSA, nasal carriage, colonization, infection, care bundle, 469
- Methionine-enkephaline, hormone receptor complex, electron transfer, 17 $\beta$ -estradiol, 819
- Mice, acclimatization, animal welfare, secretory IgA, housing conditions, fecal corticosterone, social grouping, 883
- Mice, *N*-diethylnitrosamine (DEN), liver, oxidative stress, antioxidant enzymes, 921
- Mice, PAI-1, oral cancer, transgenic, 4-NQO, DMBA, carcinogenesis, model, 1001
- MicroPET, bombesin, agonist, antagonist, copper, 583
- Microspheres, cartilage, tissue engineering, tissue repair, scaffold-free, 251
- Mimulus zeyheri*, indigenous fruit-bearing tree seed oils, Caco-2 cells, HEK-293 cells, growth suppression, essential fatty acids, *Kigelia africana*, *Ximenia caffra*, 99
- Minocycline, ionizing radiation, cytokines, lymphocytes, hematopoiesis, 743
- MiR-146a, 7, 12-dimethylbenz( $\alpha$ )anthracene, miRNA, let-7a, miR-21, 113
- MiR-21, 7, 12-dimethylbenz( $\alpha$ )anthracene, miRNA, let-7a, miR-146a, 113
- MiRNA, 7, 12-dimethylbenz( $\alpha$ )anthracene, let-7a, miR-21, miR-146a, 113
- Mitochondria, amentoflavone, cell-cycle arrest, apoptosis, breast cancer, MCF-7 cancer cells, 963
- Mitochondrial dysfunction, chlorogenic acid, apoptosis, U937 leukemia cells, caspases, 971
- MKN45 cells, gastric cancer, HIPEC, peritoneal carcinomatosis, NOD-SCID mice, 39
- MMP-9, chronic rhinosinusitis, doxycycline, CRS, IL-5, eotaxin-3, inflammatory cytokines, gelatinases, 369
- MMP-9, hepatocellular carcinoma, sorafenib, NF- $\kappa$ B, VEGF, Huh 7 cells, 671
- Model, PAI-1, mice, oral cancer, transgenic, 4-NQO, DMBA, carcinogenesis, 1001
- Mortality, implantable cardioverter defibrillators, heart failure, biomarkers, arrhythmias, proteomics, SELDI-TOF MS, 875
- Mouse model, neuroblastoma, xenograft, metastasis, cisplatin, NSG, 19
- Mouse model, non-syndromic deafness, shaker-2, DFNB3, myoXV gene, 787
- Mouse models inflammation, inflammatory bowel disease, colorectal cancer, review, 627
- Mouse, estrogen, uterus, vagina, p21 and Notch signaling, Wnt family genes, 899
- MRI, epidermoid cyst, sublingual, podoplanin (D2-40), 323
- MRI, *in vivo* imaging, cell transplantation, ALS, SPIO, umbilical cord blood stem cells, tracking, MTH53A cells, SOD1-ALS mouse, CD34<sup>+</sup>, 31
- MRSA, methicillin-resistant *Staphylococcus aureus*, nasal carriage, colonization, infection, care bundle, 469
- MS275 5-azadeoxycytine, metallothionein, stem cell, colon cancer, Musashi, dimethylhydrazine, 5-FU, rofecoxib-vioxx, 693
- MT-4, *Sasa senanensis* Rehder, leaf extract, anti-HIV, anti-UV, radical scavenging, CYP3A4 inhibition, ESR spectroscopy, HSC-2, HPC, HGF cells, 411
- MTH53A cells, *in vivo* imaging, cell transplantation, ALS, SPIO, umbilical cord blood stem cells, MRI, tracking, SOD1-ALS mouse, CD34<sup>+</sup>, 31
- Multidrug resistance, Gram-negative and Gram positive bacteria, *Escherichia coli*, *Salmonella enterica* serovar Enteritidis, *Staphylococcus aureus*, acridine orange (AO), agar method, evaluation of efflux pump activity, 203
- Multidrug resistance, hydantoin, Pg-P1, ABCB1, 293
- Multidrug-resistant tuberculosis, MDRTB, drug-resistant tuberculosis, XDRTB, phenothiazines, thioridazine, 231
- MUM1*, caeliac disease, plasma cell precursors, 859
- MUM1*, liver, plasma cell precursors, differential diagnosis, autoimmune hepatitis, 319
- Murine hematopoietic progenitor cells, radioprotection, radiation mitigation, autophagy, *p53*, carbamazepine, bone marrow stromal cells, Lewis lung carcinoma cells, 341
- Murine tumour model, memory T lymphocytes, CD8, CD44, CD62L, 553
- Musashi, metallothionein, stem cell, colon cancer, dimethylhydrazine, 5-FU, rofecoxib-vioxx, MS275 5-azadeoxycytine, 693
- Mutational analysis, colorectal cancer, BRAF, KRAS, concurrent mutation, genotyping, 537

- Mutual electron transfer, cytochrome *c*, vitamin C, formation of  $e^{-}aq$ , photolysis, 129
- MyoXV gene, mouse model, non-syndromic deafness, shaker-2, DFNB3, 787
- Nasal ala, skin cancer, nasolabial flap, island flap, nose reconstruction, 93
- Nasal carriage, methicillin-resistant *Staphylococcus aureus*, MRSA, colonization, infection, care bundle, 469
- Nasal tumor, vascular leiomyoma, angioleiomyoma, subcutaneous tumor, benign tumor, 1091
- Nasolabial cyst, podoplanin, p63, cytokeratin, dysontogenetic cyst, non-odontogenic cyst, 453
- Nasolabial flap, nasal ala, skin cancer, island flap, nose reconstruction, 93
- N*-butyl-*N*-(4-hydroxybutyl) nitrosamine, urothelial, carcinogenesis, tumours, review, 727
- N*-Diethylnitrosamine (DEN), mice, liver, oxidative stress, antioxidant enzymes, 921
- Neonate, congenital diaphragmatic hernia, gender, ECMO, 481
- Neoplasm, canine, mammary gland, carboplatin, COX-2, 375
- Nephropathy, diabetic retinopathy, stem cell stimulation, alloxan, experimental diabetes, FITC-BSA, Olimpiq Stem×Cell, 427
- Neuroblastoma, mouse model, xenograft, metastasis, cisplatin, NSG, 19
- Neurodegenerative disease, phytoestrogens, antioxidants, oxidative stress, neuroprotection, glaucoma, RGC-5 cells, 765
- Neuroprotection, phytoestrogens, antioxidants, oxidative stress, neurodegenerative disease, glaucoma, RGC-5 cells, 765
- Neutrophil gelatinase-associated lipocalin (NGAL), acute myocardial infarction (AMI), coronary artery diseases (CAD), unstable atherosclerotic plaque, matrix metalloproteinase-9 (MMP-9), prothrombin fragment (F1+2), antithrombin III, 1021
- NF- $\kappa$ B, hepatocellular carcinoma, sorafenib, MMP-9, VEGF, Huh 7 cells, 671
- NF- $\kappa$ B, magnolol, honokiol, eugenol, antioxidative activity, RAW264.7 cells, cytotoxicity, COX-2, orbital energy, 941
- N*-glycolylated gangliosides, sialic acid, cytidine monophospho-*N*-acetylneuraminic acid hydroxylase, cancer, immunotherapy, 609
- Nicotine replacement therapy, sublingual tablet, smoking cessation program, 463
- NK cell cytotoxicity, chrysin, WEHI-3 murine leukemia cells, T- and B- cells, macrophage phagocytosis, CD3, CD19, CD11b, 665
- NK cells,  $^{18}$ F-FDG-PET, lung metastasis, animal model, F344 rats, MADB 106 cells, 191
- N*-methyl-*N*-nitrosourea, breast cancer, chorionic gonadotropin, estrogen, progesterone, female Lewis rats, 361
- NOD-SCID mice, gastric cancer, HIPEC, peritoneal carcinomatosis, MKN45 cells, 39
- Non-odontogenic cyst, nasolabial cyst, podoplanin, p63, cytokeratin, dysontogenetic cyst, 453
- Non-syndromic deafness, mouse model, shaker-2, DFNB3, myoXV gene, 787
- Nonylphenol, pharmacokinetics, 17 $\alpha$ -ethynylestradiol, bisphenol A, 17 $\beta$ -estradiol, frog, *Rana rugosa*, 913
- 4-NQO, PAI-1, mice, oral cancer, transgenic, DMBA, carcinogenesis, model, 1001
- Nose reconstruction, nasal ala, skin cancer, nasolabial flap, island flap, 93
- NSAIDs, COX-2 inhibitors, IBD, experimental colitis, cyclooxygenase, review, 381
- NSG, neuroblastoma, mouse model, xenograft, metastasis, cisplatin, 19
- Obesity, transplantation, cyclophosphamide, DNA adducts, pharmacokinetics, hematopoietic cell transplant recipients, 853
- Obstetrics, labor, fetal health, low-density lipoprotein, antioxidants, maternal smoking, amniotic fluid, 813
- Obstructive sleep apnoea, mandibular advancement splint, snoring, BMI, 841
- Octreotide, docetaxel, dexamethasone, TRAMP-C1 cells, bone metastases, SSTR1-5, 75
- Odontioda* Marie Noel 'Velano' extract, cytotoxicity, apoptosis induction, oral squamous cell carcinoma, HSC-2, HSC-3, HSC-4 cell lines, 265
- Odontoglossum* Harvengtense 'Tutu', cytotoxicity, activated macrophages, osteoclastogenesis, 993
- OE19 cells, esophageal carcinoma, chemotaxis, *in vivo* model, metastasis model, 711
- Olimpiq Stem×Cell, diabetic retinopathy, nephropathy, stem cell stimulation, alloxan, experimental diabetes, FITC-BSA, 427
- Opm1 multiple myeloma cells, black tea, theaflavins, proteasome, Arp, 197
- Oral cancer, curcumin, capsaicin, visible light, photodynamic therapy, oral mucosa, 759
- Oral cancer, PAI-1, mice, transgenic, 4-NQO, DMBA, carcinogenesis, model, 1001
- Oral cavity, leiomyoma, histopathology, differential diagnosis, 161
- Oral mucosa, curcumin, capsaicin, visible light, photodynamic therapy, oral cancer, 759
- Oral squamous cell carcinoma, *odontioda* Marie Noel 'Velano' extract, cytotoxicity, apoptosis induction, HSC-2, HSC-3, HSC-4 cell lines, 265
- Oral squamous cell carcinoma, *p53* polymorphism, *p53* codon 72, toombak, Sudan, 59

- Oral tumor, lymphoepithelioma, Epstein-Barr virus, 1087
- Orbital energy, magnolol, honokiol, eugenol, antioxidative activity, RAW264.7 cells, cytotoxicity, COX-2, NF- $\kappa$ B, 941
- Orthotopic mouse models, pancreatic cancer, macrophages, tumor microenvironment, fluorescence imaging, red fluorescent protein, green fluorescent protein, 565
- OSCC, *Rhinacanthus nasutus* extract, cytotoxicity, apoptosis induction, HL-60, HSC-2, HSC-3, HSC-4 cells, 305
- OSCC, sodium fluoride, Ag(NH<sub>3</sub>)<sub>2</sub>F, 5-FU, cytotoxicity, tumor specificity, apoptosis, T98G, U87MG, HL-60 cells, 657
- Osteocalcin, bone turnover markers, bone alkaline phosphatase, PICP, BMD, elderly men, 1041
- Osteoclastogenesis, *Odontoglossum Harvengtense* 'Tutu', cytotoxicity, activated macrophages, 993
- Osteoclastogenesis, *sasa senanensis* Rehder extract, lichenoid displasia, saliva, IL-6, IL-8, 957
- Osteoprogenitor cells, pulsed electromagnetic field, bone marrow, differentiation, stromal cells, 299
- Outpatients, local anesthetic, ropivacaine, levobupivacaine, pain relief, breast surgery, 1075
- Ovarian cancer, cisplatin, selenite, xenografts, A2780 tumor cells, 549
- Ovarian cancer, simple chromosomal aberration, der(16)t(3;16), translocation, 71
- Ovarian endometriotic cyst, KISS1, KISS1R, GPR54, eutopic endometrium, ectopic endometrium, deep infiltrating endometriosis, 119
- Ovarian granulosa lutein cells, culture medium, HGL-5 cells, 823
- Overweight, elderly, gynaecological surgery, pelvic floor disorder, 1069
- Oxacillin, *Staphylococcus aureus* ATCC 25923 wild-type, *Staphylococcus aureus* HPV-107, intrinsic efflux pump, Qac efflux pump, hydantoin derivatives, inhibition of efflux pumps, reversal of resistance to oxacillin, 223
- Oxidation, Au/Cu alloy, gingival fibroblast, cytotoxicity, elution, HGF cells, 651
- Oxidative stress, biomolecular damage, cancer, inflammation, review, 395
- Oxidative stress, HAART, HIV infection, lipodystrophy, adipocyte differentiation, metabolic syndrome, saquinavir, efavirenz, stavudine, antiretroviral therapies, 287
- Oxidative stress, HAART, HIV infection, lipodystrophy, metabolic syndrome, antiretroviral therapies, 237
- Oxidative stress, *N*-diethylnitrosamine (DEN), mice, liver, antioxidant enzymes, 921
- Oxidative stress, phytoestrogens, antioxidants, neuroprotection, neurodegenerative disease, glaucoma, RGC-5 cells, 765
- P21 and Notch signaling, estrogen, mouse, uterus, vagina, Wnt family genes, 899
- P53 codon 72, *p53* polymorphism, oral squamous cell carcinoma, toombak, Sudan, 59
- P53 polymorphism, oral squamous cell carcinoma, *p53* codon 72, toombak, Sudan, 59
- P53, radioprotection, radiation mitigation, autophagy, carbamazepine, murine hematopoietic progenitor cells, bone marrow stromal cells, Lewis lung carcinoma cells, 341
- P63, nasolabial cyst, podoplanin, cytokeratin, dysontogenetic cyst, non-odontogenic cyst, 453
- PAI-1, mice, oral cancer, transgenic, 4-NQO, DMBA, carcinogenesis, model, 1001
- Pain relief, local anesthetic, ropivacaine, levobupivacaine, breast surgery, outpatients, 1075
- Pancreatic cancer, orthotopic mouse models, macrophages, tumor microenvironment, fluorescence imaging, red fluorescent protein, green fluorescent protein, 565
- Pancreatic carcinoma, EGFR, imaging, CAPAN1, HPAC, HUVECs cells, 619
- Paneth cells, duodenum, synaptophysin, lysozyme, goblet cells, 135
- PARP, doxorubicin, apoptosis, zygote, the early embryonic development, 827
- PCNA, colorectal cancer, thymidine phosphorylase, extracellular matrix components, CD34, ki-67, VEGF, 1057
- PCNA, inflammation, HOCl, amino acid chloramines, protein damage, 501
- PEG coating, biofilm, ventilation tube, streptococcus pneumoniae R6, 907
- Pelvic floor disorder, elderly, gynaecological surgery, overweight, 1069
- Peripheral venous cannula, hairy cell leukemia, HCL, leukemia cutis, 311
- Peritoneal carcinomatosis, gastric cancer, HIPEC, MKN45 cells, NOD-SCID mice, 39
- Perivalvular tissues, cardiac valves, inflammation, cardiovascular prosthetic surgery, 271
- Pg-P1, hydantoin, ABCB1, multidrug resistance, 293
- Phagocytosis, MCF-7, autophagy, apoptosis, 403
- Pharmacokinetics, 17 $\alpha$ -ethynylestradiol, bisphenol A, nonylphenol, 17 $\beta$ -estradiol, frog, *Rana rugosa*, 913
- Pharmacokinetics, transplantation, cyclophosphamide, DNA adducts, obesity, hematopoietic cell transplant recipients, 853
- Pharmacological properties, *Pistacia lentiscus*, mastic gum, biomedical properties, review, 777
- Phase angle, single-frequency bioelectrical impedance, lymphedema of the upper limb, breast cancer, resistance, 863
- Phenothiazines, multidrug-resistant tuberculosis, MDRTB, drug-resistant tuberculosis, XDRTB, thioridazine, 231



- Phimosis, BXO, circumcision, phototype, balanitis, *Lichen sclerosus*, 143
- Photodynamic therapy, curcumin, capsaicin, visible light, oral cancer, oral mucosa, 759
- Photolysis, cytochrome *c*, vitamin C, formation of e<sup>-</sup>aq, mutual electron transfer, 129
- Phototype, BXO, circumcision, balanitis, phimosis, *Lichen sclerosus*, 143
- Phytoestrogens, antioxidants, oxidative stress, neuroprotection, neurodegenerative disease, glaucoma, RGC-5 cells, 765
- PICP, bone turnover markers, osteocalcin, bone alkaline phosphatase, BMD, elderly men, 1041
- Pistacia lentiscus*, mastic gum, pharmacological properties, biomedical properties, review, 777
- Placental growth factor (PLGF), adipokines, amniotic fluid, human adiponectin, small for gestational age (SGA), appropriate for gestational age (AGA), large for gestational age (LGA), fetal growth, 327
- Plasma cell precursors, caeliac disease, *MUMI*, 859
- Plasma cell precursors, liver, *MUMI*, differential diagnosis, autoimmune hepatitis, 319
- Platelet aggregation, hepatopathy, blood fluidity, 719
- Platelet gel, VAC therapy, regenerative surgery, fistula, wound healing, 147
- Pleomorphic sarcoma NOS, athymic mice, xenograft model, soft tissue sarcoma, 559
- Podoplanin (D2-40), epidermoid cyst, sublingual, MRI, 323
- Podoplanin, nasolabial cyst, p63, cytokeratin, dysontogenetic cyst, non-odontogenic cyst, 453
- Porcine model, epidermal growth factor, epidermal growth factor receptor, liver surgery, biological therapy, liver regeneration, cetuximab, 683
- Positive lymph nodes, RXR $\alpha$ , PPAR $\gamma$ , breast cancer, 87
- Postauricular lesion, spontaneous keloid, histological exam, 173
- PPAR $\gamma$ , RXR $\alpha$ , breast cancer, positive lymph nodes, 87
- Premature neonates, extravasation, dermal substitutes, regenerative medicine, 139
- Preterm labour, mediators, immune regulation, amniotic fluid, cytokines, prostaglandins, leukotrienes, interleukins, cell adhesion molecules, review, 799
- Progesterone, breast cancer, chorionic gonadotropin, estrogen, *N*-methyl-*N*-nitrosourea, female Lewis rats, 361
- Progesterone, GnRH analogues, viability, granulosa luteinized cells, estradiol, 835
- Prostaglandins, mediators, immune regulation, amniotic fluid, preterm labour, cytokines, leukotrienes, interleukins, cell adhesion molecules, review, 799
- Prostate cancer, antisense, bcl-2, VEGF, 937
- Proteasome, black tea, theaflavins, Arp, Opm1 multiple myeloma cells, 197
- Protein damage, inflammation, HOCl, amino acid chloramines, PCNA, 501
- Proteomics, implantable cardioverter defibrillators, heart failure, biomarkers, mortality, arrhythmias, SELDI-TOF MS, 875
- Prothrombin fragment (F1+2), acute myocardial infarction (AMI), coronary artery diseases (CAD), unstable atherosclerotic plaque, matrix metalloproteinase-9 (MMP-9), neutrophil gelatinase-associated lipocalin (NGAL), antithrombin III, 1021
- Prothrombin, thromboembolism, thrombosis, coagulation factor V, genetics, genetic counseling, 165
- Pulsed electromagnetic field, bone marrow, differentiation, osteoprogenitor cells, stromal cells, 299
- Pyoderma gangrenosum*, differential diagnosis, conservative treatment, 157
- Qac efflux pump, *Staphylococcus aureus* ATCC 25923 wild-type, *Staphylococcus aureus* HPV-107, intrinsic efflux pump, hydantoin derivatives, oxacillin, inhibition of efflux pumps, reversal of resistance to oxacillin, 223
- Quorum sensing, CV026, trifluoromethyl ketones, AHL, efflux pump, 277
- Radiation fibrosis, antioxidant therapy, zebrafish, 889
- Radiation mitigation, radioprotection, autophagy, p53, carbamazepine, murine hematopoietic progenitor cells, bone marrow stromal cells, Lewis lung carcinoma cells, 341
- Radical scavenging, *Sasa senanensis* Rehder, leaf extract, anti-HIV, anti-UV, CYP3A4 inhibition, Fe(II), lignin, 259
- Radical scavenging, *Sasa senanensis* Rehder, leaf extract, anti-HIV, anti-UV, CYP3A4 inhibition, ESR spectroscopy, MT-4, HSC-2, HPC, HGF cells, 411
- Radioprotection, radiation mitigation, autophagy, p53, carbamazepine, murine hematopoietic progenitor cells, bone marrow stromal cells, Lewis lung carcinoma cells, 341
- Rana rugosa*, pharmacokinetics, 17 $\alpha$ -ethynylestradiol, bisphenol A, nonylphenol, 17 $\beta$ -estradiol, frog, 913
- Rat model, hepatocarcinogenesis, liver cancer, carcinogenesis, selenium, statins, HMGCoA reductase inhibitors, thioredoxin reductase, glutathione peroxidase, review, 527
- Rat model, uPA, C6-glioma, infiltration, glioblastoma multiforme, 571
- Rat, bone healing, diode laser, tibial fracture, 703
- Rats, *Lactobacillus pentosus* strain S-PT84, culture supernatant, autonomic nerve, brown adipose tissue, thermogenesis, 355
- RAW264.7 cells, magnolol, honokiol, eugenol, antioxidative activity, cytotoxicity, COX-2, NF- $\kappa$ B, orbital energy, 941
- Real-time PCR, *Candida*, *Aspergillus*, ITS, high-resolution melting (HRM), 979

- Reconstructive surgery, eyelid, autologous graft, surgical technique, venous graft, 447
- Red fluorescent protein, pancreatic cancer, orthotopic mouse models, macrophages, tumor microenvironment, fluorescence imaging, green fluorescent protein, 565
- Refinement, automated blood sampling, Accusampler, stress, corticosterone, food intake, body weight, BALB/c mice, 577
- Regenerative medicine, extravasation, premature neonates, dermal substitutes, 139
- Regenerative surgery, platelet gel, VAC therapy, fistula, wound healing, 147
- Resistance, single-frequency bioelectrical impedance, lymphedema of the upper limb, breast cancer, phase angle, 863
- Reversal of resistance to oxacillin, *Staphylococcus aureus* ATCC 25923 wild-type, *Staphylococcus aureus* HPV-107, intrinsic efflux pump, Qac efflux pump, hydantoin derivatives, oxacillin, inhibition of efflux pumps, 223
- Review, biomolecular damage, cancer, inflammation, oxidative stress, 395
- Review, cancer, *in vivo* models, GST-P 7-7, 647
- Review, hepatocarcinogenesis, liver cancer, rat model, carcinogenesis, selenium, statins, HMGCoA reductase inhibitors, thioredoxin reductase, glutathione peroxidase, 527
- Review, IGF-II, tumour, *in vitro*, *in vivo*, tumorigenesis, 519
- Review, inflammatory bowel disease, mouse models inflammation, colorectal cancer, 627
- Review, mediators, immune regulation, amniotic fluid, preterm labour, cytokines, prostaglandins, leukotrienes, interleukins, cell adhesion molecules, 799
- Review, medulloblastoma, central nervous system primitive neuroectodermal tumor, *in vivo* models, Sleeping Beauty transposon mutagenesis, genetic origins, 487
- Review, NSAIDs, COX-2 inhibitors, IBD, experimental colitis, cyclooxygenase, 381
- Review, *Pistacia lentiscus*, mastic gum, pharmacological properties, biomedical properties, 777
- Review, tumor model, fluorescence, GFP, FRET, biosensor, 599
- Review, urothelial, carcinogenesis, *N*-butyl-*N*-(4-hydroxybutyl) nitrosamine, tumours, 727
- RGC-5 cells, phytoestrogens, antioxidants, oxidative stress, neuroprotection, neurodegenerative disease, glaucoma, 765
- Rhinacanthus nasutus* extract, cytotoxicity, apoptosis induction, OSCC, HL-60, HSC-2, HSC-3, HSC-4 cells, 305
- Right ventricle, ultrasound contrast agent, heart failure, 869
- Risk stratification, acute coronary syndrome, chest pain, coronary computed tomography angiography, emergency department, triple-rule-out, troponin, 1035
- Rofecoxib-vioxx, metallothionein, stem cell, colon cancer, Musashi, dimethylhydrazine, 5-FU, MS275 5-azadeoxycytine, 693
- Ropivacaine, local anesthetic, levobupivacaine, pain relief, breast surgery, outpatients, 1075
- RXR $\alpha$ , PPAR $\gamma$ , breast cancer, positive lymph nodes, 87
- Saliva, *Sasa senanensis* Rehder extract, lichenoid dysplasia, IL-6, IL-8, osteoclastogenesis, 957
- Salivary gland, aquaporin 5, sialadenosis, acinar gland, 951
- Salivary glycine, template therapy, metabolite profiling, 1015
- Salmonella enterica* serovar Enteritidis, multidrug resistance, Gram-negative and Gram positive bacteria, *Escherichia coli*, *Staphylococcus aureus*, acridine orange (AO), agar method, evaluation of efflux pump activity, 203
- Saquinavir, HAART, HIV infection, lipodystrophy, adipocyte differentiation, metabolic syndrome, oxidative stress, efavirenz, stavudine, antiretroviral therapies, 287
- Sasa senanensis* Rehder extract, lichenoid dysplasia, saliva, IL-6, IL-8, osteoclastogenesis, 957
- Sasa senanensis* Rehder, leaf extract, anti-HIV, anti-UV, radical scavenging, CYP3A4 inhibition, Fe(II), lignin, 259
- Sasa senanensis* Rehder, leaf extract, anti-HIV, anti-UV, radical scavenging, CYP3A4 inhibition, ESR spectroscopy, MT-4, HSC-2, HPC, HGF cells, 411
- Scaffold-free, cartilage, tissue engineering, microspheres, tissue repair, 251
- Secretory IgA, acclimatization, animal welfare, housing conditions, mice, fecal corticosterone, social grouping, 883
- SELDI-TOF MS, implantable cardioverter defibrillators, heart failure, biomarkers, mortality, arrhythmias, proteomics, 875
- Selenite, cisplatin, ovarian cancer, xenografts, A2780 tumor cells, 549
- Selenium, hepatocarcinogenesis, liver cancer, rat model, carcinogenesis, statins, HMGCoA reductase inhibitors, thioredoxin reductase, glutathione peroxidase, review, 527
- Sentinel node biopsy, melanoma, surgery, local anaesthesia, healthcare costs, general anaesthesia, 315
- Serum biomarker analysis, *Agaricus blazei* Murill, genotoxicity, subclinical toxicity, Ames test, histopathology, ALT, AST, 437
- Serum estrogen metabolites, cervical cancer, 3, 3'-diindolylmethane, interferon- $\gamma$ , cancer prevention, K14-HPV16 transgenic mouse model, gas chromatography, 207
- Severity graduation, aortic stenosis, echocardiography, Doppler, inert gas rebreathing, hybrid approach, 1027
- Shaker-2, mouse model, non-syndromic deafness, DFNB3, myoXV gene, 787
- Sialadenosis, aquaporin 5, salivary gland, acinar gland, 951

- Sialic acid, *N*-glycosylated gangliosides, cytidine monophospho-*N*-acetylneuraminic acid hydroxylase, cancer, immunotherapy, 609
- Simple chromosomal aberration, ovarian cancer, der(16)t(3;16), translocation, 71
- Single-frequency bioelectrical impedance, lymphedema of the upper limb, breast cancer, phase angle, resistance, 863
- Single-nucleotide polymorphisms, cardiovascular risk factors, coagulation factors, DNA polymorphisms, genetic predisposition, Greece, thrombophilia, 1095
- Skin cancer, nasal ala, nasolabial flap, island flap, nose reconstruction, 93
- Sleeping Beauty transposon mutagenesis, medulloblastoma, central nervous system primitive neuroectodermal tumor, *in vivo* models, genetic origins, review, 487
- Small for gestational age (SGA), adipokines, amniotic fluid, human adiponectin, placental growth factor (PLGF), appropriate for gestational age (AGA), large for gestational age (LGA), fetal growth, 327
- Smoking cessation program, nicotine replacement therapy, sublingual tablet, 463
- Snai1, ethanol, B16-BL6, Kiss1, melanoma metastasis, E-cadherin, 47
- Snoring, obstructive sleep apnoea, mandibular advancement splint, BMI, 841
- Social grouping, acclimatization, animal welfare, secretory IgA, housing conditions, mice, fecal corticosterone, 883
- SOD1-ALS mouse, *in vivo* imaging, cell transplantation, ALS, SPIO, umbilical cord blood stem cells, MRI, tracking, MTH53A cells, CD34<sup>+</sup>, 31
- Sodium fluoride, Ag(NH<sub>3</sub>)<sub>2</sub>F, 5-FU, cytotoxicity, tumor specificity, apoptosis, OSCC, T98G, U87MG, HL-60 cells, 657
- Soft tissue sarcoma, pleomorphic sarcoma NOS, athymic mice, xenograft model, 559
- Sorafenib, hepatocellular carcinoma, NF- $\kappa$ B, MMP-9, VEGF, Huh 7 cells, 671
- SPIO, *in vivo* imaging, cell transplantation, ALS, umbilical cord blood stem cells, MRI, tracking, MTH53A cells, SOD1-ALS mouse, CD34<sup>+</sup>, 31
- Splenectomy, splenic hamartoma, splenic mass, splenic neoplasm, 1049
- Splenic hamartoma, splenic mass, splenic neoplasm, splenectomy, 1049
- Splenic mass, splenic hamartoma, splenic neoplasm, splenectomy, 1049
- Splenic neoplasm, splenic hamartoma, splenic mass, splenectomy, 1049
- Spontaneous keloid, postauricular lesion, histological exam, 173
- SSTR1-5, docetaxel, octreotide, dexamethasone, TRAMP-C1 cells, bone metastases, 75
- Stafne's cavity, anterior lingual mandibular bone depression, sublingual gland, magnetic resonance imaging, ultrasound, cone beam computed tomography, 1103
- Stafne's cavity, mandibular bone defect, lingual bone depression of mandible, bone resorption, 1045
- Staphylococcus aureus* ATCC 25923 wild-type, *Staphylococcus aureus* HPV-107, intrinsic efflux pump, Qac efflux pump, hydantoin derivatives, oxacillin, inhibition of efflux pumps, reversal of resistance to oxacillin, 223
- Staphylococcus aureus* HPV-107, *Staphylococcus aureus* ATCC 25923 wild-type, intrinsic efflux pump, Qac efflux pump, hydantoin derivatives, oxacillin, inhibition of efflux pumps, reversal of resistance to oxacillin, 223
- Staphylococcus aureus*, multidrug resistance, Gram-negative and Gram positive bacteria, *Escherichia coli*, *Salmonella enterica* serovar Enteritidis, acridine orange (AO), agar method, evaluation of efflux pump activity, 203
- Statins, hepatocarcinogenesis, liver cancer, rat model, carcinogenesis, selenium, HMGCoA reductase inhibitors, thioredoxin reductase, glutathione peroxidase, review, 527
- Stavudine, HAART, HIV infection, lipodystrophy, adipocyte differentiation, metabolic syndrome, oxidative stress, saquinavir, efavirenz, antiretroviral therapies, 287
- Stem cell stimulation, diabetic retinopathy, nephropathy, alloxan, experimental diabetes, FITC-BSA, Olimpqi Stem $\times$ Cell, 427
- Stem cell, metallothionein, colon cancer, Musashi, dimethylhydrazine, 5-FU, rofecoxib-vioxx, MS275 5-azadeoxycytine, 693
- Streptococcus pneumoniae* R6, biofilm, ventilation tube, PEG coating, 907
- Stress, automated blood sampling, Accusampler, refinement, corticosterone, food intake, body weight, BALB/c mice, 577
- Stress, dietary fat, ACTH, C57bl/6, BALB/c mice, fetal corticosterone, 213
- Stromal cells, pulsed electromagnetic field, bone marrow, differentiation, osteoprogenitor cells, 299
- Subclinical toxicity, *Agaricus blazei* Murill, genotoxicity, Ames test, histopathology, serum biomarker analysis, ALT, AST, 437
- Subcutaneous tumor, vascular leiomyoma, angioleiomyoma, nasal tumor, benign tumor, 1091
- Sublingual gland, anterior lingual mandibular bone depression, Stafne's cavity, magnetic resonance imaging, ultrasound, cone beam computed tomography, 1103
- Sublingual tablet, nicotine replacement therapy, smoking cessation program, 463
- Sublingual, epidermoid cyst, MRI, podoplanin (D2-40), 323

- Sudan, *p53* polymorphism, oral squamous cell carcinoma, *p53* codon 72, toombak, 59
- Surfactant protein C, CCSP, GCV, bone marrow, lung repair, GFP, FOXJ1, 9
- Surgery, Crohn's disease, cytomegalovirus infection, immuno-histochemistry, 151
- Surgery, melanoma, sentinel node biopsy, local anaesthesia, healthcare costs, general anaesthesia, 315
- Surgical technique, eyelid, reconstructive surgery, autologous graft, venous graft, 447
- Symptoms, abdominal pain, diagnosis, history, 335
- Synaptophysin, duodenum, paneth cells, lysozyme, goblet cells, 135
- T- and B- cells, chrysin, WEHI-3 murine leukemia cells, macrophage phagocytosis, NK cell cytotoxicity, CD3, CD19, CD11b, 665
- T24, antimicrobial peptides, (KLAKLAK)<sub>2</sub>, targeted tumor therapy, MDA-MB435S, DU145, Tet21N, Wac2 cells, breast cancer xenografts, 419
- T98G, sodium fluoride, Ag(NH<sub>3</sub>)<sub>2</sub>F, 5-FU, cytotoxicity, tumor specificity, apoptosis, OSCC, U87MG, HL-60 cells, 657
- Targeted tumor therapy, antimicrobial peptides, (KLAKLAK)<sub>2</sub>, MDA-MB435S, T24, DU145, Tet21N, Wac2 cells, breast cancer xenografts, 419
- Targeting, EG-VEGF, angiogenesis, chick embryo chorioallantoic membrane, 793
- Template therapy, metabolite profiling, salivary glycine, 1015
- Tet21N, antimicrobial peptides, (KLAKLAK)<sub>2</sub>, targeted tumor therapy, MDA-MB435S, T24, DU145, Wac2 cells, breast cancer xenografts, 419
- The early embryonic development, doxorubicin, *PARP*, apoptosis, zygote, 827
- Theaflavins, black tea, proteasome, Arp, Opm1 multiple myeloma cells, 197
- Thermogenesis, *Lactobacillus pentosus* strain S-PT84, culture supernatant, autonomic nerve, brown adipose tissue, rats, 355
- Thioredoxin reductase, hepatocarcinogenesis, liver cancer, rat model, carcinogenesis, selenium, statins, HMGCoA reductase inhibitors, glutathione peroxidase, review, 527
- Thioridazine, multidrug-resistant tuberculosis, MDRTB, drug-resistant tuberculosis, XDRTB, phenothiazines, 231
- Thrombocytopenia, hydroxyurea, Bionect Start<sup>®</sup>, circumferential wound, leg ulcers, 1053
- Thromboembolism, thrombosis, coagulation factor V, prothrombin, genetics, genetic counseling, 165
- Thrombophilia, cardiovascular risk factors, coagulation factors, DNA polymorphisms, genetic predisposition, Greece, single-nucleotide polymorphisms, 1095
- Thrombosis, thromboembolism, coagulation factor V, prothrombin, genetics, genetic counseling, 165
- Thymidine phosphorylase, colorectal cancer, extracellular matrix components, CD34, ki-67, VEGF, PCNA, 1057
- Thymus, dendritic cells, immunohistochemistry, 985
- Tibial fracture, bone healing, diode laser, rat, 703
- Tissue engineering, cartilage, microspheres, tissue repair, scaffold-free, 251
- Tissue repair, cartilage, tissue engineering, microspheres, scaffold-free, 251
- Toombak, *p53* polymorphism, oral squamous cell carcinoma, *p53* codon 72, Sudan, 59
- Tracking, *in vivo* imaging, cell transplantation, ALS, SPIO, umbilical cord blood stem cells, MRI, MTH53A cells, SOD1-ALS mouse, CD34<sup>+</sup>, 31
- TRAMP-C1 cells, docetaxel, octreotide, dexamethasone, bone metastases, SSTR1-5, 75
- Transgenic, PAI-1, mice, oral cancer, 4-NQO, DMBA, carcinogenesis, model, 1001
- Transitional cell carcinoma, canine, interleukin-2, urinary, bladder, urethral carcinoma, 931
- Translocation, ovarian cancer, simple chromosomal aberration, der(16)t(3;16), 71
- Transplantation, cyclophosphamide, DNA adducts, obesity, pharmacokinetics, hematopoietic cell transplant recipients, 853
- Trifluoromethyl ketones, quorum sensing, CV026, AHL, efflux pump, 277
- Triple-rule-out, acute coronary syndrome, chest pain, coronary computed tomography angiography, emergency department, risk stratification, troponin, 1035
- Troponin, acute coronary syndrome, chest pain, coronary computed tomography angiography, emergency department, risk stratification, triple-rule-out, 1035
- Tumor microenvironment, pancreatic cancer, orthotopic mouse models, macrophages, fluorescence imaging, red fluorescent protein, green fluorescent protein, 565
- Tumor model, fluorescence, GFP, FRET, biosensor, review, 599
- Tumor specificity, sodium fluoride, Ag(NH<sub>3</sub>)<sub>2</sub>F, 5-FU, cytotoxicity, apoptosis, OSCC, T98G, U87MG, HL-60 cells, 657
- Tumor stem cells, CSC, CD44, ALDH1A1, Ki 67, EGFR, xenograft mouse model, 593
- Tumour, IGF-II, *in vitro*, *in vivo*, tumourigenesis, review, 519
- Tumourigenesis, IGF-II, tumour, *in vitro*, *in vivo*, review, 519
- Tumours, urothelial, carcinogenesis, *N*-butyl-*N*-(4-hydroxybutyl) nitrosamine, review, 727
- U87MG, sodium fluoride, Ag(NH<sub>3</sub>)<sub>2</sub>F, 5-FU, cytotoxicity, tumor specificity, apoptosis, OSCC, T98G, HL-60 cells, 657
- U937 leukemia cells, chlorogenic acid, apoptosis, caspases, mitochondrial dysfunction, 971



- Ultrasound contrast agent, heart failure, right ventricle, 869
- Ultrasound, anterior lingual mandibular bone depression, Stafne's cavity, sublingual gland, magnetic resonance imaging, cone beam computed tomography, 1103
- Umbilical cord blood stem cells, *in vivo* imaging, cell transplantation, ALS, SPIO, MRI, tracking, MTH53A cells, SOD1-ALS mouse, CD34<sup>+</sup>, 31
- Unstable atherosclerotic plaque, acute myocardial infarction (AMI), coronary artery diseases (CAD), matrix metalloproteinase-9 (MMP-9), neutrophil gelatinase-associated lipocalin (NGAL), prothrombin fragment (F1+2), antithrombin III, 1021
- Unusual site of origin, keratocystic odontogenic tumor, buccal space, case report, 847
- UPA, C6-glioma, rat model, infiltration, glioblastoma multiforme, 571
- Urethral carcinoma, canine, transitional cell carcinoma, interleukin-2, urinary, bladder, 931
- Urinary, canine, transitional cell carcinoma, interleukin-2, bladder, urethral carcinoma, 931
- Urothelial, carcinogenesis, *N*-butyl-*N*-(4-hydroxybutyl) nitrosamine, tumours, review, 727
- Uterus, estrogen, mouse, vagina, p21 and Notch signaling, Wnt family genes, 899
- UV protection, glycyrrhizin, Kampo medicine, anti-HIV, 1007
- VAC therapy, platelet gel, regenerative surgery, fistula, wound healing, 147
- Vagina, estrogen, mouse, uterus, p21 and Notch signaling, Wnt family genes, 899
- Vasa vasorum, atherosclerosis, vascular cell adhesion molecule, intercellular adhesion molecule, high-density lipoprotein cholesterol, 243
- Vascular cell adhesion molecule, atherosclerosis, intercellular adhesion molecule, high-density lipoprotein cholesterol, vasa vasorum, 243
- Vascular leiomyoma, angioleiomyoma, subcutaneous tumor, nasal tumor, benign tumor, 1091
- VEGF, antisense, bcl-2, prostate cancer, 937
- VEGF, colorectal cancer, thymidine phosphorylase, extracellular matrix components, CD34, ki-67, PCNA, 1057
- VEGF, hepatocellular carcinoma, sorafenib, NF- $\kappa$ B, MMP-9, Huh 7 cells, 671
- Venous graft, eyelid, reconstructive surgery, autologous graft, surgical technique, 447
- Ventilation tube, biofilm, PEG coating, streptococcus pneumoniae R6, 907
- Vertical occlusal dimension, VOD, heart rate fluctuations, excessive autonomic nerve, 177
- Viability, GnRH analogues, granulosa luteinized cells, estradiol, progesterone, 835
- Visible light, curcumin, capsaicin, photodynamic therapy, oral cancer, oral mucosa, 759
- Vitamin C, cytochrome *c*, formation of e<sup>-</sup>aq, photolysis, mutual electron transfer, 129
- VOD, vertical occlusal dimension, heart rate fluctuations, excessive autonomic nerve, 177
- Wac2 cells, antimicrobial peptides, (KLAKLAK)<sub>2</sub>, targeted tumor therapy, MDA-MB435S, T24, DU145, Tet21N, breast cancer xenografts, 419
- WEHI-3 murine leukemia cells, chrysin, T- and B- cells, macrophage phagocytosis, NK cell cytotoxicity, CD3, CD19, CD11b, 665
- Wnt family genes, estrogen, mouse, uterus, vagina, p21 and Notch signaling, 899
- Wound healing, platelet gel, VAC therapy, regenerative surgery, fistula, 147
- XDRTB, multidrug-resistant tuberculosis, MDRTB, drug-resistant tuberculosis, phenothiazines, thioridazine, 231
- Xenograft model, pleomorphic sarcoma NOS, athymic mice, soft tissue sarcoma, 559
- Xenograft mouse model, tumor stem cells, CSC, CD44, ALDH1A1, Ki 67, EGFR, 593
- Xenograft, neuroblastoma, mouse model, metastasis, cisplatin, NSG, 19
- Xenografts, cisplatin, selenite, ovarian cancer, A2780 tumor cells, 549
- Ximenia caffra*, indigenous fruit-bearing tree seed oils, Caco-2 cells, HEK-293 cells, growth suppression, essential fatty acids, *Kigelia africana*, *Mimusops zeyheri*, 99
- Zebrafish, radiation fibrosis, antioxidant therapy, 889
- Zygote, doxorubicin, *PARP*, apoptosis, the early embryonic development, 827

## Authors Index

(Figures refer to page numbers)

- Aarnio MT, 151  
 Abelson KS, 213, 577, 883  
 Adachi K, 657  
 Agrogiannis G, 243  
 Ahmad F, 1  
 Ahmadova Z, 599  
 Akiyama N, 787  
 Al-Benna S, 559  
 Al-Dam A, 323, 847  
 Alonso DF, 609  
 Amaral L, 203, 223, 231, 277, 293  
 Anderson KM, 183  
 Andrade R, 921  
 Ansidei V, 447  
 Antoniadis T, 165  
 Antsaklis A, 119  
 Anzai T, 719  
 Armada A, 223, 277, 293  
 Asano K, 719  
 Asimakopoulos B, 823, 835  
 Assaf AT, 323, 453, 1045  
 Auburn K, 207  
 Avgoustidis D, 1001  
 Avolio M, 469  
 Azuma Y, 177  
 Badolato M, 315  
 Baermann-Stapel Y, 63  
 Bahary N, 889  
 Bai M, 985  
 Baldi A, 143, 161, 237, 1087  
 Baranzelli M-C, 1079  
 Barbisan LF, 647  
 Barbouti A, 985  
 Basso SMM, 469, 1041, 1049  
 Bau D-T, 403, 963  
 Beckmann MW, 813  
 Bendszus M, 571  
 Benes J, 683  
 Beppu Y, 355  
 Bergman D, 519  
 Berlitz S, 481, 863, 1069  
 Bernard ME, 9, 341  
 Bertagnolli AC, 375  
 Bette M, 951  
 Bianco A, 271  
 Björkhem-Bergman L, 527  
 Blessmann M, 323, 711, 847  
 Bobek V, 473  
 Boccellino M, 1087  
 Boenninghoff R, 619  
 Böhm JP, 151  
 Bonnetterre J, 1079  
 Borggreffe M, 1027, 1035  
 Borkeloh M, 951  
 Bortolato A, 1075  
 Boselli C, 315  
 Botsis D, 327  
 Bouraki G, 823  
 Bouvet M, 565  
 Bove P, 143  
 Brade J, 863  
 Bradlow HL, 207  
 Bramos D, 869  
 Brenn E, 107  
 Brenna S, 1021  
 Briasoulis E, 1057  
 Bruha J, 683  
 Bugiantella W, 39  
 Buhrkhul D, 859  
 Bundgaard CJ, 883  
 Bussen S, 1069  
 Caffrey PB, 549  
 Cagini C, 447  
 Camporese A, 469  
 Cantarella F, 39  
 Cao S, 9  
 Caputo C, 1087  
 Carella S, 139, 1091  
 Carlisle AD, 207  
 Caruso U, 161  
 Carvalho JJ, 63  
 Cassali GD, 375  
 Castellani E, 315  
 Cavaliere F, 537  
 Cavazzoni E, 39  
 Cave E, 99  
 Ceausu RA, 793  
 Cencetti F, 447  
 Cerasuolo F, 271  
 Cerca P, 277  
 Cesar A, 647  
 Chae S-W, 907  
 Chang J-B, 437  
 Chang W-Y, 671  
 Characiejus D, 553  
 Charalabopoulos K, 823  
 Chen H-W, 671  
 Chen L-A, 403  
 Chen YH, 403  
 Chiang I-T, 671  
 Chiang J-H, 665  
 Chiara GB, 1049  
 Chirianni A, 237, 287  
 Chiummariello S, 93  
 Chivandi E, 99  
 Chlumska A, 683  
 Cho C-H, 71  
 Choi S-H, 703  
 Chou P-L, 403  
 Choueri RB, 647  
 Chung J-G, 437, 665, 963  
 Chung M-T, 437  
 Cimpean AM, 793  
 Cobanoglu MC, 341  
 Colaço A, 727, 921  
 Costanzo C, 287  
 Covarelli P, 315, 447  
 Creatsas G, 327, 799  
 Cui X-S, 827  
 Cupisti S, 813  
 Curzen NP, 875  
 Daifoti Z, 75  
 Daigeler A, 559  
 Dalezis P, 75  
 Davidson BC, 99  
 D' Avino A, 1087  
 De Campos CB, 375  
 De Luca A, 237, 271, 287  
 De Marchis ML, 537  
 De Rosa R, 469  
 Della Rocca C, 693  
 Della-Morte D, 537  
 Depprich R, 251  
 Desmedt E, 1079  
 Dewald V, 889  
 Di Ronza S, 157  
 Diedrich K, 835  
 Diensthuber M, 593  
 Dimas KS, 777  
 Ditsch N, 87  
 Dittrich R, 813  
 Dixon T, 9, 341  
 Doczi-Keresztesi Z, 427  
 Donini A, 39  
 Donta I, 1001  
 Doukas M, 985  
 Dragonetti E, 143  
 Drenckhan A, 711  
 Dubois F, 1079  
 Durrieu L, 19  
 Dymek A, 223, 293  
 Dziwniel V, 1079  
 Džombeta T, 459  
 Eghardt V, 863  
 Eidukevičius R, 553  
 Ekström L, 527  
 Ember I, 113, 427  
 Englund A-K, 841  
 Engström W, 519  
 Epperly MW, 9, 341, 889  
 Eriksson LC, 527  
 Erlwanger KH, 99  
 Eskelinen M, 335  
 Esposito M, 299  
 Esposito V, 237, 287, 299  
 Ettorre GM, 537  
 Fallo F, 1041  
 Fanti G, 1049  
 Farkas A, 341  
 Feflea S, 793  
 Feltracco P, 1075  
 Fernandez LE, 609  
 Ferraraccio F, 271  
 Ferroni P, 537  
 Finek J, 683  
 Fink C, 1035  
 Fino P, 93, 139, 157, 311, 1053  
 Fioramonti P, 157, 311, 1053  
 Fiore P, 161  
 Fiorucci S, 39  
 Fiumarella A, 271  
 Fontaine F, 19  
 Formica V, 537  
 Fotis L, 243  
 Frančina M, 459  
 Franco M, 381  
 Francicola D, 9, 341  
 Frenkel GD, 549  
 Friedrich RE, 323, 453, 1045, 1103  
 Friese K, 87  
 Fujisaki Y, 355  
 Fujisawa S, 941, 759

- Fujiyama Oshima CT, 381  
 Funayama S, 971  
 Gabri MR, 609  
 Gaje P, 793  
 Galaktidou G, 75  
 Galani V, 985  
 Gallwas J, 87  
 Garbis S, 875  
 Gargiulo M, 237, 287  
 Gassner D, 593  
 Ge Z, 703  
 Geißler C, 593  
 Geromichalos GD, 75  
 Getoff N, 107, 129, 819  
 Girkontaitė I, 553  
 Gócze K, 113  
 Goff JP, 9, 341  
 Goldbrunner R, 571  
 Gombos K, 113  
 Gomez DE, 609  
 Graeff H, 711  
 Grande M, 143  
 Graziosi L, 39  
 Greenberger JS, 9, 341, 889  
 Gridley DS, 743  
 Gröbe A, 847, 1045, 1103  
 Gros SJ, 711  
 Grossbaier J, 369  
 Gruettner J, 1027, 1035  
 Guadagni F, 537  
 Guinan P, 183, 937  
 Haddad É, 19  
 Hafner M, 599  
 Haghi D, 1027, 1035  
 Halje M, 519  
 Hama Y, 191  
 Hambek M, 593  
 Hamm K, 1027  
 Han J, 827  
 Handschel J, 251  
 Handzlik J, 223, 293  
 Hanken H, 847  
 Hansen AK, 577  
 Hasegawa N, 787  
 Hass R, 31  
 Hassanein MK, 565  
 Hau J, 213, 577, 883  
 Hauser J, 559  
 Heggemann F, 1027  
 Heiland M, 323, 847  
 Henzler T, 1035  
 Hibino Y, 651  
 Hirano K, 651  
 Hirsch JM, 463, 841  
 Hisamitsu T, 719  
 Hoffman RM, 565  
 Hoffman TJ, 583  
 Hoffmann I, 813  
 Hoffmann TK, 571  
 Hofmann M, 191  
 Hollowell CMP, 937  
 Holubec L, 683  
 Horie N, 1007  
 Horii H, 305  
 Horii Y, 355  
 Hörmann K, 369  
 Hornemann A, 481, 863  
 Horvath A, 979  
 Houghton F, 341  
 Housa D, 473  
 Hsu F-T, 671  
 Hsu Y-N, 963  
 Hubickova-Heringova L, 473  
 Hwang J-J, 671  
 Hyvärinen A, 1  
 Ibrahim SO, 59  
 Idestrom M, 859  
 Iguchi T, 899, 913  
 Iliodromiti Z, 327, 799  
 Ioachim E, 1057  
 Ishikawa S, 719  
 Ishikawa T, 719  
 Ito S, 941  
 Itoh K, 957  
 Iwamoto S, 259  
 Izbicki JR, 711  
 Izumo T, 355  
 Jacobsen KR, 213, 577  
 Jacobson PA, 853  
 Jäkel CE, 419  
 Jalouli J, 59  
 Jalouli MM, 59  
 Jeschke U, 87  
 Ji B-C, 971  
 Johnson LA, 853  
 Juhász K, 113  
 Jukić Z, 459  
 Jung J, 427  
 Jurina K, 931  
 Juršėnaitė J, 553  
 Kadoma Y, 941  
 Kaladaridou A, 869  
 Kalampokas E, 327  
 Kalampokas T, 327  
 Kalash R, 341  
 Kalliokoski O, 213, 577, 883  
 Kanamoto T, 259, 411, 1007  
 Kanavaros P, 985  
 Kaneko M, 1015  
 Kaneko T, 1007  
 Kaneshima A, 1015  
 Karatzias G, 985  
 Karavolos S, 799  
 Kashyap AK, 765  
 Kato T, 1007  
 Katsu Y, 899  
 Kawase M, 277  
 Kawata A, 941  
 Keese M, 599, 619  
 Kehl S, 481, 1069  
 Kessler M, 619  
 Kieć-Kononowicz K, 223, 293  
 Kim G, 703  
 Kim H, 9, 341  
 Kim H-T, 71  
 Kim N-H, 827  
 Kim Y, 419  
 Kim Y-B, 703  
 Kiss I, 427  
 Kitajima M, 259, 411, 957  
 Knapp WH, 191  
 Knippenberg S, 31  
 Ko Y-C, 971  
 Kobayashi M, 651  
 Koh T, 657, 941  
 Kohonen-Corish MRJ, 627  
 Kolostova K, 473  
 Konietzschke U, 931  
 Kostaki M, 243  
 Köster F, 835  
 Kotsinas A, 395  
 Kottis G, 869  
 Koutsilieris M, 75, 119  
 Kraus P, 1035  
 Kruschinski C, 191  
 Krušlin B, 459  
 Ksieski HB, 207  
 Kubecova M, 473  
 Kuehnel S, 571  
 Kuo C-L, 665, 971  
 Kuopio TH, 151  
 Kurschat N, 711  
 Kusama K, 1007  
 Kushiro K, 47  
 Kwak Y-C, 827  
 Lai Y-C, 361  
 Laino L, 161, 1087  
 Largaespada DA, 487  
 Larson JD, 487  
 Lavallo GE, 375  
 Lazzaro D, 693  
 Le Rhun E, 1079  
 Lee C-S, 437  
 Leinung M, 593  
 Lekerud A-K, 463, 841  
 Lenhard M, 87  
 Leone B, 537  
 Leweling H, 863  
 Lež C, 459  
 Liao N-C, 437  
 Liapi A, 119  
 Libalova P, 473  
 Libera J, 251  
 Lijnen R, 1001  
 Lin C-C, 665  
 Lin J-J, 437  
 Lin J-P, 665  
 Lin L-L, 963  
 Lin S-S, 963  
 Lin W-J, 671  
 Lipponen P, 335  
 Liska V, 683  
 Listorti C, 315  
 Liu C-C, 963  
 Liu C-M, 437  
 Liu C-W, 971  
 Liu Y-C, 671  
 Lopes C, 727, 921  
 Lu C-C, 665  
 Lu H-F, 437  
 Lucariello A, 271, 287, 299  
 Ludovici G, 537  
 Lumachi F, 469, 1041, 1049, 1075  
 Lymeri M, 75  
 Ma C-Y, 971  
 Ma Y-S, 971  
 Machino M, 657, 759, 941, 957, 1015  
 Madziva MT, 99  
 Maehara K, 177, 1015  
 Magda I, 113  
 Magdeburg R, 619  
 Magkou C, 119  
 Majoros H, 979  
 Maki J, 411  
 Makri A, 119  
 Makrigiannakis A, 87  
 Mandic R, 951  
 Manente L, 237, 287  
 Manfè AZ, 1075

- Man-Kuan A, 437  
 Manome Y, 787  
 Marchese C, 139  
 Marchesini M, 1075  
 Marchi P, 381  
 Margoni A, 243  
 Marković I, 459  
 Martins A, 203, 293  
 Maruccia M, 139, 173, 1091  
 Maruyama T, 941  
 Marzano B, 1049  
 Mastorakos G, 799  
 Masuda Y, 265  
 Matković K, 459  
 Matsuta T, 259, 411, 657, 957, 1007  
 Mauricas M, 553  
 Mayr D, 87  
 Mazzarella G, 271  
 Mehrotra S, 743  
 Meier M, 31  
 Mena Acra A, 657  
 Mencarelli A, 39  
 Menditti D, 161, 1087  
 Menen RS, 565  
 Meschenmoser K, 419  
 Metallinou C, 823, 835  
 Meyer U, 251  
 Mezei T, 427  
 Mikhailidis DP, 243  
 Milano M, 1087  
 Milingos D, 119  
 Min K-W, 71  
 Mior MAA, 277  
 Mirka H, 683  
 Miszputen SJ, 381  
 Mitselou A, 1057  
 Miyagawa S, 899  
 Mladenova D, 627  
 Modolo ML, 469  
 Molnar J, 223, 231, 293, 277  
 Momiyama M, 565  
 Monarca C, 93, 173  
 Montiel Bastida NM, 657  
 Moon Y-S, 71  
 Moossa AR, 565  
 Moresco L, 147  
 Morgan JM, 875  
 Mori F, 693  
 Morita Y, 259, 411  
 Moroboshi T, 719  
 Mortier L, 1079  
 Motohashi N, 277  
 Moyo D, 99  
 Msaouel P, 119  
 Mueller A, 813  
 Mujtaba T, 197  
 Murakami Y, 941  
 Muraoka E, 759  
 Murua Escobar H, 31  
 Naarala J, 1  
 Nagai K, 355  
 Nakajima H, 651, 657  
 Nakamura T, 899  
 Nakanishi-Ueda T, 719  
 Nakashima H, 259, 411, 1007  
 Nakashima T, 355  
 Nanda PK, 583  
 Naoki U, 1007  
 Nastri L, 161  
 Naujoks C, 251  
 Neff A, 951  
 Neff W, 481  
 Ng LL, 875  
 Nikolettos N, 835  
 Nisyrios T, 1001  
 Nixon AM, 1095  
 Nkenke E, 1001  
 Noguti J, 647  
 Noh I, 907  
 Nolte I, 31  
 Nomura S, 177  
 Nordin M, 519  
 Noya G, 315  
 Núñez NP, 47  
 Nuorva KP, 151  
 Nyalendo C, 19  
 Nyirenda T, 207  
 Oda Y, 651  
 Ogihara T, 657  
 Ohkubo A, 259, 411  
 Ohta Y, 899  
 Ohtsuki S, 411  
 Oizumi H, 259, 411, 957  
 Oizumi T, 259, 411  
 Oizumi T, 957  
 Okada N, 759  
 Oliveira MM, 921  
 Oliveira PA, 727, 921  
 Ondricek AJ, 765  
 Onesti MG, 139, 157, 311, 1053, 1091  
 Onuki H, 651  
 Onuma H, 1015  
 Orlando R, 1041  
 Otero LL, 609  
 Otsuki S, 657  
 Pabst R, 191  
 Pacholska A, 1  
 Palmieri A, 93  
 Palmirota R, 537  
 Palumbo F, 173  
 Pamboucas C, 869  
 Panagiotopoulou D, 75  
 Panne U, 63  
 Pantazis P, 777  
 Pantopoulou A, 243  
 Papageorgiou A, 75  
 Papageorgiou E, 75  
 Pape E, 1079  
 Papoudou-Bai A, 985  
 Parisi P, 173, 1053  
 Parrella G, 237, 287  
 Parrella R, 237, 287  
 Passaretti D, 311  
 Patel M, 183  
 Pecaut MJ, 743  
 Pecen L, 473  
 Pei J-S, 963  
 Peixoto F, 921  
 Perdiki M, 859  
 Pereira IC, 921  
 Perna A, 237  
 Perrea D, 243, 1001  
 Persichetti P, 157  
 Peto Z, 979  
 Petraki C, 119  
 Petri S, 31  
 Pinelli A, 1021  
 Ping Dou Q, 197  
 Pinterova D, 473  
 Pires MJ, 921  
 Pissimissis N, 75  
 Pitkänen RI, 151  
 Pitule P, 683  
 Poponesi V, 315  
 Protopapas A, 119  
 Quader M, 889  
 Racek J, 683  
 Ragos V, 1001, 1095  
 Raica M, 793  
 Rajagopalan MS, 9  
 Ramanujam R, 777  
 Ramaswamy A, 951  
 Raucci L, 207  
 Rawnaq T, 711  
 Redaelli R, 1021  
 Renga B, 39  
 Révész P, 113  
 Ribeiro DA, 381, 647  
 Ribeiro Paiotti AP, 381  
 Riccardi G, 299  
 Ricci AL, 447  
 Riccio I, 299  
 Riccio V, 299  
 Ring A, 559  
 Rizos D, 327  
 Rizzo MI, 93  
 Rogers BE, 583  
 Rold TL, 583  
 Roselli M, 537  
 Rosengarten JA, 875  
 Rossi A, 1091  
 Rossoni G, 1021  
 Rubenstein M, 183, 937  
 Rubio CA, 135, 319, 859  
 Rühl I, 87  
 Rulli F, 143  
 Rwigema J-C, 9  
 Sakagami H, 259, 265, 305, 411, 651, 657, 957, 993, 1007, 1015  
 Salama SA, 501  
 Salavoura K, 165  
 Salimi U, 9  
 Samoli E, 327  
 Sand L, 59, 463, 841  
 Sangiovanni V, 237  
 Sansalone S, 143  
 Santi P, 147  
 Santorelli C, 39  
 Santos NP, 921  
 Sapkota D, 59  
 Sartelet H, 19  
 Sato T, 899  
 Satoh K, 259, 411, 993  
 Saur J, 1027  
 Sauter A, 369  
 Savarese L, 271  
 Savka MA, 277  
 Scala M, 147  
 Schaffelder R, 481  
 Schaible T, 481  
 Schenk JA, 63  
 Scheuer HA, 453, 1045, 1103  
 Schibel A, 813  
 Schmid-Bindert G, 1027  
 Schmidt RE, 191  
 Schmidt-Wolf IGH, 419  
 Schmitz I, 559

- Schneider RJ, 63  
 Schoenberg SO, 1035  
 Schuler PJ, 571  
 Schultz JD, 369  
 Scott PA, 875  
 Scuderi N, 93, 139, 173, 311, 1053, 1091  
 Seabra CD, 647  
 Segatori VI, 609  
 Seki Y, 941  
 Sepkovic DW, 207  
 Serefoglou Z, 1095  
 Serly J, 979  
 Sesti F, 395  
 Shen H, 9  
 Shen J, 355  
 Shields D, 341  
 Shimada C, 259, 411  
 Shimada J, 651  
 Shimoyama T, 1007  
 Shinto H, 913  
 Shirataki Y, 265, 305, 993  
 Sieckman GL, 583  
 Siemer J, 481  
 Sifakis S, 327, 799  
 Simonetti S, 447  
 Simopoulou M, 823  
 Siristatidis C, 799  
 Skalicky T, 683  
 Skaltsiotis E, 869  
 Skoufi C, 1057  
 Skoufi U, 1057  
 Skripuletz T, 191  
 Smith CJ, 583  
 Snapka RM, 501  
 Soda G, 1091  
 Soga T, 1015  
 Sommer JU, 369  
 Somogyvari F, 979  
 Son J, 703  
 Song J-J, 907  
 Sorvillo V, 157  
 Spagnolo F, 147  
 Spengler G, 223, 293  
 Spyridonos P, 985  
 Stano P, 469  
 Stefanaki K, 985  
 Stein J, 207  
 Steinau H-U, 559  
 Steinbach-Hundt S, 951  
 Steinbrecher M, 819  
 Steinstraesser L, 559  
 Stern-Straeter J, 369  
 Stockhaus C, 931  
 Stolz DB, 9  
 Stone B, 9  
 Stöver T, 593  
 Strada P, 147  
 Stricker I, 559  
 Su K-J, 403  
 Subki A, 277  
 Suetsugu A, 565  
 Sugimoto M, 1015  
 Sugiura T, 411, 957  
 Sulfaro S, 1049  
 Sun S-C, 827  
 Sunaga K, 259, 411  
 Sunagawa M, 719  
 Sutnar A, 683  
 Sütterlin M, 481, 863, 1069  
 Suzuki R, 265, 305, 993  
 Svoboda B, 473  
 Szabo L, 427  
 Szczodroski AF, 583  
 Szegedi E, 277  
 Szirmai M, 113  
 Taga H, 177, 1015  
 Takao Y, 913  
 Takase M, 913  
 Takemoto S, 651  
 Takos D, 869  
 Tambucci R, 143  
 Tanaka S, 957, 1015  
 Tanaka T, 993  
 Tang N-Y, 971  
 Teilmann AC, 213, 577  
 Terakubo S, 259, 411, 1007  
 Teske E, 931  
 Teymoortash A, 951  
 Thamake SI, 765  
 Tietäväinen J, 1  
 Tikovsky K, 473  
 Tilkorn DJ, 559  
 Tomassini GM, 315, 447  
 Tomita M, 1015  
 Tomomura A, 957, 993  
 Tomomura M, 957, 993  
 Toumanidis S, 869  
 Townsend PA, 875  
 Trafalis DT, 75  
 Trapasso M, 147  
 Trefil L, 683  
 Treska V, 683  
 Tretyakova N, 853  
 Trika C, 869  
 Trinkmann F, 1027  
 Trivulzio S, 1021  
 Trougakos IP, 395  
 Tsai H-F, 403  
 Tsimogiannis KE, 1057  
 Tsironis C, 1057  
 Tsitsilonis OE, 395  
 Tsubura A, 361  
 Tsuda T, 259, 411  
 Tsuruoka N, 355  
 Tucci G, 143  
 Tuschy B, 863, 1069  
 Tzivras D, 243  
 Ueda J-Y, 265, 305  
 Umemura N, 265, 305  
 Vaena A, 1001  
 Vagvolgyi C, 979  
 Vairaktaris E, 165, 1001, 1095  
 Varga ZG, 277  
 Vasconcelos-Nóbrega C, 727  
 Vaske B, 191  
 Verikokos C, 243  
 Vernerova Z, 473  
 Viglietti R, 237, 287  
 Viita H, 1  
 Villa M, 143  
 Vince GH, 571  
 Vishwanatha JK, 765  
 Visoso Salgado A, 657  
 Vitoratos N, 327  
 Viveiros M, 223  
 Vlachos IS, 243  
 Von Hörsten S, 191  
 Vougiouklakis T, 1057  
 Voumvourakis C, 165  
 Voutilainen ME, 151  
 Vrachnis N, 327, 799  
 Vrekoussis T, 87  
 Vycital O, 683  
 Vylliotis A, 1095  
 Wagenblast J, 593  
 Wagner S, 571  
 Walder G, 129  
 Wallström M, 463  
 Walter MA, 63  
 Walter T, 1035  
 Wang H, 9, 341  
 Wang J-J, 403  
 Wang Q-L, 827  
 Wang S-C, 963  
 Wang W-H, 671  
 Watanabe K, 657  
 Watanabe M, 787  
 Watanabe S, 657  
 Wefstaedt P, 31  
 Wei C-W, 403  
 Weiher H, 419  
 Weissenbacher T, 87  
 Weller MG, 63  
 Weng S-W, 971  
 Werner JA, 951  
 Wiegand S, 951  
 Wienhoff BE, 583  
 Wiesmann H-P, 251  
 Willenbrock S, 31  
 Wirth T, 1  
 Wu M-F, 437  
 Wu S-H, 971  
 Yagublu V, 599  
 Yamamoto M, 993  
 Yamazaki A, 651  
 Yamazaki T, 651  
 Yang J-S, 665, 971  
 Yapijakis C, 165, 1001, 1095  
 Yasui T, 957  
 Yeh M-Y, 437  
 Yiang G-T, 403  
 Ying S, 107  
 Ylä-Herttua S, 1  
 Yokote Y, 651  
 Yoshizawa K, 361  
 Yu C-S, 665  
 Yu Y-L, 403  
 Yuhara K, 941  
 Yuri T, 361  
 Zairi F, 1079  
 Zeb M, 875  
 Zeidan B, 875  
 Zhang X, 9, 341  
 Zustin J, 323, 453, 847, 1045



## Errata

Volume 26, No 1, pages 96 and 97: Figures should be placed in the correct position as follows:



Figure 1. *Nasolabial flap. Operative technique. Note the transposition of the flap.*




Figure 2. *Island flap. Operative technique. Note the advancement of the flap.*




Figure 3. *Immediate results of surgery. A: Nasolabial flap. B: Island flap.*






Figure 4. Status at 6-month follow-up. A: Nasolabial flap. B: Island flap.




Figure 5. Status at 12-month follow-up. Detail of the profile. A: Nasolabial flap. B: Island flap.




Figure 6. Status at 12-month follow-up. Detail of the tip. A: Nasolabial flap. B: Island flap.

## Instructions to Authors 2013

*General Policy.* IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research. The principal aim of IN VIVO is to provide for the prompt (print and online) publication of accepted articles, generally within 1-2 months from final acceptance.

Manuscripts will be accepted on the understanding that they report original unpublished works that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to IN VIVO will be subject to review, when appropriate, by two members of the Editorial Board. The Editors reserve the right to improve manuscripts on grammar and style.

The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and at all times the animals must be treated humanely. The Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society must be followed.

The Editors and Publishers of IN VIVO accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

*NIH Open Access Policy.* The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in IN VIVO, for public archiving in PubMed Central.

*Copyright.* Once a manuscript has been published in IN VIVO, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without written consent of the Managing Editor or Publisher.

*Format.* Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

*Manuscripts.* Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "review", "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

*Figures.* All figures (whether photographs or graphs) should be clear, high contrast, at the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Colour plates are charged.

*Tables.* Each table should be submitted on a separate page, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

*Nomenclature and Abbreviations.* Nomenclature should follow that given in "Chemical Abstracts", "Index Medicus", "Merck Index", "IUPAC - IUB", "Bergey's Manual of Determinative Bacteriology", The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

*References.* Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973.

*Clinical Trials.* Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "NCT"). Please note that there is no space between the prefix "NCT" and the number. Example: NCT00001789.

*Ethical Policies and Standards.* IN VIVO agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 ([www.icmje.org](http://www.icmje.org)). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

*Submission of Manuscripts.* Please follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your article twice.):

1. To submit your article online please visit: IIAR-Submissions (link to: <http://www.iar-anticancer.org/submissions/login.php>)
2. You can send your article via e-mail to [journals@iar-anticancer.org](mailto:journals@iar-anticancer.org) (mail to: [journals@iar-anticancer.org](mailto:journals@iar-anticancer.org)). Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (\*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies to the following address:

John G. Delinassios, International Institute of Anticancer Research (IIAR), Editorial Office of ANTICANCER RESEARCH, IN VIVO and CANCER GENOMICS & PROTEOMICS, 1st km Kapandritiou-Kalamou Road, P.O. Box 22, GR-19014 Kapandriti, Attiki, GREECE.

Submitted articles will not be returned to Authors upon rejection.

*Galley Proofs.* Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Requests should be addressed to the Editorial Office.

Copyright© 2013 International Institute of Anticancer Research (J.G. Delinassios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitter in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

online from January 2009



# in vivo

International Journal of Experimental and Clinical Pathophysiology and Drug Research

PRINT ISSN: 0258-851X, ONLINE ISSN: 1791-7549

**General Policy:** IN VIVO is an international peer reviewed journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frame of comparative physiology and pathology. Articles are drawn from scientific areas including oncology, pharmacology, chemotherapy, biotherapy, immunology, radiology, toxicology, genetics, cytology, endocrinology, nutrition, comparative pathology, development, biotechnology. Special focus of the journal is the publication of works on: (a) experimental development and application of new diagnostic procedures; (b) pharmacological and toxicological evaluation of new drugs and drug combinations; (c) development and characterization of models of biomedical research. The principle aim of IN VIVO is to provide for the prompt publication of accepted articles, generally within 1-2 months from final acceptance.

IN VIVO supports (a) the aims and research projects of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH.

**Publication Data:** IN VIVO is published bimonthly. Each annual volume contains six issues. Annual Authors and Subject Indexes are included in the sixth issue of each volume.

**Copyright:** Once a manuscript has been published in IN VIVO, the legal ownership of all published parts of the paper has passed from the Author to the Journal.

**Annual Subscription Rates 2012:** Institutional, print: Euro 875.00, online: Euro 855.00, print & online: Euro 890.00; Personal, print: Euro 472.00, online: Euro 452.00 print & online: Euro 490.00. Prices include rapid delivery and insurance. Previous volumes of IN VIVO (Vol. 1-25, 1987-2011) are available at 50% discount on the above rates.

IN VIVO is also published online with Stanford University HighWire Press from the January 2009 issue with access to full text/PDF articles from all previous volumes since January 1st, 2004. For 2012 online/print subscription information, please visit the IN VIVO-IIAR website [www.iiar-anticancer.org](http://www.iiar-anticancer.org) or [www.iv.iiarjournals.org](http://www.iv.iiarjournals.org)

**Subscription orders:** Orders can be placed at agencies, bookstores, or directly with the publisher. Checks should be made payable to

J.G. Delinassios, Athens, Greece. In Japan, contact Woodbell Scope, Inc., 4-22-11, Kitakassai, Edogawa-ku, Tokyo 134, Japan.

Articles in IN VIVO are regularly indexed in bibliographic services, including PubMed, Index Medicus, MEDLINE, Biological Abstracts, BIOSIS, Chemical Abstracts, Excerpta Medica, Elsevier Bibliographic Database, EMBASE, Compendex, GEOBASE, EMBiology, Elsevier BIOBASE, FLUIDEX, World Textiles, Scopus, CANCER-LIT Database, University of Sheffield Biomedical Information Service (SUBIS), Current Clinical Cancer, AIDS Abstracts, Progress in Palliative Care, Update-Research Information Systems Inc., Inpharma-Reactions Datastar, BRS, Reference Update (I.S.I.), Research Alert (I.S.I.), Google Scholar, BioBase, MedBase, Investigational Drugs Database, VINITI Abstracts Journal, PubsHub, Sociedad Iberoamericana de Información Científica (SIIC) Databases.

The Editors and Publisher of the journal IN VIVO accept no responsibility for the opinions expressed by the contributors or for the content of the advertisements appearing herein.

Authorization to photocopy items for internal or personal use, or the internal or personal clients, is granted by IN VIVO, provided that the base fee of \$2.00 per copy, plus 0.40 per page is paid directly to Copyright Clearance Center, 27 Congress Street, Salem, MA 01970, USA. For those organizations that have been granted a photocopy license by CCC, a separate system of payment has been arranged. The fee code for users of the Transactional Reporting Service is 0258-851 X 2011 \$2.00 + .40.

**Correspondence** (subscription orders, reprint orders, disposition of submitted manuscripts, change of address, general editorial matters, advertising rate requests) should be addressed to: Dr. J.G. Delinassios, Managing Editor.

**Editorial Office:** International Institute of Anticancer Research (IIAR), 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O.B. 22, Attiki 19014, Greece. Tel & Fax: +30-22950-53389.

**E-mails:**

**Editorial Office:** [journals@iiar-anticancer.org](mailto:journals@iiar-anticancer.org)

**Managing Editor:** [editor@iiar-anticancer.org](mailto:editor@iiar-anticancer.org)

For more information about IN VIVO and the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH, please visit the IIAR website: [www.iiar-anticancer.org](http://www.iiar-anticancer.org); [www.iv.iiarjournals.org](http://www.iv.iiarjournals.org)